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ABSTRACT 
Adipose tissue is a highly vascularized endocrine tissue. Due to the ever growing 
problem of obesity, the interest in determining mechanisms behind adipose tissue 
imbalances and identifying substances causing metabolic disturbances in adipose 
tissue is increasing. There are several drug treatments targeting vasculature and/or 
adipose tissue currently available and constantly new ones being developed including 
cancer, eye condition, insulin sensitizing and obesity treatments. Hence drug 
development needs reliable and relevant models for development and testing of 
these treatments. In addition, more attention has been focused on chemicals in our 
living environment that inadvertently affect adipose tissue. These obesogens need to 
be identified as they are especially harmful to fetuses and children. In order to 
identify these, relevant test systems are needed. Most adipose tissue related research 
is still conducted on animals or animal cells. Due to the species-to-species differences 
in adipose tissue regulation, cell models depicting human biology are greatly needed.  
The aim of this study was to develop an in vitro vascularized adipose tissue model. 
A bottom-up approach was utilized, first optimizing the building blocks for the 
model and then moving on to combining these components. First, serum-free 
induction medium was developed for induction of in vitro vascularization (i.e. 
angiogenesis model) in human adipose stromal cells (hASC) and human umbilical 
vein endothelial cell (HUVEC) co-cultures. Second, a protocol for inducing insulin 
sensitive adipocytes from hASC was developed. In the third step, vasculature and 
adipocytes were combined using simplified induction protocols to provide a proof 
of concept model of vascularized adipose tissue and to determine the optimal culture 
time, timing of induction media, and timing of seeding of hASC and HUVEC. 
Finally, we combined the two optimal components, insulin sensitive adipocyte 
protocol and vasculature utilizing the culture set-ups that were found to be optimal 
for creating the vascularized adipose tissue model. We studied the predictivity of this 
model by exposing it to chemicals, including insulin, with known effects on adipose 
tissue, and compared responses to those found in literature. 
Results showed that the angiogenesis model induced with this serum-free 
medium produced an extensive vascular network with morphology resembling 
vessels in vivo including the intact endothelial layer, basement membrane, 3D tubules 
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with lumen, extracellular matrix proteins and surrounding pericytes. The adipocytes 
differentiated from hASC with the new protocol accumulated lipids, showed mature 
adipocytes markers and responded to insulin by lipolysis inhibition and glucose 
uptake. The vascularized adipose tissue model contained an in vivo-like vascular 
network and mature adipocytes that were responsive to insulin. The interaction of 
adipocytes with vascularization was seen to result in faster maturation of adipocytes 
and better insulin sensitivity. Also the impact of chemicals on vascularized adipose 
tissue was different than on adipocytes alone. 
The angiogenesis model with serum-free induction and the insulin sensitive 
adipocyte model are relevant in vitro models that can be used independently for 
studying angiogenesis and adipogenesis. The combined model, vascularized adipose 
tissue model, is a useful tool for adipose tissue research, including toxicological, drug 
discovery and cell biology research applications. 
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TIIVISTELMÄ 
Rasvakudos on verisuonitettu endokriininen kudos. Kasvavan 
liikalihavuusepidemian takia rasvakudoksen toiminnan ja aineenvaihdunnan sekä 
näiden häiriötilojen tutkiminen ja rasvakudokseen vaikuttavien aineiden 
tunnistaminen on noussut entistä tärkeämmäksi tutkimusaiheeksi. Verisuonituksen 
ja rasvakudoksen toimintaan ja määrään pyritään tietoisesti vaikuttamaan lääkkeillä. 
Lääkkeiden toiminta täytyy osoittaa ennen kuin lääkkeet päätyvät markkinoille. 
Elinympäristössä on myös kemikaaleja, joiden vaikutuksia rasvakudokseen ei ole 
tiedostettu. On tärkeää tunnistaa nämä obesogeenit sillä ne ovat erityisen haitallisia 
sikiöille ja kehittyville lapsille. Jotta nämä voidaan tunnistaa, tarvitaan luotettavia 
testisysteemejä. Rasvakudokseen liittyvät tutkimukset tehdään kuitenkin edelleen 
useimmiten eläimillä tai eläinsoluilla. Lajien väliset erot rasvakudoksen säätelyssä 
ovat kuitenkin huomattavia ja siksi tarvitaan solumalleja, jotka kuvaavat ihmisen 
biologiaa  
Tässä tutkimuksessa kehitettiin verisuonitettu rasvakudosmalli ihmisen soluista. 
Tutkimuksessa kehitettiin ensin erillään mahdollisimman luonnollisen kaltaiset in 
vitro verisuonet ja rasvasolut, jonka jälkeen nämä yhdistettiin verisuonitetuksi 
rasvakudokseksi. Verisuonten muodostumista varten kehitettiin seerumiton 
kasvatusliuos rasvan stroomasolujen ja napanuoran endoteelisolujen 
yhteisviljelmässä käytettäväksi (angiogeneesimalli). Seuraavaksi kehitettiin protokolla 
insuliiniherkkien rasvasolujen erilaistamiseksi rasvan stroomasoluista. Kolmannessa 
vaiheessa verisuonitus yhdistettiin rasvasoluihin yksinkertaisia menetelmiä käyttäen, 
jotta saatiin selville sopiva viljelyaika mallille, solujen siirrostusajankohta sekä 
erilaistuksen aikaansaavien kasvatusliuosten lisäysjärjestys verisuonitetun rasvamallin 
aikaansaamiseksi. Näitä parhaiksi havaittuja viljelyolosuhteita hyväksi käyttäen 
yhdistettiin luonnollisen kaltaiset verisuonet ja rasvasolut verisuonitetuksi 
rasvamalliksi. Tämän mallin ominaisuudet ja vaste kemikaaleille, myös insuliinille, 
tutkittiin ja varmistettiin, että malli ja sen toiminta ovat luonnollisen rasvakudoksen 
kaltaisia. 
Tulokset osoittivat, että angiogeneesimalliin muodostui hyvä verisuoniverkosto, 
jossa suonissa oli endoteelikerros jota ympäröi tyvikalvo. Suonet olivat 
kolmiulotteisia putkia, joissa oli lumen ja soluväliaine ja perisyytit ympäröivät näitä 
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suonia. Rasvasolut keräsivät rasvaa, ilmensivät kypsän rasvasolun geenejä ja reagoivat 
insuliiniin lipolyysin estymisellä ja glukoosin sisäänotolla. Verisuonitetussa 
rasvakudosmallissa olevat suonet olivat luonnollisten suonien kaltaisia, rasvasolut 
olivat edelleen kypsiä rasvasoluja ja malli reagoi insuliinille oikein. Verisuonituksen 
vaikutus rasvasoluihin nähtiin rasvasolujen nopeampana kypsymisenä ja 
parantuneena insuliiniherkkyytenä. Verisuonten nähtiin myös vaikuttavan 
kemikaalivasteisiin mallissa. 
Kaikki kolme mallia, verisuonet, rasvasolut ja verisuonitettu rasva ovat itsenäisesti 
käytettäväksi soveltuvia malleja angiogeneesin ja adipogeneesin tutkimiseen. 
Verisuonitettua rasvakudosmallia voidaan käyttää laajasti rasvakudoksen tutkimiseen 
mm. toksikologian, lääkekehityksen ja solubiologian aloilla. 
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ABBREVIATIONS 
3D three dimensional 
3R  reduction, refinement and replacement 
AA  ascorbic acid 
ANG +T  adipogenesis/angiogenesis medium  
ANG -I  angiogenesis medium w/o insulin 
ANG angiogenesis medium 
Angpt  angiopoietin 
ATE adipose tissue extract 
ATEm ATE medium 
BSA  bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
COLIV collagen IV 
ECM  extracellular matrix 
EGM-2  endothelial cell growth medium-2 
eNOS  endothelial nitric oxide synthase 
FABP4 fatty acid binding protein 4 
FBS  fetal bovine serum 
FCS fetal calf serum 
FGF-2 fibroblast growth factor 2 
Glut  glucose transporter 
(h)ASC (human) adipose stromal cells 
hASCm hASC medium  
HE  heparin 
HUVEC  human umbilical vein endothelial cells 
HY  hydrocortisone 
IGF-1 insulin-like growth factor I 
IL  interleukin 
IRS  insulin receptor substrate proteins 
LPL  lipoprotein lipases 
MMP  matrix metalloproteinase 
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MSC  mesenchymal stem cells 
PDGFR(-β)   platelet derived growth factor (β) 
PDK  phosphoinositide-dependent protein kinase 
PI3K  phosphatidylinositol-3 kinase 
PKA  protein kinase A 
PPAR  peroxisome proliferator–activated receptor 
PRDM16 PR domain containing 16 
RT  room temperature 
SEM  scanning electron microscopy 
SFM serum-free medium 
SMM Smooth muscle myosin heavy chain,  
t3  3,3’,5-triiodo-l-thyronine sodium salt 
TEM  transmission electron microscopy 
TZD thiazolidinedione 
UCP-1 uncoupling protein 1 
ve-cadherin vascular endothelial cadherin 
VEGF  vascular endothelial growth factor 
VEGFR  vascular endothelial growth factor receptor 
vWf  von Willebrand factor 
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1 INTRODUCTION 
In recent years, the development of human research models that depict in vivo human 
tissues and biology has become increasingly important due to pressure from 
regulatory, scientific and ethical aspects to replace animal testing with non-animal 
approaches. Following the introduction of EU acts such as REACH and cosmetics 
regulations (European Union 2010, European Union 2009, European Union 2006), 
the need and interest for official in vitro tests has increased. The reduction, refinement 
and replacement (3R) principle, and ethical aspects they represent, have long been 
one motivation to reduce and replace animal tests with in vitro methods, with work 
in this field continuing (Hampshire et al. 2018, Mallia et al. 2018, Franco et al. 2018). 
In addition to the regulatory and ethical aspects, more and more evidence shows 
the differences between human and rodent biological processes, with adipose tissue 
being one example tissue clearly presenting such differences (Heinonen 2015, 
Chandrasekera et al. 2014, Al-Awar et al. 2016). As adipose tissue and its metabolism 
differ so greatly between rodents and humans, it is of special importance to find 
replacements for animal tests in the field of adipose research.  
Due to the continuously growing problem of obesity and related diseases (World 
health organization WHO 2018), biological adipose tissue research is more and more 
important and the need to develop new relevant therapeutics and understand the 
underlying mechanisms behind adipose related diseases is great. Among the diseases 
related to adipose tissue are diabetes mellitus, hypertension, stroke, cardiovascular 
disease, dyslipidemia, gallbladder disease, cancer, respiratory disease, arthritis and 
gout (Pi-Sunyer 2009). Health issues related to adipose tissue are linked to an increase 
in the amount of white adipose tissue rather than that of brown (Fruhbeck et al. 
2009). Great efforts have been put into elucidating the pathophysiological 
mechanisms by which obesity induces or amplifies its major adverse consequences 
and for developing effective therapies towards obesity and its associated disorders 
(Cao 2014). Environmental factors, which might impact adipose tissue and be part 
of the increase in obesity, have also raised interest (Heindel et al. 2018, Muscogiuri 
et al. 2017, Janesick et al. 2016, Holtcamp 2012).  
In addition to being energy storage, adipose tissue is an active endocrine organ, 
which is particularly closely associated with the vascular system. Enlargement of the 
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adipose tissue can be supported by new blood vessel formation, neovascularization, 
or by dilation and remodeling of the already existing capillaries (Christiaens et al. 
2010). Studies have shown that induction of vessel expansion could counteract 
obesity and related metabolic complications (Robciuc et al. 2016, Elias et al. 2012). 
The attempt to introduce vascularization into in vitro adipocyte cultures has been 
challenging due to the commonly used chemical cocktails utilized for adipocyte 
differentiation. The compounds in this chemical cocktail have been shown to inhibit 
endothelial proliferation and tubule formation (Kang et al. 2009, Sheu et al. 2006).  
While developing in vitro models, in addition to biological relevance, regulatory 
aspects have to be taken into consideration. The repeatability and reproducibility of 
an assay should be ensured already during development of the new methods. OECD 
has determined the criteria that in vitro tests should pass in order to be suitable for 
regulatory use (Environment Directorate 2005). 
The ultimate aim of this study was to create a vascularized adipose tissue model 
to be used as a tool for adipose tissue research and chemical testing to better depict 
human biology. The individual optimized components; induced vascularization and 
differentiated adipocytes, should also be able to be utilized independently. These 
three models provide versatile tools for a variety of research applications.  
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2 LITERATURE REVIEW 
2.1 Chracteristics of adipose tissue 
Adipose tissue is typically divided into two main types, brown and white adipose 
tissue. Whereas white adipose tissue is the primary energy storer, brown is specialized 
in fat burning for heat generation and energy expenditure through non-shivering 
thermogenesis, where triglycerides are oxidized for heat production to protect 
against cold and simultaneously obesity (Hyvonen et al. 2014, Choi et al. 2010a, 
Lefterova et al. 2009). 
The most well known characteristic of white adipose tissue is its energy storing 
ability. Adipose tissue is highly dynamic tissue, able to rapidly increase or decrease 
its mass in response to changes in the energy balance of the body (Hyvonen et al. 
2014, Sun et al. 2011). This allows continuous expansion and regression of 
subcutaneous adipose tissue deposits throughout adult life (Harrington et al. 2004). 
In addition, adipose tissue insulates heat and serves as mechanical support for the 
body (Rosen et al. 2014). The loss of adipose tissue due to injury can impair normal 
functions, such as range of motion, but also affects the cosmetic and emotional well-
being of the patient (Patrick 2001).  
White adipose tissue is the predominant type of fat in adult humans (Lefterova 
et al. 2009) and brown is present mainly in infants (Hyvonen et al. 2014, Choi et al. 
2010a). The amount of brown tissue decreases in humans as the body matures (Choi 
et al. 2010a). The morphological difference between white and brown adipocytes is 
that white stores lipids in one large lipid droplet, whereas brown contains several 
smaller lipid droplets (Hyvonen et al. 2014, Peirce et al. 2014). In brown adipocytes, 
mitochondrial uncoupling protein 1 (UCP-1) is responsible for energy expenditure 
(Fedorenko et al. 2012). In obesity, white adipose tissue suffers inflammation and 
oxidative stress associated with insulin resistance, leading to metabolic syndrome and 
other systemic alterations (Boyer et al. 2015, Wensveen et al. 2015). As most health 
issues related to adipose tissue are linked to white adipose tissue, a white adipose 
tissue in vitro model would be very beneficial to extrapolate mechanisms behind 
diseases such as those related to diabetes mellitus. 
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Although white adipose tissue is named “white”, the color of the tissue is 
influenced by diet. Carotenoid and tocopherol, are known to accumulate in human 
adipose tissue in varying amounts depending on dietary intake; beta-carotene 
(provitamin A), lycopene and alpha-tocopherol (vitamin E) being the most 
predominant compounds (Chung et al. 2009, Parker 1988). These colorful and fat 
soluble compounds obtained through the diet, mainly from fruits and vegetables, 
change the color of adipose tissue more yellow than white (Kirton et al. 1975). More 
than just influencing the color of adipose tissue, carotenoids and their metabolic 
products have been shown to impact a variety of adipose tissue characteristics 
including lipid metabolism, metabolic diseases and insulin resistance (Bonet et al. 
2015, Bonet et al. 2012, Landrier et al. 2012). Higher intake of carotenoids is 
associated with lower levels of low-grade inflammation in relation to overweightness, 
obesity and metabolic syndrome (Calder et al. 2011). Carotenoids and their metabolic 
products have also been shown to inhibit adipogenesis and the fat storage capacity 
of mature adipocytes through suppression of PPARγ and PPARγ target genes in 
adipocytes (Amengual et al. 2011, van Helden et al. 2011). Due to the inflammation 
and adiposity lowering effects of carotenoids, they have also been proposed as a 
treatment option for obesity related conditions. One example is Astaxanthin, a 
xanthophyll carotenoid, which was shown to prevent obesity and fatty liver disease 
(Ikeuchi et al. 2007). 
Adipose tissue is one of the most vascularized tissues in the body (Cao 2013). In 
addition to transporting nutrients, oxygen and waste, vasculature produces local 
growth factors and cytokines, impacting adipose tissue functions (Cao 2014). In turn, 
adipose tissue secretes pro- and anti-angiogenic factors to modulate the vasculature 
(Christiaens et al. 2010, Cao 2014). In addition to vascularization, adipose tissue also 
interacts with interstitium. Interstitium has been proposed as a new organ in recent 
years, however there is still debate whether it can truly be counted as an organ (Benias 
et al. 2018, Neumann 2018). Regardless of the classification of the interstitium, the 
composition of interstitial fluid has great relevance on adipose tissue functions in 
health and disease development, due to their close proximity. Signaling molecules 
produced in other organs move through the interstitium prior to reaching 
adipocytes, for example insulin (Nielsen et al. 2005, Jansson et al. 1993), which 
modulates glucose and lipid metabolism in adipocytes. Adipocytes secrete 
compounds including those of glucose and lipid metabolism and these either 
accumulate in interstitial fluid or are transferred to other organs through blood or 
lymphatic vessels (Chakraborty et al. 2019). Dead adipocytes release free lipids to the 
interstitium, which are scavenged by macrophages (Cinti et al. 2005). Accumulation 
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of macromolecules into the interstitial fluid are suspected to be a link between 
obesity and local inflammation and further, leading to the development of metabolic 
disturbances related to obesity (Angrim et al. 2013, Ouchi et al. 2011).  
Adipose tissue influences both lipid and glucose metabolism. Adipose tissue 
secretes factors, which mediate physiological processes such as appetite, 
inflammatory responses, glucose metabolism, systemic insulin sensitivity, 
angiogenesis, blood pressure and reproductive function (Gu et al. 2013, Lau et al. 
2005). In healthy adipose tissue, the release of fatty acids from adipose tissues into 
circulation and the uptake and oxidation in peripheral tissues are in homeostasis 
(Unger 2003). In obesity, energy intake exceeds the storage capacity of adipose tissue, 
which triggers an inflammatory response in expanding tissue as well as increased 
lipolysis, leading to alterations in circulatory fatty acid concentrations and glucose 
(Danforth 2000).  
The size of fat storage in the body is highly variable, ranging from 5 to 60% of 
total body weight (Lee et al. 2013). Depots of adipocytes can be found in 
stereotypical locations throughout the body. The depots include subcutaneous (e.g. 
arm and gluteal adipose tissue), visceral (intra-abdominal) and ectopic (e.g. 
intramuscular) adipose tissue. Subcutaneous adipose tissue depots are the main 
adipose tissue deposits consisting of >80% of total body fat in humans (Lee et al. 
2013). The different depots differ significantly from each other. Fat depots have 
differences in their abilities to store and release fatty acids, synthesize and secrete 
adipokines and in their plasticity (Lee et al. 2013, McLaughlin et al. 2011, Fain et al. 
2004, Rosen et al. 2006). These characteristics also define the metabolic outcomes 
of homeostatic changes in the depots. For example, an increase in subcutaneous 
adipose tissue is not associated with increased risk of insulin resistance, whereas 
visceral adipose tissue is (McLaughlin et al. 2011). Subcutaneous adipose tissue is 
known to be less metabolically active than visceral adipose tissue (Fain et al. 2004). 
Visceral adipose tissue adipocytes are sensitive to lipolytic stimuli, whereas in 
structural depots such as those around the eyes and in heel pads, do not release 
stored lipids easily (Rosen et al. 2006).  
2.1.1 Cells and components in adipose tissue and their functions 
Adipose tissue does not contain only adipocytes. In adipose tissue, 20-60% of the 
cells are mature adipocytes, 10% resident macrophages and the rest are other stromal 
vascular cells (Hyvonen et al. 2014, Lanthier et al. 2014, Karastergiou et al. 2010). 
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Stromal vascular cells include fibroblasts, immune cells, leukocytes, endothelial cells, 
pericytes, adipose stem cells and extracellular matrix (ECM) components (Hyvonen 
et al. 2014, Choi et al. 2010a, Karastergiou et al. 2010, Astori et al. 2007, Poulos et 
al. 2010). In addition, adipose tissue contains blood vessels, lymph nodes and nerves 
(Corvera et al. 2014, Kim et al. 2008, Bartness et al. 2014). Adipocytes are supported 
by an ECM composed of collagen types I, II, III, IV, V, and VI and other ECM 
proteins (Nakajima et al. 1998, Flynn et al. 2006). The ECM forms fat lobules in 
adipose tissue (Bucky et al. 2008).  
In white adipocytes the unilocular lipid droplet can occupy 95% of the cell 
volume and thus determine the size of the cell, ranging from 20 to 200 micrometers 
(Lee et al. 2013, Sugihara et al. 1987a). Only vertebrates have specialized cells that 
are recognized as adipocytes (Ottaviani et al. 2011). Triglycerides are the major 
storage molecules for fatty acids and used in addition to energy needs as synthesis 
material for membrane lipids (Yen et al. 2008). Characteristics of mature adipocytes 
are the ability for lipogenesis and release of fatty acids in lipolysis, insulin sensitivity 
and secretion of adipocyte-specific proteins. The lipolysis process can be induced by 
epinephrine, norepinephrine, ghrelin, growth hormone, testosterone, and cortisol 
binding activating adenylate cyclase, or by a drop in circulating insulin levels (Holm 
et al. 2000).  
In circulatory blood, triglycerides are transported in multi-molecular lipoprotein 
particles (Mead et al. 2002). Lipoprotein lipases (LPL) released by adipocytes are 
needed for the utilization of circulating triglycerides by adipocytes (Frayn et al. 2003, 
Kersten 2014). LPL is transported to capillary endothelium (Kersten 2014), where it 
catalyzes the hydrolysis reaction that produces non-esterified fatty acids and 2-
monoacylglycerols (Mead et al. 2002, Rutkowski et al. 2015). Several binding and 
transport proteins, such as CD36 and fatty acid transport protein family members 
participate in transporting non-esterified fatty acids into adipocytes (Rutkowski et al. 
2015). These non-esterified fatty acids are esterified and form triglycerides for 
storage within the lipid droplets in adipocytes (Rutkowski et al. 2015).   
In lipolysis, triglycerides are broken into glycerol and free fatty acids (FFA) that 
can then be oxidized locally or by other organs (Rosen et al. 2014, Rutkowski et al. 
2015). Lipolysis is driven by β-adrenergic signaling in adipocytes. The binding of 
catecholamines to β-adrenergic receptors increases the concentration of cellular 
cyclic adenosine monophosphate, which in turn activates lipolytic enzymes through 
the stimulation of protein kinase A (PKA) (Zechner et al. 2005). Adipose triglyceride 
lipase, hormone-sensitive lipase and monoglyceride lipase are three examples of 
major lipolytic enzymes (Rosen et al. 2014). Adipose triglyceride lipase initiates 
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hydrolysis of triglyceride that produces diacylglycerols and free fatty acids (Zechner 
et al. 2005), while hormone-sensitive lipase and others complete the process of 
lipolysis and generate glycerol and free fatty acids (Rosen et al. 2014). 
Human adipose stromal cells (hASC) are cells from the stromal vascular fraction, 
adipose mesenchymal stem cells, that have multi-potent differentiation potential and 
can differentiate into bone, cartilage, muscle, and adipose tissue (Kokai et al. 2014, 
Tsuji et al. 2014). Expanded ASC include also progenitor cells that can differentiate 
into mature endothelial cells and participate in blood vessel formation (Lindroos et 
al. 2011). The name adipose stromal cell was recommended by the Mesenchymal and 
tissue stem cell Committee of the international society, and designated for the 
stromal vascular fraction cells (Dominici et al. 2006). hASC can be obtained in high 
numbers from adipose tissue, cultured and expanded in vitro (Girandon et al. 2011). 
As adipose stromal cells are obtained from adult tissue, their use does not raise the 
ethical issues such as the use of embryonic stem cells. This makes them an interesting 
source of cells for regenerative medicine (Tsuji et al. 2014). In addition, ASC are 
genetically more stable in a long-term culture than e.g. mesenchymal stem cells 
(MSC) from bone marrow (Lindroos et al. 2011). ASC can be obtained from 
different fat depots and from various species, human and animal adipose tissue, 
which enables the study of differences between adipose tissue depots and species 
(Gregoire et al. 1998, Armani et al. 2010). 
ASC also have immunomodulatory effects, which is a positive feature in tissue 
engineering. ASC have been shown to participate in host defense (Saillan-Barreau et 
al. 2003). They are capable of changing the inflammatory profile of macrophages in 
vitro into an anti-inflammatory phenotype, hence suppressing inflammatory response 
(Lindroos et al. 2011, Hanson et al. 2011, Gonzalez-Rey et al. 2010). ASC are known 
to secrete several soluble factors, such as angiogenic factors (e.g. vascular endothelial 
growth factor, VEGF), anti-apoptosis factors (e.g. insulin-like growth factor I, IGF-
1), hematopoietic factors (e.g. colony stimulating factors and interleukins), and 
hepatocyte growth factor (Ong et al. 2013). 
The definition of ASC requires them to be (1) plastic-adherent in standard cell-
culture conditions; (2) multipotent in vitro, i.e., able to differentiate into adipocytes, 
chondrocytes and osteoblasts; and (3) positive for CD73, CD90, and CD105, and 
negative for CD11b or CD14, CD19 or CD79α, CD34, CD45, and HLA-DR on 
their surface immunophenotype (Dominici et al. 2006). Time and/or passage of ASC 
in vitro causes changes in the surface antigen profile (Mitchell et al. 2006). ASC and 
MSC surface immunophenotypes resemble each other with a similarity greater than 
90% after two or more passages in vitro (Gimble et al. 2007). ASC display stromal 
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markers, such as CD29, CD44, CD73, CD90 and CD166 (Gimble et al. 2007), 
pericyte markers, such as CD140a and CD140b, and cytoskeletal markers, such as 
vimentin and α–smooth muscle actin (Traktuev et al. 2008). The presence of CD34 
on human ASC is not found in MSC (Pittenger et al. 1999).  To separate ASC from 
bone marrow MSC, they should be positive for CD36 and negative for CD106 
(Bourin et al. 2013).  
A specific subpopulation of stromal cells has been identified that efficiently 
differentiates into adipocytes and forms functional adipose depots in vivo. These cells 
show Lin−, Sca1+, CD34+, CD24+, a7−, and a platelet derived growth factor receptor 
(PDGFR) α + expression pattern (Tang et al. 2008, Joe et al. 2010, Rodeheffer et al. 
2008). Similarly to this more efficient subpopulation, differences between ASC 
derived from different fat depots have been found, which might explain differences 
in the expansion of these depots in response to nutrient excess (Joe et al. 2009).  
2.1.2 Adipokines 
Adipose tissue secretes numerous growth factors, hormones, pro- and anti-
inflammatory cytokines, enzymes and matrix proteins as well as coagulation and 
complement factors (Poulos et al. 2010, Traktuev et al. 2008, Kilroy et al. 2007, 
Trayhurn 2005). The factors secreted by adipose tissue are called adipokines. 
Adipose tissue secretes proteins including leptin, adiponectin, resistin, tumor 
necrosis factor α, interleukin (IL) 6 and 1β, plasminogen activator inhibitor-1, fatty 
acid binding protein 4 (FABP4), VEGF, hepatocyte growth factor, transforming 
growth factor β, fibroblast growth factor (FGF) and matrix metalloproteinases 
(MMP), and tissue inhibitors of metalloproteinases (Fasshauer et al. 2015, 
Karastergiou et al. 2010,). These factors function in an endocrine, paracrine and 
autocrine manner and have a variety of effects including angiogenic, adipogenic and 
immune reactions. They are secreted by adipocytes, macrophages, stroma vascular 
fraction cells and preadipocytes (Fasshauer et al. 2015).  
Leptin and adiponectin are the most abundant adipokines produced and released 
by adipocytes (Karastergiou et al. 2010, Galic et al. 2010). Although they have 
opposing functions, they both regulate whole body energy homeostasis via the 
hypothalamus (Galic et al. 2010, Coelho et al. 2013). They both also have metabolic 
effects on multiple different tissues (Galic et al. 2010).  
Leptin is a peptide hormone mainly produced and secreted by mature adipocytes 
(Gregoire 2001). Specifically, the subcutaneous fat depot is a major source of leptin 
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(Wajchenberg 2000). The main effect of leptin is regulation of energy balance, which 
is mostly mediated by receptors located in the central nervous system (Coelho et al. 
2013, Gregoire 2001, Kershaw et al. 2004). As the size of adipocyte lipid storage 
increases, the expression and levels of leptin increase (Tritos et al. 1997, Mantzoros 
et al. 1997). Thus, leptin concentrations are higher in obese individuals and increase 
along with increased energy intake. In addition to the role in energy homeostasis 
regulation, leptin has versatile effects on other tissues as well, as it regulates 
endocrine systems, the immune system, hematopoiesis, angiogenesis and bone 
development (Kershaw et al. 2004). 
Adiponectin stimulates appetite and reduces energy expenditure and thus has the 
opposite functions to leptin (Coelho et al. 2013). Adiponectin is secreted exclusively 
by mature adipocytes (Wang et al. 2008, Hu et al. 1996). Adiponectin is expressed 
more in VAT than SCAT (Freedland 2004, Motoshima et al. 2002). There is a 
significant negative correlation between circulating adiponectin levels and body 
weight, insulin resistance and blood pressure (Fasshauer et al. 2014). Two 
adiponectin receptors have been reported, adipoR1 and adipoR2 (Yamauchi et al. 
2003). The biological effects of these receptors depend on the blood concentration 
of adiponectin and also tissue specificity (Itoh et al. 2011, Kadowaki et al. 2005). 
Adiponectin has gained a lot of interest due to its insulin sensitizing, anti-
inflammatory, and antiapoptotic properties (Fasshauer et al. 2014, Ye et al. 2013). 
Peroxisome proliferator–activated receptor (PPAR) γ ligands, which can function as 
insulin sensitizers have also been shown to increase adiponectin expression and 
plasma concentration in vivo and in vitro (Maeda et al. 2001). 
FABP4 is a cytoplasmic fatty acid chaperone expressed primarily in adipocytes 
and also associated with the development of insulin resistance and atherosclerosis 
(Wu et al. 2014, Cao et al. 2013, Garin-Shkolnik et al. 2014). FABP4 levels are higher 
in visceral fat than subcutaneous, and also higher in obese adipose tissue with 
diabetes than healthy. (Garin-Shkolnik et al. 2014). FABP4 attenuated adipocyte 
differentiation by negatively regulating PPARγ levels occurs in macrophages and 
adipocytes by triggering ubiquitination and subsequent proteosomal degradation of 
PPARγ (Garin-Shkolnik et al. 2014).  
As adipose tissue also produces and secretes many proangiogenic factors, the 
regulation of angiogenesis in adipose tissue is possibly based on the local balance 
between proangiogenic and antiangiogenic factors produced by the tissue itself 
(Christiaens et al. 2010).  Angiogenic factors produced by adipose tissue include 
different members of the VEGF family, hepatocyte growth factor, placental growth 
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factor, FGF-2, angiopoietin-1 and -2 (Angpt-1 and 2), leptin, platelet derived growth 
factor-β (PDGF-β), and transforming growth factor-α (Christiaens et al. 2010). 
2.1.3 Adipogenesis 
New adipocytes develop through adipogenesis. Adipogenesis begins with a 
determination phase in which stem cells transform into committed preadipocytes 
(Rosen et al. 2006). Commitment is followed by a growth arrest, which is followed 
by the signalling of a specific mixture of adipogenic and mitogenic factors needed 
for the terminal differentiation step (Gregoire 2001). The second phase of 
adipogenesis is terminal differentiation, in which preadipocytes transform into 
insulin-sensitive, lipid synthesizing and releasing mature adipocytes that secrete 
adipocyte-specific secretory products (Rosen et al. 2006, Stephens 2012). 
The differentiation process includes chronological changes in the expression of 
early, intermediate and late mRNA and protein markers (Gregoire et al. 1998). 
Activation of over 2000 genes is required to reach the status of a fully mature 
adipocyte (Guo et al. 2000). Commitment is established by intracellular factors 
including Zfp423 and S6K1, early B cell factor 1 and transcription repressor TCF7L1 
(Chen et al. 2013). Commitment of stem cells to preadipocytes also involves bone 
morphogenetic protein signaling (Huang et al. 2009), whereas WNT signalling 
(Christodoulides et al. 2009, Prestwich et al. 2007) and the hedgehog signalling 
pathway inhibit the commitment phase (Cousin et al. 2007, Pospisilik et al. 2010). 
The formed preadipocytes express CD29, CD34, SCA1, PDGFR-α and CD24 (Chen 
et al. 2013, Berry et al. 2014). 
In the differentiation of preadipocytes into mature adipocytes, the nuclear 
receptor PPARγ is a master regulator, playing a critical role in systemic lipid and 
glucose metabolism (Tontonoz et al. 1994). The expression of PPARɣ is induced by 
C/EBPβ and C/EBPδ (Rosen et al. 2014, Rosen et al. 2006, Bucky et al. 2008). 
PPARγ and C/EBP-β activate, then C/EBP-α, which directly induces many 
adipogenic genes and activates PPARγ (Rosen et al. 2006). The differentiated 
adipogenic state is maintained by the activation of C/EBP-α induced by PPARγ, 
which creates a positive feedback signal (Daquinag et al. 2011). C/EBPα is 
considered to have an important function in the activation and maintenance of 
terminally differentiated adipose tissue (Wu et al. 1996). 
Activated PPARγ and C/EBPα induce genes expressed in mature adipocytes 
involved in insulin sensitivity, lipogenesis and lipolysis. These include FABP4, CD36, 
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fatty acid synthetase, insulin regulated glucose transporter (Glut) 4, leptin, 
lipoprotein lipase (LPL), and adiponectin, all of which contain peroxisome 
proliferator response elements (Daquinag et al. 2011, Tontonoz et al. 2008, Lowe et 
al. 2011, Lefterova et al. 2008).  
PPARγ has two different isoforms that are expressed: PPARγ1 and PPARγ2. 
PPARγ2 is the more adipocyte-specific isoform of PPARγ (Ren et al. 2002, Escher 
et al. 2001), and it is transcriptionally regulated by nutrition (Ren et al. 2002, Werman 
et al. 1997). PPARγ2 is shown to be critical for the storage of lipids in adipocytes 
instead of other organs, and hence, its proper expression is highly important in 
obesity (Medina-Gomez et al. 2007).  
Also transcriptional factors including Krox20, KLF4, TLE3 and CREB promote 
adipogenesis (Chen et al. 2013). TLE3, a target gene of and a cofactor for PPARγ 
enhances adipogenesis by activating PPARγ and suppressing WNT 
activity/expression, but TLE3 also competes with PR domain containing 16 
(PRDM16) protein for PPARγ binding, which promotes white adipogenesis and 
inhibits brown adipocyte formation (Villanueva et al. 2013). The regulation of 
adipogenesis includes also other relevant signaling molecules besides transcriptional 
factors. The activation of the mitogen-activated protein kinase kinase/extracellular 
signal regulated kinase signaling pathway and p38 mitogen-activated protein kinase 
signaling pathway are mecessary for the adipogenesis process (Bost et al. 2005, 
Farmer 2005). In addition to these pathways, insulin, IGF-1, glucocorticoids and 
factors increasing intracellular cyclic adenosine monophosphate (cAMP) 
concentration act as promoters of adipogenesis (Gregoire et al. 1998). Insulin and 
lipids activate sterol-regulatory element binding protein 1c and this in turn also 
induces PPARɣ and subsequently adipogenesis (Daquinag et al. 2011). Sterol-
regulatory element binding protein 1c further activates a variety of genes together 
with PPARɣ and C/EBPPα. 
The morphological transformation of fibroblast-like shaped preadipocytes into 
more spherical preadipocytes is also a regulator of adipogenesis (Gregoire 2001). 
This shape changing leads to changes in ECM that promotes expression of C/EBPα 
and/or PPARγ (Gregoire 2001, Selvarajan et al. 2001). During the adipogenesis 
process, the number of mitochondria significantly increases (Wilson-Fritch et al. 
2003) to facilitate increased metabolic demands (Wilson-Fritch et al. 2004). 
At the terminal phase of differentiation, enzymes of triacylglycerol synthesis and 
degradation are activated and unilocular lipid storage is formed (Rosen et al. 2014, 
Gregoire 2001, Rosen et al. 2000). Expression of adiponectin (Flynn et al. 2008) and 
glucose transporter Glut4 are connected to the terminal stage of differentiation 
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(Gregoire et al. 1998). Adiponetin is a hormone that decreases the amount of FFA 
glucose and triacylglycerol in serum (Fruebis et al. 2001). Adiponectin is only 
expressed and secreted from adipose tissue (Kershaw et al. 2004). Another 
adipokine, leptin is produced and secreted mainly by mature adipocytes (Gregoire 
2001). FABP4 in adipocytes has been found to be a critical link between hormone 
action, lipid metabolism and cellular functions (Maeda et al. 2001, Furuhashi et al. 
2008). This is seen in the terminal stage of adipocyte differentiation where lipid 
accumulation elevates FABP4, which reduces PPARγ (Garin-Shkolnik et al. 2014) 
by triggering ubiquitination and subsequent proteosomal degradation of PPARγ 
(Rodriguez et al. 2007, van Beek et al. 2007, Yang et al. 2007). 
2.2 Characteristics of blood vessels 
Vascularization is essential for the growth and repair of organs and tissues. In 
adipose tissue, the vascular network needs to remodel itself in response to the 
shrinking or enlargement of the tissue to ensure sufficient blood flow to the tissue. 
Enlargement of the adipose tissue can be supported by new blood vessel formation 
(neovascularization) or by remodeling and dilating of the already existing capillaries 
(Christiaens et al. 2010).   
The majority of substance exchange in tissues occurs through capillaries. In blood 
vessel walls, endothelial cells act as a selective barrier between the blood stream and 
tissues (Goddard et al. 2013). Vesicular trafficking, complex junction rearrangements 
and refined cytoskeletal dynamics control the dynamic and sensitive regulation of 
endothelial permeability (Goddard et al. 2013). This allows substance exchange to 
be adjusted with regards to environmental changes, facilitates immune surveillance 
and enables the deposition of matrix proteins outside the vascular wall when repair 
is needed (Goddard et al. 2013). In addition to this barrier function, endothelial cells 
have also role in the control of haemostasis and vasomotor tone (Lehle et al. 2010). 
2.2.1 Cells and structure of blood vessels 
All blood vessels are lined with endothelial cells regardless of size. Mature 
vasculature also has recruited mural cells, deposited extracellular matrix and has 
organ-specific specialization of cells, such as surface receptors and inter-endothelial 
junctions.  
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Endothelial cells are stable cells, however during neovascularization the turnover 
time of endothelial cells is accelerated and can be as fast as 5 days (Kalluri 2003). 
Endothelial cells vary greatly in their gene expression profile and function depending 
on their location (Lehle et al. 2010). Markers of endothelial cells from different 
tissues have been identified and can be used to selectively isolate specific 
subpopulations. Endothelial cell markers include von Willebrand factor (vWf) 
antigen, CD31, CD144, vascular endothelial growth factor receptor (VEGFR) 2, and 
endothelial nitric oxide synthase (eNOS) (Lehle et al. 2010, Szoke et al. 2012). 
VEGFR2 is widely expressed in endothelial cells regardless of their source, but 
VEGFR3 expression is shown to be excluded from arterial cells (Lehle et al. 2010).   
Human umbilical vein endothelial cells (HUVEC) are widely used in vascular 
studies because they are relatively easy to obtain and culture. As they are derived 
from the umbilical vein, they are macrovascular cells. The morphology of endothelial 
cells is cobblestone-like (Szoke et al. 2012). The health condition of the umbilical 
cord donor from which HUVEC are obtained has been shown to influence function 
of the cells. HUVEC isolated from healthy newborns with type 1 diabetic mothers 
showed a 20–40% reduced resistance to shear stress, changes in plasma membrane, 
decreased rates of glucose uptake and an increase in the size of mitochondria, Weibel 
Palade bodies and rough reticulum (Lehle et al. 2010). HUVEC obtained from 
pregnancies resulting in healthy newborns with a family history of diabetes mellitus 
type 2 showed deficient nitric oxide synthesis and altered expression of eNOS 
mRNA (Lehle et al. 2010). For these reasons donors of primary cells for tissue 
engineering need to be carefully selected. 
The basement membrane surrounding endothelial cells in blood vessels is an 
approximately 50 - 100 nm thick specialized extracellular matrix that separates 
endothelial cells from surrounding tissue (Morris et al. 2014). The main components 
of basement membrane are collagen IV, perlecan, laminins and nidogens (Timpl et 
al. 1996, Halfter et al. 2013).  Basement membrane supports and stabilizes vessels 
but also helps control the permeability of capillaries (Senger et al. 2011).  
Pericytes are support cells that surround the endothelial layer and participate in 
regulation of blood flow at a capillary level (Sarkar et al. 2012, Stapor et al. 2014). 
Capillaries lack the smooth muscle layer present in larger blood vessels. However, 
pericytes express actin and desmin, which are two proteins important in smooth 
muscle function, and are able to contract (Sarkar et al. 2012, Stapor et al. 2014). 
Pericytes also influence vascular permeability by altering endothelial gene expression 
(Daneman et al. 2010).  
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Maturate networks are branched and capable of expanding to meet local, tissue-
specific demands (Jain 2003). Capillaries are the smallest blood vessels of the body 
consisting of a single layer of endothelial cells surrounded by basement membrane 
and pericytes (Jain 2003). The diameter of capillaries is about the same as that of one 
red blood cell (Ross et al. 2010), about 4-10 μm (Ko et al. 2007). Capillaries can only 
deliver oxygen and nutrients to a distance of up to 200 μm and thus angiogenesis is 
required to reach cells further away during new tissue formation (Carmeliet et al. 
2000). Two types of capillaries exist, fenestrated and continuous. Fenestrated 
capillaries are more permeable than continuous capillaries (Risau 1998).  
2.2.2 Angiogenesis 
The formation of blood vessels is a vital process in growth and organ development. 
Formation of new blood vessels can occur by two different processes; vasculogenesis 
and angiogenesis. In the embryo, a primitive vascular network is formed by 
vasculogenesis in which endothelial precursor cells form new vessels. The process 
where these vessels sprout is called angiogenesis and is the main mechanism of new 
blood vessel development in adult individuals. It creates a network of arteries, veins 
and capillaries which enable the exchange of gases and metabolites. To reach the 
organization of a fully functional vessel system, the immature vascular network must 
mature at the level of the vessel wall. This maturation involves recruitment of mural 
cells, deposition of extracellular matrix and organ-specific changes in cell features, 
such as surface receptors and inter-endothelial junctions (Carmeliet et al. 2011, 
Ucuzian et al. 2007).  
The basic method of angiogenesis consists of an increase in the number of 
endothelial cells, their migration through the extracellular matrix, intercellular 
junction formation, lumen formation, organization of perivascular cells, anastomosis 
with existing vessels, and finally the circulation flowing through the new blood vessel 
(Corvera et al. 2014, Carmeliet et al. 2011, Ucuzian et al. 2007). In order for the 
cascade of angiogenesis to occur, a wide range of pro- and anti-angiogenic factors 
(growth factors, chemokines, angiogenic enzymes, endothelial specific receptors, 
and adhesion molecules) are needed (Liekens et al. 2001).   
Angiogenesis is initiated, when endothelial cells detect angiogenic signals, which 
are released in response to hypoxic, metabolic or pathophysiological conditions by 
inflammatory, tumour or tissue specific cells (Carmeliet et al. 2011, Mammadov et 
al. 2011, Auerbach et al. 2003, Auerbach 2008). There are numerous angiogenic 
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factors involved in angiogenesis including fibroblast growth factors (e.g. FGF-2), 
vascular endothelial growth factor (VEGF), Angpt-1 (Ucuzian et al. 2007). The 
activated endothelial cells start releasing proteases such as MMP family members 
and the plasminogen activator system, which leads to basement membrane 
degradation (Ucuzian et al. 2007, Goding 2009). Due to the activity of MMPs, 
pericytes detach from basal membrane and ECM is degraded (Jain 2003, Carmeliet 
et al. 2011). Nitric oxide dilates vessels followed by VEGF increasing the 
permeability of the endothelial cell layer in existing vessel (Jain 2003, Carmeliet et al. 
2011). This leads to the release of plasma proteins out of the vessel and this leaked 
plasma serves as a matrix for endothelial cells as they move with the help of integrin 
interactions (Jain 2003, Carmeliet et al. 2011). One endothelial cell acts as a tip cell 
leading the endothelial cells according to signals such as VEGF receptors, 
neuropilins and Notch ligands DLL4 and JAGGED1 (Carmeliet et al. 2011). VEGF 
and other mitogenic signals also lead to the proliferation of endothelial cells thus 
providing enough cells to form the endothelial layer for new vessel branches 
(Corvera et al. 2014, Jain 2003). The action of VEGFs is controlled by the Notch-
signaling pathway, which is responsible for the responsiveness of endothelial cells to 
VEGFs. Thus, the development of angiogenic sprouts is mostly mediated by the 
dynamic interactions of VEGFs, Notch and their ligands (Corvera et al. 2014). The 
initiation of lumen development in newly developed endothelial cords is triggered 
by the apical-basal polarity of the endothelial cells (Charpentier et al. 2014).    
Immature vessels are stabilized in the final steps of angiogenesis by recruiting 
mural cells, either pericytes or smooth muscle cells, and by forming ECM (Ucuzian 
et al. 2007, Gerhardt et al. 2003). Four pathways have been recognized to be involved 
in the stabilization process. Transforming growth factor β induces genes, whose 
products are necessary for basement membrane formation (Holderfield et al. 2008).  
PDGF, PDGFR-β, sphingosine-1-phosphate-1 (S1P1) and endothelial 
differentiation sphingolipid G-protein coupled receptor 1 (EDG1) enable the 
recruitment of mural cells (Jain 2003, Carmeliet et al. 2011). The angiopoietin 1-Tie-
2 pathway signal further stabilization of endothelial cell–mural cell interactions (Jain 
2003).  
When sufficient neovascularization has occurred, the endothelial cells become 
quiescent, and the vessels remain, or regress, if no longer needed (Liekens et al. 
2001). This is induced by the down-regulation of angiogenic factors or increased 
local concentrations of angiogenesis inhibitors (Liekens et al. 2001).  
Due to the complex nature of the formation and maintenance of the vascular 
network, it is sensitive to disturbances caused by regulatory failures but also due to 
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external effects such as exposures to environmental chemicals. The results are seen 
in ischemia in myocardial infarction, neurodegenerative disorders and obesity-
associated disorders that are caused by inadequate vessel maintenance or growth 
causes (Potente et al. 2011). Excessive vascular growth or abnormal remodeling are 
linked to conditions such as cancer, inflammatory disorders and eye diseases 
(Potente et al. 2011). Moreover, failures in embryonic vascular development can 
cause various problems from benign vascular malformation to embryo lethality and 
congenital defects (Knudsen et al. 2011). Exposure to various chemicals can also 
lead to inhibition of the angiogenesis process (Toimela et al. 2017). The effect of 
angiogenesis influencing chemicals can be seen on multiple levels of angiogenesis 
(Knudsen et al. 2011). To identify an adverse outcome pathway for each type of 
vascular adverse outcome, the effects of known chemicals have to be studied on 
gene and protein expression level (remodeling, ECM interactions), cell level 
(motility, proliferation), organ level and whole organism level (Knudsen et al. 2011). 
Accurate and validated in vitro angiogenesis models are already available and shown 
to recognize angiogenesis and vasculogenesis inhibiting chemicals (Toimela et al. 
2017, Sarkanen et al. 2011).  
2.3 Obesity and adipose tissue 
Obesity and overweightness are associated with type 2 diabetes, multiple cancer 
types, sleep apnea, asthma, degenerative joint disease, hypertension, renal failure, 
stroke, and cardiovascular disease, gallbladder disease, respiratory disease, arthritis 
and gout (Pi-Sunyer 2009, Switzer et al. 2013, van Baak 2013). Understanding the 
mechanisms behind changes detected in adipose tissue biology during obesity is 
important as fat tissue acts as an endocrine organ that regulates systemic metabolism 
and hence influences the whole body (Kershaw et al. 2004).  
Obesity is characterized by an increase in the amount of adipose tissue and 
changes in adipose tissue metabolism caused by the increase. In rat studies obesity 
has been seen to develop first by enlargement of the existing adipocytes, hypertrophy 
and then by an increase in adipocyte numbers, hyperplasia (Cleary et al. 1979). When 
adipocytes enlarge they become insulin-resistant, hyperlipolytic and resistant to the 
anti-lipolytic effect of insulin (Ibrahim 2010). Visceral tissue contains more large 
adipocytes in contrast to subcutaneous, which contains more small adipocytes. Small 
adipocytes are more insulin-sensitive and have a high avidity for free fatty acid and 
triglyceride uptake, preventing their deposition in non-adipose tissue (Misra et al. 
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2003, Marin et al. 1992). Adipocytes of visceral adipose tissue are lipolytically more 
active than in subcutaneous in both lean and obese subjects (Van Harmelen et al. 
1997). As visceral adipose tissue drains directly into the portal vein system it 
contributes more to plasma free fatty acid levels, thus providing an important link 
between visceral adipose tissue and the developmental of insulin resistance and type 
2 diabetes (Van Harmelen et al. 1997). Due to these biological connections, the 
increase in visceral adipose tissue is more dangerous than an increase of 
subcutaneous adipose tissue. 
The growth of adipose tissue is supported by either new blood vessel formation, 
or by dilating and remodeling of existing blood vessels (Christiaens et al. 2010). In 
adipose tissue, angiogenesis can be a response to hypoxia caused by proliferation 
and/or adipocyte enlargement, or the result of developmental and/or metabolic 
signals in adipose tissue (Corvera et al. 2014). There are several studies supporting 
the role of hypoxia as a trigger for angiogenesis (Corvera et al. 2014, Trayhurn 2013, 
Pasarica et al. 2009). However, angiogenesis/vasculogenesis precedes adipogenesis 
and blood vessel ECM develops before adipose tissue ECM development in fetal 
development (Hausman et al. 2004).  
Hypoxia in expanding adipose tissue (Yin et al. 2009) also leads to accelerated 
apoptosis and necrosis in adipose tissue in obesity (Strissel et al. 2007). The 
enlargement of adipocyte cell size and increase in cell death are associated with 
chronic inflammation and insulin resistance in obesity. These in turn, inhibit 
adipogenesis of pre-adipocytes (Yin et al. 2009, Yun et al. 2002). The lack of 
sufficient vascularization further contributes to hypoxia and inflammatory responses 
in the adipose tissue of obese individuals (Ye 2011). 
Obesity leads to changes in the levels of adipokine secretion, and recruitment of 
macrophages that release pro-inflammatory cytokines such as tumor necrosis factor 
α, transforming growth factor b and IL-6 (Bastard et al. 2002). These increasing 
levels of cytokines contribute to obesity-associated complications including insulin 
resistance (Yue et al. 2005). In insulin-resistant obese humans and animals, leptin 
levels are increased (Tritos et al. 1997, Mantzoros et al. 1997) and adiponectin levels 
are decreased (Fasshauer et al. 2014). The reported anti-diabetogenic activity of 
leptin and adiponectin is based on their common capacity to enhance insulin action 
in both skeletal muscle and liver. In accordance with this anti-diabetogenic 
categorization, leptin administration to humans with severe lipodystrophy partially 
reverses their insulin resistance and hyperlipidaemia (Oral et al. 2002).  
In obesity, there is also an increase in the number of immune cells present in 
adipose tissue. Macrophage infiltration into adipose tissue has been shown to 
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temporally precede systemic insulin resistance in mice (Xu et al. 2003). However, T-
cell accumulation, impaired glucose tolerance and insulin sensitivity preceded 
macrophage accumulation in another mouse study (Kintscher et al. 2008). 
Macrophage infiltration has been shown to positively correlate to the size of 
adipocytes, with a higher presence of hypertrophic adipocytes as opposed to 
hyperplastic adipocytes (Wang et al. 2001).  
Lymphangiogenesis (formation of lymphatic vessels), a process similar to 
angiogenesis, is also linked to obesity and its modulation has also been proposed as 
a way of controlling obesity and related complications. The relationship between 
lymphatic vessels and obesity is bidirectional, e.g., defects in lymphatic function 
contribute to the development of obesity and vice versa. Impaired lymphatic 
function in mice has been shown to lead to activation of genes related to adipocyte 
differentiation and adipose tissue hypertrophy and proliferation (Aschen et al., 2012, 
Harvey et al. 2005). On the other hand, lymphatic function is impaired in obese 
patients (Scallan et al. 2015, Greene at el. 2012). Impairment of lymphatic vessels 
can lead to the development of lymphedema. Lymphedema results in a reduced 
ability to clear macromolecules within the interstitial space by the lymphatic system, 
which might have a role in the development of obesity related inflammation in 
hypertrophic adipose tissue (Arngrim et al. 2013). Due to the versatile interactions 
of adipose tissue and lymphatic vessels, VEGF-D, a growth factor inducing 
lymphangiogenesis, has been proposed as a treatment option for adipose tissue 
related complications. Overexpression of VEGF-D in adipose tissue in mice leads 
to enhanced glucose clearance, lower insulin levels, reduced liver triglycerides and a 
reduced number of macrophages in adipose tissue (Chakraborty et al. 2019). They 
also exhibited a more rapid and increased glycerol flux from adipose tissue, 
suggesting that lymphatic vessels take part in the clearance of glycerol from 
interstitial fluids (Chakraborty et al. 2019). 
2.4 Functions of insulin  
Insulin is a hormone secreted by the β cells of islets of Langerhans in the pancreas. 
Insulin maintains normal blood glucose levels by inducing cellular glucose uptake, 
modulating carbohydrate, lipid and protein metabolism, and increasing cell division 
and growth through its mitogenic effects (Wilcox 2005). Insulin is secreted from the 
pancreas in response to a rise in blood glucose levels in a bi-phasic manner; the first 
response is a rapid phase of insulin secretion (fed state), which is followed by a more 
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sustained and less intense release (basal state) of the hormone (Kahn et al. 1997). 
For insulin-dependent tissues such as muscle and adipose tissue, insulin is essential 
for the intra-cellular transport of glucose (Wilcox 2005). 
2.4.1 Effects of insulin on adipose tissue 
The regulation of adipose tissue metabolism is one of the central functions of insulin 
(Cohen 2006). Insulin signals the abundance of exogenous energy, which leads to 
suppression of fat breakdown and an increase in its synthesis in adipose tissue. When 
circulating glucose concentration is high, insulin binds to its receptor and causes the 
translocation of Glut4 from cytosol to the cell surface, which allows glucose 
transportation into adipocytes (Rutkowski et al. 2015, Watson et al. 2007). Insulin-
stimulated Glut4 is the predominant glucose transporter type in adipocytes although 
basal levels of the insulin-independent glucose transporter Glut1 is also present at 
the cell membrane of adipocytes (Rutkowski et al. 2015). Adipocyte-specific Glut4 
deletion in adipocytes has been shown to cause skeletal and hepatic insulin 
resistance, indicating that Glut4 mediated glucose uptake into adipocytes is critical 
in glucose homeostasis (Abel et al. 2001). Glucose is not only needed for ATP 
production but also for effective adipocyte lipid packaging (Bederman et al. 2009, 
Guan et al. 2002).  
Insulin stimulates the uptake of amino acids and glucose into adipocytes initiating 
signaling via effectors like phosphatidylinositol-3 kinase (PI3K) and AKT1/2 (Kim 
et al. 2004, Garofalo et al. 2003). Binding of insulin to the insulin receptor elicits 
autophosphorylation of the receptor, leading to binding of various scaffold proteins, 
including insulin receptor substrate proteins (IRS) (Taniguchi et al. 2006, Cohen 
2006). Phosphorylation of IRS1 leads to its association with the p85 regulatory 
subunit of PI3K. This association leads to the recruitment of the p110 catalytic 
subunit of PI3K to plasma membrane, resulting in conversion of 
phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate. 
This in turn, facilitates additional signaling events by binding to phosphoinositide-
dependent protein kinase (PDK) 1, PDK2 and AKT. Colocalization of PDKs and 
AKT leads to the activation of AKT by phosphorylation at Thr308 of PDK1 and 
Ser473 of PDK2, and phosphorylation of downstream targets such as glycogen 
synthase kinase-3 and the AS160 Rab GTPase-activating protein, which in turn 
interact with the small GTPase RAB10 to facilitate translocation of Glut4 to the cell 
surface (Sano et al. 2007). (Muoio et al. 2008) Hyperstimulation of adipocytes with 
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insulin has been shown to induce a negative feedback response, downregulating 
Glut4 by a protein kinase CK2-dependent mechanism (Ma et al. 2014). Insulin has 
also been shown to inhibit FABP4 release from adipocytes in vitro, in mice and in 
humans, and that FABP4 and insulin form an endocrine loop coordinating the β-cell 
response to obesity (Wu et al. 2014).  
In lipid metabolism, insulin promotes the synthesis and storage of triglycerides 
and inhibits their catabolism, lipolysis (Rutkowski et al. 2015, Watson et al. 2007, 
Choi et al. 2010b). The inhibition of lipolysis is achieved by activating 
phosphodiesterase 3B, which inactivates the function of cAMP (Choi et al. 2010b). 
Thus downstream activation of PKA, adipose triglyceride lipase and hormone-
sensitive lipase is inhibited (Choi et al. 2010b). Insulin inhibits lipolysis also indirectly 
through increased uptake of glucose (Rutkowski et al. 2015). Puryvate, a metabolite 
of glucose enters the citric acid cycle but a portion is also metabolized into lactate. 
As lactate exits adipocytes, it initiates an autocrine and paracrine lactate loop that 
mediates insulin-dependent inhibition (Ahmed et al. 2010). Formation of cAMP and 
down-stream activation of PKA is inhibited by lactate binding to the G protein-
coupled receptor GPR81, thus leading to the inhibition of lipolysis (Ahmed et al. 
2010).   
2.4.2 Effects of insulin on vasculature 
Insulin also has effects on vasculature. In conduit arteries insulin increases arterial 
plasticity/compliance and blood pressure; in resistance arterioles blood pressure and 
total blood flow to tissues; pre-capillary arterioles tissue perfusion, and capillaries 
exchanges of nutrients, oxygen and hormones between the plasma and tissue 
interstitium (Zheng et al. 2015). These effects are significant especially in resistive 
vessels and precapillary arterioles in fat tissue (Safar et al. 2013). Peripheral arteries 
are surrounded by more muscle cells and hence are more sensitive to the actions of 
insulin than central elastic arteries and arterioles, which have less muscle cells 
surrounding them.  
Vascular endothelial cells express insulin receptors, IGF-1 receptors and hybrid 
insulin/IGF-1 receptors. Binding of insulin to insulin receptors modifies the balance 
of vasodilation and vasoconstriction activities. Insulin signals vasodilation through 
the PI3K/AKT/eNOS signal pathway, which leads to an increase in the production 
and bioavailability of nitric oxide. The vasoconstriction by insulin is induced through 
endothelin-1 via the mitogen-activated protein kinase (MAPK) pathway (Muniyappa 
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et al. 2013). Nitric oxide production causes a decrease in vascular tone and vascular 
smooth muscle cell proliferation, adhesion of inflammatory cells and platelet 
aggregation to endothelium (Katusic et al. 2014). 
2.5 In vitro models as relevant research tools 
In vitro (in glass) cell studies are performed with cells outside a living organism, 
generally in flasks, Petri dishes, and cell culture well plates. In vitro cell models are 
developed for multiple reasons. Firstly, studies performed in animals do not exactly 
depict human biology and hence a relevant human model should be developed. 
Secondly, ethical reasons encourage the use and development of better in vitro models 
to reduce and replace the need for test animals (Hampshire et al. 2018, Mallia et al. 
2018, Franco et al. 2018). The use of in vitro models has also increased by the 
introduction of EU legislations such as REACH and cosmetics regulations 
(European Union 2010, European Union 2009, European Union 2006). However, 
the validity of in vitro models needs to be confirmed through characterization of cell 
identity, physiological architecture and functionality, after which formal validation 
should be performed to show repeatability, reproducibility and relevance for the 
intended purpose (Bale et al., 2014; Hartung, 2011, Environment Directorate 2005). 
When developing in vitro models, all aspects of the cell culture have to be carefully 
thought through. For developing relevant human cell models, the use of human cells 
is important. Especially so, when effects of tested chemicals might be caused by 
metabolites of the chemical (Ginis et al. 2004, Mestas et al. 2004, Rangarajan et al. 
2003). Moreover, an important advantage of in vitro models is the possibility to create 
patient-specific systems using patient derived cells. These personalized models could 
be used to explore treatment options and study disease mechanisms and metabolic 
parameters that vary between patients. 
Defined medium composition and the developmental stage of the model system 
are critical, especially when the test model will be used for chemical safety studies. 
Serum is not a necessary component as human MSC have been shown to maintain 
their immunophenotype and multilineage potential in serum-free medium 
(Patrikoski et al. 2013, Mark et al. 2013). Serum-free medium with xeno-free and 
defined supplements is critical for in vitro models to decrease variation between 
experiments due to unknown components in medium, and further, unknown 
binding properties of these components (Shen et al. 2013, Brunner et al. 2010, 
Gottipamula et al. 2013, van der Valk et al. 2010). 
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Biomaterials are also often used in in vitro cultures. Many biomaterials have been 
developed and used in tissue engineering (Choi et al. 2010a). These biomaterials are 
relevant especially in implantable tissue engineered applications. However, in 
toxicological studies the additional components such as biomaterial scaffolds may 
interfere with cell–cell interactions or cause unwanted and unknown interactions 
between materials and the studied chemicals or the cells in the system (Norotte et al. 
2009, Higgins et al. 2003, Williams 2008).  
Several in vitro models have been developed to mimic angiogenesis and vascular 
structures as well as adipogenesis and adipose tissue. Current models include 2D and 
3D culture systems and range from simple monocultures to models containing 
multiple cell types. Models of in vitro angiogenesis and vascular structures are 
presented in Table 1. For adipose tissue research, some vascularized adipose tissue 
models have been developed. Current human cell in vitro vascularized adipose tissue 
models are listed in Table 2.  
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Table 1.  Examples of different in vitro angiogenesis and vasculature mimicking cultures 
Assay Cells Biomaterial Serum Reference 
Collagen Assay Primary human endothelial cells 
(e.g., human umbilical vein 
endothelial cells or human coronary 
artery endothelial cells 
type I 
Collagen 
FBS (Evans 2015) 
Matrigel Assay Primary human endothelial cells 
(e.g., human umbilical vein 
endothelial cells or human coronary 
artery endothelial cells 
Matrigel FBS (Evans 2015) 
Gelatin assay Microvascular Endothelial Cells or 
human umbilical vein endothelial 
cells 
gelatine FBS (Bahramsoltani 
et al. 2016) 
Endothelial+ 
Fibroblast 
Coculture Assay 
Primary human endothelial cells 
(e.g., human umbilical vein 
endothelial cells or human coronary 
artery endothelial cells + Primary 
human fibroblast cells or The BJ 
human foreskin fibroblasts/human 
embryonic lung fibroblasts (HLF-1) 
none FBS (Sarkanen et al. 
2011, Evans 
2015, Bishop et 
al. 1999, Guo et 
al. 2014) 
Endothelial+ 
hASC or smooth 
muscle cell 
Coculture Assay 
primary endothelial cells + 
hASC/coronary artery SMCs and 
human aortic SMCs 
none FBS/ no 
serum 
(Merfeld-Clauss 
et al. 2010, 
Sarkanen et al. 
2012a), Original 
publication I 
3D spheroid  Clustered HUVEC collagen 
matrix 
not 
available 
Promocell, 
Heidelberg, 
Germany 
Microbead 
angiogenesis 
assay 
HUVEC cytodex-3-
microcarrier 
beads, 
collagen 
matrix 
FBS (Mombeinipour 
et al. 2013) 
Cryopreserved 
blood vessels 
Vessel cells - Fetal calf 
serum 
(FCS) 
(Muller-
Schweinitzer 
1994) 
Chip 
microchannels 
HUVEC + primary fibroblasta fibrin FBS (Ryu et al. 2015) 
In vitro vessels by 
bioprinted 
biomaterials 
Endothelial cells   (Song et al. 2014, 
Kim et al. 2017, 
Haase et al. 
2017) 
3D printing in 
vitro vessels with 
microfluidics 
HUVEC+murine fibroblast 10T1/2 
cells  
gelatin 
methacrylate 
FBS (Song et al. 2014, 
Kim et al. 2017, 
Haase et al. 
2017, Yang et al. 
2016) 
 
  
 38 
 
Table 2.  Existing ways of producing vascularized adipose tissue in vitro 
Cells Biomaterial Adipogenesis induction Serum Reference 
hASC +HUVEC silk scaffold 7 days: DMEM/F-12, 3% FBS, 1% 
penicillin–streptomycin, 33 μM 
biotin, 17 μM pantothenate, 1 μM 
insulin, 1 μM dexamethasone, 
500 μM IBMX, and 5 μM TZD  
FBS (Kang et al. 
2009) 
liquefied adipose 
tissue 
silk scaffold DMEM/F-12, 10% FBS, 1% 
abtibiotic-antimycotic, 1μM 
insulin, 500 μM IBMX, 1 μM 
dexamethasone, 50μM 
indomethacin 
FBS (Abbott et al. 
2016) 
human pre-
adipocytes+human 
endothelial cells 
fibrin Endothelial medium, 10% FCS, 
(±VEGF, FGF-2) 
FCS (Borges et al. 
2007) 
dermal fibroblast+ 
bone marrow MSC+ 
hASC+ HUVEC 
no DMEM-high glucose, 100 mm 
indomethacin, 500 mm IBMX, 
0.5 mg/ml insulin, 3 mm 
dexamethasone, 270 μm 
ascorbate 2-phosphate, and 10% 
FBS 
FBS (Sorrell et al. 
2011) 
hASC+microvascular 
endothelial 
no DMEM/F12, 3% FCS, 250 μM 
AA, 100 nM insulin, 0.2 nM T3, 
1 μM dexamethasone, 0.25 mM 
IBMX and 1 μM rosiglitazone  
FCS (Aubin et al. 
2015) 
 
hASC+HUVEC Collagen I/ 
alginate 
microspheres 
DMEM, 1 μM dexamethazone, 
0.5 mM  
IBMX, 10 μM insulin 
no (Yao et al. 
2013) 
 
hASC+dermasl 
microvascular 
endothelial cells 
Collagen I Adipocyte Basal Medium with 
high glucose, 1 μmol 
dexamethasone, 1 μg/mL human 
insulin, 500 μmol IBMX and 100 
μmol indomethacin, suppl. A 
no (Volz et al. 
2018a) 
 
2.5.1 Differences between human and animal adipose tissue 
A wide variety of animal models have been developed for studies of adipose tissue 
and obesity (Al-Awar et al. 2016, Lai et al. 2014). Although they have increased 
understanding of the basic biology of tissues and mechanisms behind diseases, 
animal models have ethical problems (Heinonen 2015, Chandrasekera et al. 2014, 
Al-Awar et al. 2016, Sade 2011).  
There is more and more evidence that the complex pathways of lipid metabolism 
are mostly species specific and results obtained translate poorly to humans 
(Chandrasekera et al. 2014, Al-Awar et al. 2016, Lai et al. 2014, Bergen et al. 2005). 
As adipose tissue and its metabolism differ so greatly between rodents and humans 
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(Chandrasekera et al. 2014), it is of special importance to find replacements for 
animal tests in adipose research. Differences are also seen in the mouse derived cell 
lines 3T3-L1 and 3T3-F442A, which undergo adipogenesis during in vitro culturing 
but lack the single large lipid droplet characteristic of mature in vivo adipocytes 
(Serlachius et al. 2004) and instead have a fibroblast-like phenotype (Sugihara et al. 
1987b, Sugihara et al. 1986). Additionally murine differentiated cells secrete only 1-
2% of the leptin secreted by primary mature adipocytes (MacDougald et al. 1995) 
and do not work in a similar manner in human and mice (Bowles et al. 2001). The 
correct endocrine functions are important in research models of adipose tissue as 
there is emerging interest in studying environmental chemicals and their impact on 
adipose tissue. Endocrine disruptor chemicals are one class of chemicals known to 
cause various health impacts by affecting endocrine organs including adipose tissue 
(Kabir et al. 2015).  
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3 AIMS OF THE STUDY 
The goal of this study was to develop an insulin sensitive vascularized adipose tissue 
model that could be used for biomedical research and chemical testing. The specific 
aims were the following: 
1. To develop a serum-free medium for inducing in vitro vasculature 
(angiogenesis model) based on the co-culture of hASC and HUVEC (I) 
2. To develop a differentiation method for producing insulin sensitive 
adipocytes (II) 
3. To develop a proof of concept model of vascularized adipose tissue; 
finding the optimal culture time, timing of adipogenesis induction and 
angiogenesis media, and timing of cell seeding. (III) 
4. To create a protocol for producing an insulin sensitive vascularized 
adipose tissue model by combining the optimal culture conditions, 
insulin sensitive adipocyte protocol and vasculature induced with serum-
free medium (IV) 
5. To confirm that the developed test model is suitable for testing chemicals 
by studying the effects of known chemicals on the model (IV) 
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4 MATERIALS AND METHODS 
4.1 Ethical considerations 
This study conforms to the principles outlined in the Declaration of Helsinki. 
Human adipose tissue samples were obtained from surgical operations and human 
umbilical cords were received from caesarean sections with individual written 
informed consent from Tampere University Hospital, Tampere, Finland. The use of 
hASC and HUVEC were approved by the Ethics Committee of the Pirkanmaa 
Hospital District, Tampere, Finland with the permit numbers R03058 and R08028, 
followed by permits R15161 and R15033, respectively. 
4.2 Materials 
Cell culture reagents: EGM™-2 Endothelial Cell Growth Medium-2 (EGM-2, 
Lonza Group Ltd), collagenase I (Invitrogen, Paisley, Scotland, UK), DMEM/F12 
(Gibco, Invitrogen, Carlsbad, CA, USA), human serum (Lonza Group Ltd, Basel, 
Switzerland), Human serum (PAA), L-Glutamine (Gibco), 3,3’,5-Triiodo-L-
thyronine sodium salt (T3, Sigma), Bovine serum albumin (BSA, PAA), BSA 
(Biosera (Boussens, France), BSA (Roche Diagnostics Corporation, Indianapolis, 
USA). Sodium puryvate (Gibco), ITS Premix (BD), Penicillin/streptomycin (Gibco), 
MycoAlert® Mycoplasma Detection Kit (Lonza Group Ltd); ascorbic acid (AA), 
heparin (HE) sodium salt from bovine intestinal mucosa and hydrocortisone (HY), 
Transferrin, Seleniuous acid purchased from Sigma; Vascular endothelial growth 
factor (VEGF, R&D systems), FGF-2 (R&D systems), Troglitazone (Trogl; Sigma-
Aldrich, St. Louis, MO, USA), Tryple™ express (Gibco), Ficol-paque plus (GE 
Health care, Buckinghamshire, UK), Triton-X100 (MP Biochemicals, Ohio, USA), 
PBS (Gibco), DPBS (Gibco), Chemically defined lipid concentrate (Life 
technologies, Carlsbad, CA), UpCell plates (ThermoFisher), insulin (Sigma). 
Chemicals: Rosiglitazone (Cayman Chemical), Chlorpyrifos (Sigma), Prochloraz 
(Sigma), Mancozeb (Sigma), Butylparaben (Sigma), 15-Deoxy-Δ12,14-Prostaglandin 
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J2 (Sigma), Bisphenol A (Sigma), Rt2 First Strand Kit (Qiagen), Bis-(2-Ethylhexyl) 
Phthalate (Sigma), Tributyltin Chloride (Sigma). 
Commercial analysis kits: Pierce™ BCA Protein Assay Kit (Thermo Scientific, 
Waltham, MA, USA), Cell Proliferation Reagent WST-1 (Roche Life Science, 
Indianapolis, IN, USA), AdipoRed Assay reagent (Lonza), Quantikine ELISA for 
adiponectin, leptin and aP2 (R&D Systems, Abingdon, UK), Human Total 
Adiponectin/Acrp30 Quantikine ELISA Kit (R&D Systems), Human Leptin 
Quantikine ELISA Kit (R&D Systems) and Human FABP4 Quantikine ELISA Kit 
(R&D Systems), EnzyChrom Adipolysis Assay Kit (BioAssay Systems, Hayward, 
CA, USA). 
FACS reagents: CD73, CD90 and CD105, eNOS- phycoerythrin IgG1 (PE, 
#560103), CD144-FITC IgG1 (#560411), CD73-Phycoerythrin-Cyanine IgG1 (PE-
CY7, #561258), CD309-PE IgG1 (#560872), CD68-FITC IgG2b (#562117), 
CD90-FITC IgG1 (#561969), CD105-V450 IgG1 (#561447), CD34-APC IgG1 
(#561209), CD140b-PE IgG2a (#558821), CD31-V450 IgG1 (#561653), CD45-PE 
IgG1 (#560975), CD14-FITC IgG1 (#561712). Isotype controls, Mouse IgG1-PE-
CY7 (#557872), mouse IgG1-PE (#559320), mouse IgG1-FITC (#555748), mouse 
IgG2b-FITC (#556655), mouse IgG1-V450-(#642268), mouse IgG1-APC 
(#550854), mouse IgG2a-PE (#551438) all from BD Biosciences 
(Erembodegem,Belgium); NG2-PE IgG1 (#FAB2585P), vWf-A2-allophycocyanin 
IgG2b (APC, #IC27641A) and mouse IgG2b-APC (#IC0041A) from R&D 
Systems. , BD™ CompBeads (BD). 
Commercial PCR related reagents: RNase-free DNase set (Qiagen), RNAeasy 
minikit (Qiagen), Human Angiogenesis RT2 Profiler™ PCR Array (Qiagen, 
Valencia, California, USA), PureLink RNA Mini kit (Ambion/Life Technologies), 
VILO kit (Invitrogen), PureLink DNase treatment (Life Technologies), RNA QC 
kit v2.0 (Qiagen, Venlo, the Netherlands), iScript cDNA synthesis kit (Bio-Rad, 
Hercules, CA, USA), iQTM SYBR Green Supermix (Bio-Rad), high sensitivity DNA 
analysis kit (Agilent Technologies, Santa Clara, CA, USA), ITaq universal SYBR 
green one-step kit (Biorad), 96.96 Dynamic Array Chip for Gene Expression 
(Fluidigm).  
Other reagents: [3H]-2-deoxy-D-glucose (Perkin Elmer, Waltham, MA, USA), 
OptiPhase HiSafe 2 oscillation liquid (Perkin Elmer), formaldehyde (Thermo Fisher 
Scientific), Fluoroshield™ with DAPI (Sigma), NucBlue™ Live ReadyProbes™ 
Reagent (Thermo Fisher Scientific). 
Equipment: Varioskan™ Flash Multimode Reader (Thermo Scientific), flow 
cytometer FACSCAnto II (BD), BioRad CFX96 Real Time System (BioRad 
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Laboratories, USA), Cell-IQ (Chipman tech., Tampere, Finland), μPlate (Thermo 
Fischer), QIAxcel Advanced (Qiagen), Agilent 2100 Bioanalyzer (Agilent 
Technologies), Fluidigm Biomark HD (Fluidigm), liquid scintillation counter 
Wallac1410 (Perkin Elmer), Nikon Eclipse inverted fluorescence microscope with 
Digital Sight DS-U2 camera (Nikon, Tokyo, Japan), LSM710 with Zeiss Axio 
Observer Z1 inverted microscope (Carl Zeiss, Oberkochen, Germany),  
Programs: BD FACSDiva™ Software (BD), CFX96 Real-Time System software 
(Bio-Rad), Microsoft Excel 2010 and 2013 (Microsoft Corporation, Redmond, WA, 
USA), Fluidigm’s BioMark Data Collection Analysis program (version 4.1.3), Cell-
IQ Analyzer (CM Technologies Oy), ImageJ software (National institutes of health, 
NIH, Maryland, USA), GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA, 
USA), PCR Array Data Analysis Web Portal 
(http://www.SABiosciences.com/pcrarraydataanalysis.php), ZEN 2012 software 
(Carl Zeiss), Adobe Photoshop CS3 software (Adobe Systems Incorporated, San 
Jose, CA, United States), NIS Elements (Nikon, Tokyo, Japan) 
4.3 Cells and extracts from primary tissues 
4.3.1 Isolation and culture of human adipose stromal cells (I,II, III and IV) 
hASC used in the study were heterogenous cell populations obtained by isolating 
stromal vascular fraction cells of human adipose tissue. hASC were isolated from 
human adipose tissue by using a mechanical and enzymatic procedure described 
previously (Sarkanen et al. 2012a). Briefly, human adipose tissue specimens were 
mechanically cut into small pieces and enzymatically digested with 0.15% collagenase 
I in DMEM/F12. hASC were cultured in hASC medium (Table 3). Cells were tested 
for mycoplasma contamination before experimental use. Seeding density of hASC 
was 20000 cells/cm2 for experiments, unless otherwise stated. hASC were used at 
passage 2 for experiments. 
4.3.2 Isolation and culture of human umbilical vein endothelial cells (I,III 
and IV) 
HUVEC used in the study were isolated from donated umbilical cords. HUVEC 
were isolated by cannulating the umbilical cord vein and infusing the vein with 0.05% 
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collagenase I as described previously (Sarkanen et al. 2011). HUVEC were cultured 
in EGM-2 Medium. Before use cells were tested for mycoplasma contamination. 
Seeding density of HUVEC was 4000 cells/cm2 and HUVEC were at passage 4 in 
co-cultures. 
4.3.3 Adipose tissue extract (II, III and IV) 
Adipose tissue extract (ATE) was produced as described previously (Sarkanen et al. 
2012b) but with a modification to the ratio of medium to fat. Briefly, the human 
adipose tissue sample was manually cut into small pieces. The sample was then 
incubated in DMEM/F12 containing 2 parts manually dissected fat and 3 parts 
DMEM/F12, for 24 h at 37 °C in 5 % CO humified atmosphere. This was then 
centrifuged at 200g for 3 min and liquid filtered through a 0.2-μm filter. The protein 
content of the extract was analyzed with a BCA kit using BSA as a standard. Results 
were measured after 30 min incubation at 37 °C at 562 nm. The ATE was stored at 
−20 °C until used. Batches were not pooled. 
4.3.4 Quality control of isolated cells (I) 
hASC were cultured in hASC medium for 6-7 days and HUVEC were cultured in 
EGM-2 medium for 3 days prior to surface marker expression analysis by flow 
cytometry. Flow cytometric analyzed 250,000 cells per sample. 
The cells were washed once with 1% BSA in PBS, centrifuged at 131 x g for 5 
min, after which they were stained either for intracellular markers (eNOS and vWf) 
or surface markers (all other studied markers available with FACS). Fixation and 
permeabilization were only performed when staining intracellular markers. The 
fixation was conducted in 2 % paraformaldehyde in PBS at room temperature (RT) 
followed by centrifugation of 500 x g for 5 min. Permeabilization was performed by 
10 min incubation in 0.1% Triton-X100 in PBS at RT followed by centrifugation of 
500 x g for 5 min. Cells were washed once or twice with 1% BSA before addition of 
antibodies. Labelled antibodies were added into cell suspension in cold 1% BSA and 
incubated on ice for 30 min in the dark. Cells were washed once with 1% BSA and 
twice with PBS. Surface marker stained cells were centrifuged at 200 x g for 5 min 
and intracellular marker stained cells were centrifuged for 5 min at 500 x g. Flow 
cytometry analysis was performed with cells suspended in ice cold PBS and 5000 
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events were analyzed per sample. Compensation was done with compensation 
particles. 
Positive expression was obtained by gating 98% of event isotype control results 
and then inverting the gate to obtain a percentage of positively stained cells in 
samples. The results were calculated as percentages with SD. 
For continuous quality control, hASC batches were analyzed for their expression 
of markers CD73, CD90 and CD105 before experimental use (Original publications 
II-IV) to ensure the isolated population fulfilled the minimal criteria set by The 
International Society for Cellular Therapy (Dominici et al. 2006). 
4.4 Differentiation methods 
4.4.1 Angiogenesis model i.e. vasculature component (I) 
Co-culture of hASC and HUVEC was established as described previously (Sarkanen 
et al. 2012a) but with the addition of serum-free angiogenesis medium. Different 
angiogenesis induction media were developed and tested to find the best medium 
composition for angiogenesis stimulation. The most optimal medium chosen and 
currently utilized in the model (Toimela et al. 2017) is depicted here. The time 
sequence of the culture protocol of the angiogenesis model and its control is 
depicted in Table 4. 
hASC were seeded in EGM-2 followed by seeding of HUVEC in EGM-2 
medium after 1-3 hours. The day after plating, angiogenesis medium was applied to 
the co-culture (see Table 3). Results were compared to previously used EGM-2 
induced vasculature and to the basal serum-free medium of the amgiogenesis 
medium (undifferentiated cells control).  
During the development of the angiogenesis medium, the concentrations of AA, 
HE and HY were optimized. The tested concentrations of AA were 0, 50, 100, 200, 
500, 1000 and 2000 μg/ml; of HY 0, 20, 200, 1000, and 2000 ng/ml and of HE 0, 
50, 500, 10000 and 50000 ng/ml. The co-cultures were grown for 6 days prior to 
analysis. Stimulation medium was changed once during the 6 day culture.  
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Table 3.  Culture media used in the study, their abbreviations and content. 
Medium Abbreaviation Content 
hASC  
medium 
hASCm DMEM/F12 
10 % Human serum  
2 mM L-glutamine 
Serum-free medium SFM DMEM/F12 
2.56 mM L-glutamine 
0.1 nM T3 
ITS Premix: 
  1.15 μM: 6.65μg/ml insulin 
  6.65 μg/ml Transferrin 
  6.65 ng/ml seleniuous acid 
1 % BSA 
2.8 mM Sodium puryvate  
ATE  
medium 
ATEm 1800 μg/ml ATE 
DMEM/F12 
10 %  Human serum 
2 mM  L-glutamine 
100 IU/ml Penicillin (50 IU/μl in III and IV) 
0.1 mg/ml streptomycin (50μg/μl in III and IV) 
Angiogenesis  
medium 
ANG Serum-free medium supplemented with 
200 μg/ml AA 
0.5 μg/ml HE 
5.5 μM: 2 μg/ml HY 
10 ng/ml VEGF 
1 ng/ml FGF-2 
Angiogenesis 
medium w/o insulin 
ANG -I DMEM/F12 
2.56 mM  L-glutamine 
0.1 nM T3 
6.65 μg/ml Transferrin 
6.65 ng/ml Seleniuous acid 
1% BSA 
2.8 mM  Sodium puryvate 
200 μg/ml AA 
0.5 μg/ml  HE 
2 μg/ml  HY 
10 ng/ml VEGF 
1 ng/ml FGF-2 
Adipogenesis/angiog
enesis medium 
ANG +T Angiogenesis medium supplemented with  
9 μM Troglitazone 
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Table 4.  Time sequence of the culture of the angiogenesis model, insulin sensitive adipocytes and 
vascularized adipose tissue and their control protocols. Ficol=Ficol Paque Plus 
Protocol name Day 0 Day 1  Day 3/ 
Day4  
Day 6/ 
Day7 
Day8 Day 10 Day 14 
Undifferentiated 
cells control for 
angiogenesis 
model 
seeding 
hASC & 
HUVEC in  
EGM-2 
SFM SFM analysis    
Previous 
angiogenesis 
model 
seeding 
hASC & 
HUVEC in  
EGM-2 
EGM-2 EGM-2 analysis    
Angiogenesis 
model 
seeding 
hASC & 
HUVEC in  
EGM-2 
ANG ANG analysis    
Undifferentiated 
hASC  
seeding 
hASC in 
hASCm 
hASCm SFM SFM - SFM analysis 
Previous 
adipocyte 
protocol 
seeding 
hASC in 
hASCm 
ATEm ATEm ATEm - ATEm analysis 
Insulin sensitive 
adipocyte 
protocol 
seeding 
hASC in 
hASCm 
ATEm ANG +T - - ANG -I analysis 
Undifferentiated 
cells control for 
vascularized 
adipose tissue 
seeding 
hASC in 
hASCm 
hASCm 
+ 25μl 
Ficol 
SFM 
+25μl 
Ficol 
HUVEC 
in  
EGM-2  
SFM 
+25μl Ficol 
SFM+25μl 
Ficol 
analysis 
Adipocyte 
control for 
vascularized 
adipose tissue 
model 
seeding 
hASC in 
hASCm 
ATEm
+25μl 
Ficol 
ANG+T 
+25μl 
Ficol 
 ANG+T 
+25μl Ficol 
(chemical 
exposure) 
ANG –I 
+ 25μl Ficol 
(chemical 
exposure) 
analysis 
Vascularized 
adipose tissue 
model 
seeding 
hASC in 
hASCm 
ATEm
+25μl 
Ficol 
ANG+T 
+25μl 
Ficol 
seeding 
HUVEC 
in  
EGM-2 
ANG+T 
+25μl Ficol 
(chemical 
exposure) 
ANG –I 
+25μl Ficol 
(chemical 
exposure) 
analysis 
4.4.2 Insulin sensitive adipocytes (II) 
To develop a protocol for insulin sensitive adipocytes differentiated from hASC, 
several media were tested with different combinations. Here the protocol producing 
the most promising adipocytes is depicted. 
hASC were plated in hASC medium (Table 3). The following day, differentiation 
began according to Table 4 utilizing differentiation media seen in Table 3. A 
combination of hASC medium and serum-free medium was used as the 
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Undifferentiated cell control and the Previous adipocyte protocol was used as a 
reference for the differentiation (Table 4). The total culture time was 14 days, except 
for the long-term culture, which was cultured for 12 weeks. For the long-term culture 
there were no medium changes after day 10. Due to the medium loss caused by 
evaporation, DMEM/F12 was added when needed and once a week 0.04 v/v % of 
a chemically defined lipid concentrate was added to supply energy. 
4.4.3 Combining vascularization and adipocytes (III) 
Several protocols were tested and compared for their ability to create vascularized 
adipose tissue. Protocols varied in cell number, cell plating time-point and the 
differentiation process (adipogenesis induced prior to angiogenesis or vice versa). 
Adipogenesis was induced with the ATE medium and angiogenesis with 
angiogenesis medium (Table 3). The most prominent from these two protocols were 
continued with and are presented in Table 5. Three types of controls were used: 
Undifferentiated hASC+HUVEC (Table 5), vasculature control i.e. Angiogenesis 
model (Table 4) and adipocyte control i.e. Previous adipocyte protocol (Table 4). All 
cells were seeded in EGM-2. HUVEC were seeded on top of hASC in a 50 μl aliquot, 
either on day 0 or day 7 depending on the protocol (according to Table 5). 
Differentiation media were changed on days 4, 8 and 11.  
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Table 5.  Plating and differentiation details of different protocols for combining vascularization and 
adipocytes 
Protocol name hASC  
plating 
 
Seeding 
density  
(cells/cm2) 
HUVEC  
plating 
Seeding 
density  
(cells/cm2) 
Medium  
on  
days 1-7 
Medium on  
days 8-14 
Undifferent-
iated hASC+ 
HUVEC 
Day 0 40000 Day 0 4000 SFM SFM 
P1  Day 0  
Day 7 
20000  
20000  
Day 7 4000 ATE m ANG  
P6  Day 0 20000  Day 0  4000  ANG ATEm 
4.4.4 Vascularized adipose tissue model (IV) 
Serum-free ANG medium and the differentiation media sequence of the Insulin 
sensitive adipocyte protocol were combined with the culture conditions of P1 to 
create optimized vascularized adipose tissue. P1 was optimized by lowering the 
number of seeded hASC to 20000 cells/cm2. For vascularized adipose tissue hASC 
were plated on day 0. On days 1, 4, 8 and 11 media were changed according to Table 
4. On day 7 HUVEC were plated after first removing 100μl of culture media from 
wells and then adding HUVEC in 100μl of EGM-2. Undifferentiated control 
contained hASC and HUVEC cells cultured in basic media corresponding to media 
used in the differentiation (Undifferentiated cells control for vascularized adipose 
tissue, Table 4). Adipocytes were differentiated with the Insulin sensitive adipocyte 
control protocol with the addition of one replenishment of medium and 
macromolecule ficol (Adipocyte control for vascularized adipose tissue, Table 4). 
Total medium volume used per well was 500μl and after each media change, Ficol-
paque plus was added to each well at 25μl per 500μl of culture media. The different 
media compositions can be seen in Table 3. Endpoint analyses were performed at 
day 14. 
4.5 Chemical exposure (IV) 
The effect of the nine chemicals Rosiglitazone, Chlorpyrifos prochloraz, Mancozeb 
(MANC), Butylparaben, 15-Deoxy-Δ12,14-prostaglandin J2, Bisphenol A, bis-(2-
ethylhexyl) phthalate and tributyltin chloride were studied for their impact on lipid 
accumulation, mitochondrial activity and amount of vasculature in the vascularized 
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adipose tissue. The effects of selected chemicals were compared between adipocytes 
and vascularized adipose tissue also at the gene expression level, in addition to the 
above mentioned analysis. Details of chemicals are found in Table 6. 
Chemical exposures were performed on day 8. After one week of exposure, 
analyses were performed. The purity of chemicals used was acknowledged when 
making dilutions. Vehicle controls for all chemicals were exposed to the same diluent 
concentration in which the chemicals were diluted. EC50 values were calculated 
using GraphPad Prism 6.05 software using the “log(inhibitor) vs. response - Variable 
slope” equation. 
Table 6.  Information and concentrations of chemicals used in this study. 
Chemical CAS number Concentrations tested Diluent 
15-Deoxy-Δ12,14-
prostaglandin J2 
87893-55-8 3,15;1;0,315;0,1;0,0315;0,01;0,
003;0,001 μg/ml 
0.5% DMSO 
BIS-(2-
ETHYLHEXYL) 
PHTHALATE  
117-81-7 100, 31.6, 10, 31.7, 1, 0.32, 0.1, 
0.0032 μg/ml 
0.5% DMSO 
Bisphenol A 80-05-7 99.4, 31.45, 9.95, 3.15, 0.5, 0.3, 
0.0995, 0.03 μg/ml 
0.5% DMSO 
Butylparaben 94-26-8 500, 158, 50, 16, 5, 1.5, 0.5, 
0.15 μg/ml 
medium 
Chlorpyrifos 2921-88-2 100, 31, 10, 3.1,  1, 0.3, 0.1, 
0.03 μM 
0.5% Ethanol 
Mancozeb  8018-01-7 0.5, 0.16, 0.05, 0.016, 0.005, 
0.0015, 0.0005, 0.00015 μg/ml 
medium 
Prochloraz 67747-09-5 5000, 1000, 500, 250, 50, 5, 
0.5, 0.05μM 
0.5% Ethanol 
Rosiglitazone 122320-73-4 139.9, 44, 14, 4.4, 1.4, 0.44, 
0.14, 0.044 μM 
 
0.5% DMSO 
TRIBUTYLTIN 
CHLORIDE 
1461-22-9 325.5, 103, 32.5, 10.3, 3.25, 
1.04, 0.33, 0.11 ng/ml 
0.5% DMSO 
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4.6 Analysis methods for both vasculature and adipocytes 
4.6.1 WST-1 (II, III, IV) 
WST-1 reagent was added to culture medium at a ratio of 10μl/100μl of medium on 
day 14. After 1.5 h (adipocytes and controls) or 1h (vascularized adipose tissue and 
controls) incubation at 37 °C in 5 % CO, the absorbance was measured at 450 nm 
as a multipoint measurement. 
4.6.2 PCR  (I, II, III, IV) 
For gene analysis by quantitative real-time PCR, cell cultures were washed with PBS 
and total RNA was extracted from cultures using an extraction kit following the 
manufacturer’s protocol. Genomic DNA contaminations were eliminated during 
RNA isolation with reagents suitable for use with RNA isolation kits. Reverse 
transcription of total RNA to cDNA was performed following manufacturer’s 
instructions for cDNA transcription kit use.  
Gene expression assessment of the angiogenesis model utilized the Human 
Angiogenesis RT2 Profiler™ PCR Array for 84 key angiogenesis related genes. The 
previous angiogenesis model was used as a control for expression change 
calculations in the web portal designed for the kit. A two-fold change compared to 
the housekeeping gene GAPDH was considered relevant. 
The analysis of adipocytes and controls was performed with the gene-specific 
primer pairs seen in Table 7. Relative gene expression results were calculated by 
normalizing Ct values with the geometric mean of two housekeeping genes SDHA 
and 36B4.  
For combining of adipocytes and vasculature, RNA was first analyzed for its 
purity by the 260/280nm absorbance ratio and quality of RNA samples was checked 
using QIAxcel. Primer concentration was 300 nM, and the amount of template was 
30 ng. Thermal cycling conditions were as follows: 95°C 3 min., 95°C 10 sec., 51–
65°C (gradient) 15 sec., 72°C 30 sec., repeated 40 times. Melt curve analysis was 
performed at 55–95°C (0.5°C increments/10 sec.). The quality of amplified DNA 
was studied with micro-capillary electrophoresis using a DNA analysis kit according 
to manufacturer’s instructions. The relative quantification of mRNA expression data 
was calculated using the ΔΔCt method with the following equation:  
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2(Ct(mean of housekeeping genes SDHA and 36B4, studied protocol)-Ct(Gene of interest, studied protocol))/ 
 2(Ct(mean of housekeeping genes SDHA and 36B4, control)-Ct(Gene of interest, control)) 
For expression analyses, the previous adipocyte protocol was used as a control.  
In the vascularized adipose tissue model, gene expression studies of insulin 
exposed cultures were performed by adding 500μM insulin for 24h prior to RNA 
isolation. A one-step PCR kit was utilized directly after RNA isolation using 30 ng 
of template and primers at a concentration of 300nM. Melt curve analysis was 
performed for each run. Results were calculated with the ΔΔCt method and 36B4 as 
a housekeeping gene. In calculations, unexposed and insulin exposed samples were 
analyzed using undifferentiated cells as the control and chemical exposed cultures 
were compared to corresponding vehicle controls. To inspect stage of vascular 
maturation in the model, a panel of 30 genes was analyzed with the fluidigm system. 
The details of the fluidigm analysis methods and primers used can be found in 
Original publication IV. 
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Table 7.  Primer sequences used in this study. 
Gene Primer sequence Publication 
used in 
36B4 Forward- ATGCTCAACATCTCCCCCTTCTCC 
Reverse- GGGAAGGTGTAATCCGTCTCCACAG 
 
II, III,IV 
ADCY5 Forward- TCTCCTGCACCAACATCGTG 
Reverse- CATGGCAACATGACGGGGA 
II 
Adiponectin Forward- GGCCGTGATGGCAGAGAT 
Reverse- CCTTCAGCCCGGGTACT 
 
II, III, IV 
FABP4 Forward- GCTTTTGTAGGTACCTGGAAACTT 
Reverse- ACACTGATGATCATGTTAGGTTTGG 
 
II, III, IV 
CIDEA Forward- GATGCCCTCGTCATCGCTAC 
Reverse- GCGTGTTGTCTCCCAAGGTC 
II 
Glut4 Forward- TGGGCGGCATGATTTCCTC 
Reverse- GCCAGGACATTGTTGACCAC 
 
II, III 
Leptin Forward- GCCCTATCTTTTCTATGTCC 
Reverse- TCTGTGGAGTAGCCTGAAG 
 
II, III 
PGC1-D Forward- GCTTTCTGGGTGGACTCAAGT 
Reverse- GAGGGCAATCCGTCTTCATCC 
II 
PPARγ Forward- GATCCAGTGGTTGCAGATTACAA 
Reverse- GAGGGAGTTGGAAGGCTCTTC 
 
II, III, IV 
PPARγ2 Forward-CAGTGTGAATTACAGCAAACC 
Reverse- ACAGTGTATCAGTGAAGGAAT 
III, IV 
Prdm16 
 
Forward- CGAGGCCCCTGTCTACATTC 
Reverse- GCTCCCATCCGAAGTCTGTC 
II 
RIP140 Forward- GGATCAGGTACTGCCGTTGAC 
Reverse- CTGGACCATTACTTTGACAGGTG 
II 
SDHA Forward- CATGCTGCCGTGTTCCGTGTGGG 
Reverse- GGACAGGGTGTGCTTCCTCCAGTGCTCC 
II, III 
UCP1 Forward- CAATCACCGCTGTGGTAAAAAC 
Reverse- GTAGAGGCCGATCCTGAGAGA 
II 
Glut4 Forward- CGT CGG GCT TCC AAC AGA TA  
Reverse- CAC CGC AGA GAA CAC AGC AA 
IV 
Leptin Forward- AGG GAG ACC GAG CGC TTT C  
Reverse- TGC ATC TCC ACA CAC CAA ACC 
IV 
PPARα Forward- GGC GAA CGA TTC GAC TCA AG 
Reverse- TCC AAA ACG AAT CGC GTT GT 
IV 
Glut1 Forward- GCT GTG CTT ATG GGC TTC TC 
Reverse- CAC ATA CAT GGG CAC AAA GC  
IV 
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4.6.3 Immunocytochemistry (I, II, III, IV) 
To visualize structures in the angiogenesis model, insulin sensitive adipocytes and 
vascularized adipose tissue model, immunocytochemical staining was performed. 
Angiogenesis models were fixed with 70% ethanol with a 20 min incubation at RT or with 
4% formaldehyde for 20 min at RT. After fixation, cells were permeabilized with 0.5% Triton-
X100 at RT for 15 min and non-specific binding sites were blocked with 10% BSA at RT for 
30 min. Primary antibodies were diluted with 1% BSA, applied to cells and incubated for 1h 
at RT or overnight at +4°C. Cells were then incubated with secondary antibodies diluted in 
1% BSA in DPBS for 40 min at RT. Washes between treatments were performed with PBS 
or DPBS. Nuclei were stained with DAPI in the bedding reagent (II, IV) and with NucBlue in 
the long-term culture of insulin sensitive adipocytes (unpublished). The antibodies used can 
be found in Table 8. 
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Table 8.  Antibodies used in immunostainings for this study 
Antibody 
Produced 
in Target 
Used 
dilution 
Product 
number, 
Manufacturer 
Public
ation 
anti- human von 
Willebrand factor IgG 
rabbit endothelial cell  1:100 F3520, Sigma I, III, IV 
anti- human smooth 
muscle actin (clone 1A4) 
mouse common pericytic 
marker 
1:200 M0851, DAKO I 
anti- human smooth 
muscle myosin heavy 
chain (clone hSM-V) 
mouse vascular smooth 
muscle cell marker 
1:800 M7786, Sigma I 
anti- human collagen IV 
(clone COL-94) 
mouse basement 
membrane marker 
1:500 C1926, Sigma I, III, IV 
 anti- human occludin 
(clone 1G7) 
mouse tight junctions 1:300 WH0004950M1, 
Sigma 
I 
anti- human vascular 
endothelial cadherin 
(CD144, Clone 55-7H1) 
mouse Vascular adherens 
junctions 
1:50 555661, BD 
Pharmingen 
I 
anti- human platelet 
derived growth factor 
receptor-β (clone PDGFR-
B2) 
mouse pericytic and 
smooth muscle cell 
progenitor marker 
1:800 P7679, Sigma I 
anti- human calponin 
(clone hCP) 
mouse contractile smooth 
muscle cell marker 
1:800 C2687, Sigma I 
anti- human collagen IV  Rabbit basement 
membrane marker 
1:500 ab6586, abcam IV 
anti- human CD140b-PE 
(Clone  28D4) 
mouse pericytic and 
smooth muscle cell 
progenitor marker 
1:24 558821, BD 
Biosciences 
IV 
anti- human CD144-FITC (
 Clone  55-7H1) 
mouse Vascular adherens 
junctions 
1:24 560411, BD 
Biosciences 
IV 
anti-rabbit IgG 
tetramethylrhodamine 
(TRITC) 
goat  1:50 T6778, Sigma I, III, IV 
anti-rabbit IgG A568  goat  1: 400 A11011, 
Invitrogen 
I 
anti-mouse IgG fluorescein 
isothiocyanate (FITC) 
goat  1:100 F4143, Sigma I, III, IV 
 
4.7 Analysis methods of the vascular network 
4.7.1 Quantitative analysis of vascular-like network formation (I, III and IV) 
Immunostained vascular networks were imaged using Cell-IQ with a 10x objective 
and 5x5 grid. Images were stitched together and converted to 8-bit gray scale, with 
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background subtracted and finally the binary threshold function was adjusted to 
obtain the best contrast of the vascular-like network against background. With these 
settings, the total area of the vascular-like network was calculated as the total number 
of pixels in images with a set threshold. For the analysis of tubules in vascularized 
adipose tissue, the protocol was optimized for size restriction and circularity 
exclusion to exclude the fluorescent adipocytes. 
4.7.2 Electron microscopy of vascular structures (I) 
The Angiogenesis model was cultured in 24-well UpCell plates for transmission 
electron microscopy (TEM) and on glass cover slips coated with 0.1% gelatin for 
scanning electron microscopy (SEM). Cells were washed twice with PBS prior to 
fixation. SEM specimens were fixed in 2% glutaraldehyde in 0.1 M phosphate buffer. 
TEM specimens were detached from the temperature sensitive plate and transferred 
to fixative with a 1% glutaraldehyde, 4% formaldehyde mixture in 0.1 M phosphate 
buffer for 10 min. The cell sheet was immersed in 2% agarose in distilled water. 
Details of the SEM and TEM imaging procedures can be found in Original 
publication I.  
4.8 Analysis methods of Adipocytes 
4.8.1 Triglyceride accumulation (II, III and IV) 
The triglyceride accumulation was determined using Adipored. The accumulation of 
triglycerides was analyzed from the same wells from which the WST-1 analysis was 
done by using Adipored according to the manufacturer’s instructions. Briefly, at the 
end point of cultivation, the culture was washed with DPBS. AdipoRed reagent 
diluted with PBS was added to the plate and after 10 min incubation at RT, 
fluorescence was measured as a multipoint measurement using the excitation 
wavelength of 485 nm and measuring emission at 572 nm. In order to quantify the 
amount of accumulated triglycerides per cell, Adipored values were divided by WST-
1 values. 
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4.8.2 Analysis of secreted proteins (III, IV) 
Media samples were analysed for their concentration of adiponectin, leptin and 
FABP4 secreted by adipocytes. Commercial ELISA kits were utilized according to 
manufacturer’s instructions. Absorbance was measured at 450nm and at 540nm 
(background signal). Sample concentrations were calculated from standard curves. 
To normalize results, the relative cell number i.e. WST-1 results were utilized.  
In the combination study Protocol 1 and Protocol 6 were compared to different 
controls due to the cytokine-rich composition of ATE, which is present in the 
medium of Protocol 6 at time point analysis. Protocol 1 was compared to medium 
sample of the angiogenesis model and Protocol 6 to the previous adipocyte protocol 
also containing ATE at day 14.  
4.8.3 Glucose uptake test (II, IV) 
To analyze glucose uptake in response to insulin, the following protocol was utilized. 
At day 14, DMEM/F12 was added to cells and incubated for 2h at 37 °C in 5 % CO. 
Cells were then exposed to 100 nM or 500 nM insulin and incubated at 37 °C in 5 
% CO for 30 min, and [3H]-2-deoxy-D-glucose at an amount of 0.2 μCi/well added 
for another 20 min. The cells were washed twice with ice-cold PBS and then lysed 
in 0.1 % sodium dodecyl sulfate (SDS). The radioactivity of samples was measured. 
If results were normalized total protein content was utilized. 
4.8.4 Inhibition of lipolysis (II, IV) 
For analysis of lipolysis inhibition of adipocytes in response to insulin, released 
glycerols were measured. At day 14, medium was removed, cells washed with PBS, 
and DMEM/F12 added to cells. After 1-2 hours, 2 μM Isoproterenol (Sigma) was 
added and incubated for 1.5-2h after which 100 nM or 500 nM insulin (Sigma-
Aldrich) was added. After 15 min, 30 min or 45 min incubation, medium was 
collected. The amount of glycerol released was assessed with an EnzyChrom 
Adipolysis Assay Kit according to manufacturer’s instructions. The fluorescence was 
measured at 530 nm and 585 nm. If results were normalized with total protein 
content, cells were lysed with 0.1 % SDS for the measurement of total protein 
content. 
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4.9 Statistical analysis (I, II, III, IV) 
Statistical analyses were performed and graphs processed with GraphPad Prism. The 
results were subjected to one-way or two-way ANOVA followed by Dunnett’s post-
test, Tukey’s post-test, Sidak’s multiple comparison test or Fisher’s LSD test 
depending on the materials in question. The results were reported as mean ± SD and 
differences were considered significant when p < 0.05*, p < 0.01** and p < 0.001***. 
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5 RESULTS 
The outline of the study is presented in Figure 1. The figure depicts the aims of the 
study, the models developed and the features utilized in the final vascularized adipose 
tissue model. 
 
 
Figure 1.  Outline of the study; aims, developed models and their features utilized in the vascularized 
adipose tissue. Blocks shaded with grey are in vitro models utilizable for e.g. biomedical 
and toxicological research. 
5.1 Cell quality control (I) 
Phenotypic characterization of hASC and HUVEC isolated from donor tissue 
samples was performed by flow cytometric analysis. The specific percentages of 
markers can be found in Original manuscript I, Table 2.  
hASC were shown to express mesenchymal stem cell markers (CD73, CD90 and 
CD105) and pericyte marker (PDGFR-β i.e. CD140b). The hASC population 
showed low expression of endothelial markers (CD144 and CD31) and 
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macrophage/monocyte markers (CD68 and CD14) and moderate expression of 
hematopoietic markers CD34 and CD45. According to minimal criteria for 
mesenchymal stem cells, they must 1) be plastic-adherent, 2) differentiate to 
osteoblasts, adipocytes and chondroblasts in vitro and 3) express CD105, CD73 and 
CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 
and HLA-DR surface molecules (Dominici et al. 2006). The population obtained 
with the isolation method used in this study fulfills the first and second criteria as 
shown in earlier studies. The results of this study show positivity for CD73, CD90 
and CD105, confirming presence of mesenchymal stem cells, but also shows the 
heterogeneous nature of the population as hematopoietic markers were higher than 
in a pure stem cell population. The isolated cell population was the whole stromal 
vascular fraction of the adipose tissue hence the presence of different stromal cell 
types is expected and desirable.  
To ensure the presence of stem cells in the cell population, quality criteria were 
set for the isolated hASC populations. Based on the results of flow cytometry, only 
batches expressing >50% of the positive markers CD73, CD90 and CD105 were 
accepted for use. 
The characterization of HUVEC showed the endothelial marker CD31 and 
specialized vascular endothelial marker CD144 were expressed at high levels. Also 
markers CD105 and CD73 were moderately expressed in HUVEC indicating the 
presence of precursor cells. The marker for macrophages/monocytes (CD68) and 
mural cells (NG2) were expressed at low levels.  
As vascular formation ability was the most important feature of HUVEC in this 
study, flow cytometric analysis was omitted from the quality control analysis of 
isolated HUVEC. The vascular formation ability of HUVEC batches was tested 
according to (Sarkanen et al. 2011).  
5.2 Angiogenesis model with serum-free stimulation medium (I) 
In original publication I, several different angiogenesis stimulation media were tested 
to find the one inducing the most optimal vascular formation in the hASC and 
HUVEC co-culture. The chosen medium was serum-free defined medium, which 
could be modified to a xeno-free composition if necessary.  
The developed angiogenesis medium contained AA, HE and hydrocortisone 
(HY) in addition to the angiogenic growth factors VEGF and FGF-2. The 
concentrations of VEGF and FGF-2 were optimized in the previous study (Sarkanen 
 61 
 
et al. 2011). The concentrations of AA, HE and HY were optimized (See original 
publication I, Fig. 2) and a dose dependent curve was obtained for AA, which 
stimulated angiogenesis at the lower concentrations and caused inhibition at higher 
concentrations (Fig. 2). The optimal concentrations for AA, HE and HY separately 
were AA 100 μg/ml, HE 50 μg/ml, and HY 0.2 μg/ml. After combining, the final 
optimized AA, HE, HY concentrations were AA 200 μg/ml, HE 500 ng/ml and HY 
2 μg/ml. The angiogenesis medium (ANG) produced a dense uniformly distributed 
vascular network with connected branches, and intact endothelial and basement 
membrane layers (Fig. 2).  
Comparison of vascular structures induced by EGM-2 and ANG at the mRNA 
level showed up-regulation of Angpt1, F3, FIGF, IGF-1, Leptin, MDK, MMP2, 
MMP9, PGF, and down-regulation of CCL11, CXCL9, FN1, IL-6, IL-8, 
SERPINE1, transforming growth factor B2, THBS2, TIMP1 in ANG. 
The electron microscopy images showed that the vascular structures were three 
dimensional (3D) tubules, contain lumen and are surrounded by extracellular matrix 
(ECM) fibers (Fig. 2). In addition, the presence of junctions, pericytes and other 
contractile vascular muscle cells was shown in the immunostaining results (Fig. 3). 
Immunostaining and electron microscopy analyses also showed that there is on-
going angiogenesis as the vascular structures were in different stages of maturation 
(original publication I).  
The ECM components seen in the electron microscopy were produced by the 
vascular structures thus creating a natural 3D scaffold. The interaction between the 
ECM and vascular network directs vessel growth (Hoying et al., 2014; Du et al., 
2014). This angiogenesis model provides an in vivo-like test system without added 
artificial scaffolding that could interfere with cell-cell interactions or affect 
toxicological applications of the model. 
 
 
 62 
 
 
Figure 2.  Results from the development of serum-free angiogenesis medium. A) The effect of different 
ascorbic acid concentrations on angiogenesis depicted as area of vascular structures in 
pixels. B) Electron microscopy images of vasculature. ECM=extracellular matrix, L= lumen) 
Scale bar in transmission image 2μm and in scanning image 1μm. C) Morphology of 
vascular structures in new Angiogenesis medium (ANG), commercial EGM-2 and in basal 
serum-free medium (SFM). Antibodies used are Collagen IV (FITC, green), vWf (TRITC, 
red) and the co-localization seen in the merged image. Scale bars 100 μm in each figure. 
Figure modified from Original publication I. 
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Figure 3.  Angiogenesis model induced with novel angiogenesis medium contains vascular smooth 
muscle cells (top row), pericytes (middle row) and adherens junctions (bottom row) around 
and inbetween endothelial cells stained with vWf. Scale bar 100 μm in each image. SMM= 
Smooth muscle myosin heavy chain, PDGFR-β= Platelet derived growth factor receptor β, 
ve-cadherin=vascular endothelial cadherin, vWf=von Willebrand factor. Figure modified 
from Original publication I. 
5.3 Insulin sensitive adipocytes (II) 
Several medium compositions were tested to find the optimal differentiation 
protocol for producing insulin sensitive adipocytes from a hASC monoculture in 
vitro. The most promising protocol (protocol 7 in original publication II), induced 
good lipid accumulation in adipocytes, which expressed mature adipocyte marker 
genes and responded to insulin with increased glucose uptake and inhibition of 
lipolysis (Fig. 4). In this protocol, hASC had a 3-day induction with ATE medium 
(ATEm), 6 days in serum-free medium supplemented with 1.15 μM insulin and 9.06 
μM Troglitazone (ANG+T), followed by 4 days in a defined serum- and insulin-free 
stimulation medium (ANG-I).  
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The developed protocol for insulin sensitive adipocytes induced lipid 
accumulation in fewer cells than the previously used ATE medium, but the size of 
lipid storage in individual cells was greater. hASC differentiated with this protocol 
consistently showed the highest and most stable expression of PPARγ, Glut4, AP2 
and adiponectin. Expression of leptin mRNA remained low.  
Glucose uptake by undifferentiated control cells and developed protocol 
adipocytes was studied by employing [3H]deoxyglucose (Fig. 4), with results showing 
a significant insulin-induced enhancement of glucose uptake at a 100 nM 
concentration of insulin in insulin sensitive adipocytes when compared to the 
undifferentiated control. The ability of insulin to inhibit lipolysis in undifferentiated 
control cells and adipocytes differentiated with the new protocol was analyzed by 
measuring glycerol released into growth medium after exposure of cells to 0, 100 or 
500 nM insulin. Inhibition of lipolysis in adipocytes was evident with 500 nM insulin, 
at all studied time points. 
To investigate whether the differentiation protocol selectively induced a brown 
or white adipocyte-like phenotype, gene expression typical for brown adipocytes, 
PRDM16, CIDEA, UCP1, and PGC1α (Shinoda et al. 2015, Seale et al. 2007) and 
white adipocytes, ADCY5, RIP140 (Knigge et al. 2015, Sawada et al. 2010, Maffei et 
al. 1995, Zhang et al. 1994) were studied. Gene expression analysis of white and 
brown adipocyte specific gene markers showed no specific tendency towards either 
adipocyte type; of the studied genes, all were expressed except RIP140, which was 
only marginally expressed.  
Under long-term culture, adipocytes continued to mature without additional 
differentiation agents. Adipocytes in long-term culture showed the typical 
morphology of mature adipocytes; one large lipid storage and the nucleus pushed to 
the side (Fig 5, unpublished data). 
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Figure 4.  Characteristics of insulin sensitive adipocytes. A) Confocal image of lipid staining with 
adipored reagent in undifferentiated cells and insulin sensitive adipocytes, nuclei stained 
with DAPI, scale bar 100 μm B) The differentiated insulin sensitive adipocytes showed 
expression of mature adipocytes, FABP4 and Adiponectin. C) Triglyceride accumulation 
quantification D) Inhibition of lipolysis by 500nM was seen with 15 min, 30min and 45min in 
insulin sensitive adipocytes. E) Glucose uptake was increased at 100nM insulin. ***p<0.001. 
Figure modified from Original publication II. 
 
 
Figure 5.  Phase contrast images combined with fluorescent images of long term culture of insulin 
sensitive adipopcytes at a) 3 weeks b) 4 weeks and c) 6 weeks. Insert of mature adipocytes 
seen especially from 4 weeks onwards. NucBlue was used for nuclei staining. Scale bar 
100μm. Unpublished data. 
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5.4 Combining vasculature and adipocytes (III) 
The order for induction of angiogenesis and adipogenesis, plating sequence of cells 
and cell numbers for the vascularized adipose tissue model were determined in 
experiments presented in original publication III. As a result, two protocols were 
selected as the best options for creating vascularized adipose tissue, although both 
needed additional optimization depending on the application used. Protocols P1 and 
P6 from study III were found to be the best options for combining vasculature and 
adipocytes. In protocol 1 hASC were plated on day 0 and day 7 giving a total of 
40000 hASC/cm2. HUVEC were plated on day 7. The adipogenesis was induced in 
the first week and angiogenesis the second week. In protocol 6, hASC and HUVEC 
were plated on day 0 and angiogenesis was induced during the first week of culture 
with adipogenesis during the second week. ATEm was used for adipogenesis 
induction and EGM-2 induction. 
Results showed both protocols accumulated lipids, formed extensive vascular 
networks, and also secreted ap2 and leptin (Fig. 6). The morphology of cultures 
showed less branching in P1 (Fig. 6F), which was seen in the total area of vasculature 
(Fig. 5B). Both protocols produced cultures expressing relevant adipocyte markers 
(Fig. 7).  P1 showed a higher expression of PPARγ, Leptin and Adiponectin whereas 
P6 showed a higher expression of aP2, PPARγ2 and Glut4. 
Adipogenesis and angiogenesis were both successfully induced. Different cell 
plating and differentiation protocols had a notable effect on the resulting cell model 
and its technical repeatability. The results showed the presence of vasculature helped 
pre-adipocytes mature in a shorter time than with induction of angiogenesis post-
adipocyte differentiation. However, in co-cultures where angiogenesis was induced 
first (P6), cells tended to detach easier from well plates than when adipogenesis was 
induced first (P1). This problem could be addressed with coating i.e. adding more 
attachment sites to culture vessels, however coating materials could potentially cause 
unwanted and unknown interactions between the studied cells or chemical assembly 
(Williams 2008). 
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Figure 6.  Characteristics of combined vascularization and adipocytes on day 14. A) Adipocyte control 
and both protocols P1 and P6 show lipid accumulation and B) vascular formation, although 
P1 produced significantly less tubules than the angiogenesis model or P6. The 
measurement of secreted proteins C) Adiponectin, D) leptin and E) FABP4 showed 
secretion of Leptin and FABP4 with both protocols and Adiponectin with P6. Secretion of P1 
was compared to the serum-free medium and P6 to the Previous adipocyte control to 
equalize the effect of the cytokine rich ATE used in adipogenesis induction. The bars 
represent means with SD. *p<0.05, **p<0.01 and ***p<0.001. F) Shows the morphology of 
the vascularized adipose tissue with protocols P1 and P6 on day 14. Lipids are seen in 
orange/red, tubules were stained with anti-vWf-TRITC (red) and anti-ColIV- FITC (green). 
Images were obtained with a Nikon Eclipse Ti-S inverted fluorescence microscope and with 
10x objective, scale bar at 100 μm. Figure modified from Original publication III. 
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Figure 7.  The expression of adipose tissue specific gene markers in the P1 and P6 protocols. 
Expression of the control (Previous adipocyte protocol) shown with a grey line. P1 showed 
higher expression of PPARγ, Leptin and Adiponectin. P6 showed higher expression of aP2, 
PPARγ2 and Glut4. P1 showed significantly increased expression of adiponectin compared 
to the adipocyte control. The bars represent means with SD. *p<0.05. Figure modified from 
Original publication III. 
5.5 Vascularized adipose tissue (IV) 
The serum-free ANG medium and differentiation media sequence of the Insulin 
sensitive adipocyte protocol were combined to create optimized vascularized adipose 
tissue. The culture conditions found to be optimal in P1 (14 day culture time, seeding 
hASC on day 0 and HUVEC on day 7, and inducing adipogenesis first followed by 
angiogenesis induction) were utilized here. Adipocytes were differentiated with 
Insulin sensitive adipocyte control with the addition of one replenishment of 
medium and the macromolecule ficol (Adipocyte control for vascularized adipose 
tissue). This same medium sequence was utilized for both angiogenesis and 
adipogenesis induction to produce the vascularized adipose tissue model.  
Results show that adipocytes in monoculture and optimized vascularized adipose 
tissue share similar general characteristics. The vascularized adipose tissue showed 
good lipid accumulation, proper vasculature and secretion of proteins FABP4, leptin 
and adiponectin. The secretion of adiponectin was significantly increased in 
vascularized adipose tissue compared to the corresponding adipocyte control 
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indicating the presence of more mature adipocytes in the vascularized culture. The 
lipid accumulation per cell seemed to be lower in adipocytes of the vascularized 
culture than in adipocytes alone, but the observation of lipid storage size could not 
be confirmed by quantitation. The quantitative results of lipid accumulation, vascular 
are and protein secretion can be seen in Original manuscript IV.  
The morphology of the vascularized adipose tissue can be seen in Figure 8. 
Vascularization formed in the vascularized adipose tissue model was analyzed by 
immunostaining and a panel of angiogenesis related genes, also in samples exposed 
to insulin. Staining showed CD144 i.e. ve-cadherin junctions located in the tubules 
and CD140b i.e. PDGFR-β on the surface of tubules (Fig. 8). Gene expression 
results show on going angiogenesis as well as mature tubules (Original publication 
IV, Tab. 3S). The individual genes that were up-regulated (2 fold or more compared 
to non-insulin treated cultures) in response to insulin were PDGF (0.67±0.52, with 
insulin 1.36±0.20), FGFR2 (3.34± 2.65, with insulin 7.43± 3.99) and ve-cadherin 5 
(0.69±0.58, with insulin 1.39±0.25).  
 
 
Figure 8.  Morphology of the vascularized adipose tissue. A) Lipids stained with adipored (orange), 
both adipocyte control and vascularized adipose tissue. B) Confocal immunostaining 
images: CD144 (green) i.e. ve-cadherin junctions can be found in the tubules stained with 
Collagen IV (red). Nuclei stained with DAPI (blue). Bottom row: CD140b (green) i.e. PDGFR-
β align along tubules (in red) indicating presence of pericytes. Scale bars 100μm. Figure 
modified from Original publication IV. 
The responses to insulin were studied in both adipocytes and the vascularized 
adipose tissue model to see whether there was a difference in the presence of 
vasculature. In gene expression analysis on the effect of insulin and vascularization, 
Glut1 was shown to be significantly down-regulated in response to insulin (Fig. 9A). 
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In addition, the trend of upregulation by insulin can be seen in Glut4 in both 
cultures. Expression of Leptin increased in the vascularized adipose tissue model in 
response to insulin. When comparing unexposed cultures of vascularized adipose 
tissue and adipocytes, significant upregulation of Glut1 and leptin was seen in 
vascularized adipose tissue (Fig. 9A). However, there was no difference between the 
cultures for secreted leptin (Original publication IV). Inhibition of lipolysis was 
found to be faster in the vascularized adipose tissue model. In vascularized adipose 
tissue, inhibition could be seen after 15min of 500 nM insulin concentration (Fig. 
9B) but in adipocytes alone, the response was seen after 30 min. Both cultures 
increased glucose uptake in response to insulin equally (Fig. 9C). 
 
Figure 9.  Insulin responses in adipocyte control and vascularized adipose tissue. A) Expression of 
the adipose tissue related genes Glut1, leptin and Glut4 in adipocytes with and without 
vasculature and with or without 500nM insulin. Glut1 and leptin are up-regulated in 
vascularized adipose tissue compared to adipocytes. Glut1 is significantly down-regulated 
in response to insulin. A trend towards upregulation by insulin can be seen for Glut4 in both 
cultures. B) Glucose uptake in response to insulin was equal in both cultures with 100nM 
and 500nM insulin. C) Significant inhibition of lipolysis was seen in the vascularized adipose 
tissue model after 15 min of 500nM insulin exposure whereas in adipocytes inhibition was 
only seen after 30 min. Figure modified from Original publication IV. 
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5.6 Effect of chemicals on vascularized adipose tissue (IV) 
The in vitro human vascularized adipose tissue model was exposed to nine chemicals 
(Rosiglitazone, Chlorpyrifos prochloraz, Mancozeb (MANC), Butylparaben, 15-
Deoxy-Δ12,14-prostaglandin J2, Bisphenol A, bis-(2-ethylhexyl) phthalate and 
tributyltin chloride). The exposure time was 7 days and were performed in the 
second week of culture. The effect of chemicals on lipid accumulation, 
mitochondrial activity/viability and vascularization was quantified. The results of 
these can be seen in Table 9. Both adipocytes and vascularized adipose tissue were 
exposed to three of these chemicals: rosiglitazone, prochloraz and chlorpyrifos and 
were also analyzed for gene expression.  Exposure to 4.4μM Rosiglitazone increased 
expression of FABP4 and adiponectin compared to the corresponding unexposed 
cultures in both adipocytes and vascularized adipose tissue (Fig. 10). Glut4 was also 
slightly up-regulated in both cultures. In the vascularized adipose tissue, the 
expression of leptin was also increased. Exposure to 50μM Prochloraz increased 
PPARα expression significantly in the vascularized adipose tissue and expression of 
other studied markers was lowered. Expression of leptin was significantly higher in 
vascularized adipose tissue exposed with 10μM Chlorpyrifos than in adipocytes. 
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Figure 10.  Adipocytes and the vascularized adipose tissue model exposed to 4.4μM rosiglitazone, 
50μM prochloraz and 10μM chlorpyrifos. A) Rosiglitazone increased expression of FABP4 
and adiponectin compared to the corresponding unexposed cultures in both adipocytes 
alone and with vascularization. Glut4 was also slightly up-regulated in both cultures. In the 
vascularized adipose tissue model the expression of leptin was also increased. B) 
Expression of PPARα increased in vascularized adipose tissue after exposure to 50μM 
prochloraz. Other markers were down-regulated.C) Leptin expression increased in 
vascularized adipose tissue in response to 10μM Chlorpyrifos. Grey lines indicate the level 
of unexposed corresponding cultures. Figure modified from Original publication IV. 
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Table 9.  The results of the chemical exposures of vascularized adipose tissue. 
Chemical 
EC50 
Mitochondria 
activity 
Effect on 
mitochondria 
activity 
EC50 lipid 
accumulation 
Effect on 
adipogenesis 
Effect on 
Angiogenesis 
Rosiglitazone - no effect - weak stimulator 
increase with 
0-1.4μM 
Prochloraz 181.6 μM decrease 187.2 μM decrease no effect 
Chlorpyrifos 73.51 μM increase - inhibitor & increase no effect 
Mancozeb  
90.24 μg/ml decrease 84.01 μg/ml inhibitor 
increase in 
non-toxic 
concentrations 
Butylparaben 433.8 μg/ml decrease 340.8 μg/ml inhibitor no effect 
15-Deoxy-
Δ12,14-
prostaglandin 
J2 
2.675 μg/ml increase 0.1038 μg/ml inhibitor 
increase in 
higher 
concentrations 
Bisphenol A 
65.3 μg/ml decrease 0.5442 μg/ml inhibitor 
increase in 
higher non-
toxic 
concentrations 
Bis-(2-
ethylhexyl) 
phthalate  
0.1634 μg/ml decrease 0.03 μg/ml and 10μg/ml 
inhibitor 
(biphasic 
effect) 
significant 
increase 
Tributyltin 
chloride 106.2 ng/ml increase 312.8 ng/ml Stimulator 
inhibition in 
lower 
concentrations 
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6 DISCUSSION 
6.1 Building blocks of in vitro models 
The development of in vitro cell models aims to develop as in vivo-like tissues as 
possible in vitro. This was the goal also in the development of the models presented 
in these studies (I, II, III, IV). Several aspects have to be considered in order to 
succeed. In vivo tissues get multiple signal types from their surroundings; soluble 
factors (nutrients, growth factors, hormones, O2 and CO2, Ca2+, Mg2+), cell-cell 
interactions (density, confluence, cell junctions), cell-matrix interactions (physical 
and chemical characteristics of a matrix, charge configuration, composition of extra 
cellular matrix) and cell architecture and polarity (basolateral nutrient supply) 
(Brunner et al. 2010, Duval et al. 2017).  
In vitro models are still far from reaching the exact and optimal growth 
environment of cells corresponding to an in vivo environment, but the field is 
evolving and more complex culture systems are continuously developed. In vivo cells 
are in a 3D matrix and usually have cell-to-cell contact with a variety of cell types 
(Novakofski 2004). 3D models help to bridge the gap between animal models and 
2D in vitro models (Turner et al. 2014, Kang et al. 2007, Wang et al. 2009). The 
angiogenesis model developed in study I was shown to contain 3D tubule structures. 
These are valuable as they can function as a natural 3D scaffold for other cell types, 
including adipocytes (III, IV). Although the models developed here were closer to 
2D than 3D models, they contain 1) multiple stromal cell types due to the 
heterogeneity of hASC and hence have cell-cell interactions with relevant cell types, 
2) cell-matrix interactions with the ECM produced by these cells as shown in study 
I, and 3) the 3D structure of vasculature showing the correct architecture in these 
models (I).   
The fact that some disease characteristics have only been detected in 3D, but not 
2D cell culture systems supports the use of 3D models (Girandon et al. 2011, Lowe 
et al. 2011, Turner et al. 2014, Cukierman et al. 2002). Often 3D culture models 
contain a complex biomaterial scaffold into which cells are seeded, but they can also 
be spheroid cultures with or without biomaterial. On the other hand, the less 
exogenous substances, such as biomaterials, added into a culture, the more 
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controlled the environment and thus more is known about the interactions taking 
place in the culture. The cultures in this study are free from exogenously added ECM 
proteins (I, II, III, IV). This way also additional unknown interactions between 
biomaterials and the studied chemicals can be avoided, also avoiding interference to 
cell-cell interactions. The natural scaffolding provided by vasculature brings cultures 
closer to an in vivo environment without the need for artificial scaffolds.  
Although the focus of this study was high-throughput testing, the aim was still to 
form as in vivo-like a tissue as possible, keeping in mind their applicability for 
toxicology testing. This means all components in cultures should be defined and not 
cause unknown interactions with tested chemicals. By connecting different in vitro 
tissues through a blood circulation mimicking medium system, more complexity is 
obtained, while still maintaining high-throughput. The adipocytes (II) and 
vasculature (I) presented here can be cultured together as shown, or separately in 
chip chambers using the developed serum-free medium, which was shown to be 
suitable for angiogenesis and adipogenesis induction (III, IV). In addition, other cell 
and tissue types can also be added to these types of systems to create multi-tissue 
culture systems.  One obstacle in compiling complex multi-tissue cultures has been 
the development of a suitable universal media to connect the different tissues. In 
order to combine two or more tissues in the same culture, suitability of the medium 
for all cell types is crucial. The serum-free medium developed in study I would be a 
good candidate as a universal medium, as it can also be modified easily according to 
the needs of specific applications.  
6.2 Role of cells in tissue models 
Cells are the most important components in in vitro cultures. Primary cells have many 
favorable characteristics even though they have also disadvantages. When working 
with primary cells one can be sure of the right characteristics of that cell type 
compared to in vivo. However, primary cells can quickly lose their characteristics 
when cultured ex vivo. These cells can secrete an extracellular matrix in vivo, but this 
ability decreases according to number of cell passages. Moreover, primary cells suffer 
from batch to-batch variations, causing discrepancy in results. For these reasons, the 
same cell passage number should always be used in experiments and relevant quality 
controls like expression of key markers and functions relevant to cell type are needed 
to ensure reproducibility.  
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Primary HUVEC were utilized in these studies as the endothelial cell population 
(I, II, III, IV). In primary HUVEC, along with an increase in passage number, the 
expression of eNOS is decreased (Shi et al. 2004) and migration ability decreases 
(Liao et al. 2014), hence the passage number used in this study was fixed at 4 (I, II, 
III and IV). An alternative for primary cells would have been the use of endothelial 
cell lines. However, endothelial cell lines for example have been seen to respond 
poorly to cytokines (Lidington et al. 1999), express integrins differently compared to 
primary endothelial cells (Baranska et al. 2005), have different regulation of cell 
proliferation and apoptosis (Boerma et al. 2006), and immortalized endothelial cells 
can also be incapable of migration and tube formation in vitro (van Beijnum et al. 
2008). Although the use of HUVEC, large vein endothelial cells, has been criticized 
in small vessel models, they are well characterized and an easily obtainable primary 
cell type. The use of tissue specific endothelial cell sources should also be considered 
for more relevant in vitro vasculature. 
In study I, phenotypic analysis of the building blocks of the vascular model, i.e., 
hASC and HUVEC, was performed using flow cytometry. High expression of the 
endothelial markers CD144 and CD31 was shown to be present in the HUVEC 
population. We showed that HUVEC have a strong expression of CD105 (endoglin), 
which has been shown to have a significant role in VEGF-induced angiogenesis (Liu 
et al. 2014). The level of CD73, which suppresses pro-inflammatory responses in 
human endothelial cells (Grunewald et al. 2010) was high in our HUVEC and the 
population did not show presence of macrophages/monocytes (CD68). Pericyte 
marker NG2 was also low, indicating the absence of mural cells in the HUVEC 
population. Based on these marker expressions, the endothelial population lacked 
immune and mural cells. 
The use of adipose stem cells was easily justified through the aim of creating 
vascularized adipose tissue. In addition, the use of HUVEC and hASC in 
angiogenesis models was reported earlier (Traktuev et al. 2008, Merfeld-Clauss et al. 
2010, Sarkanen et al. 2012a). hASC have been shown to secrete angiogenic and 
antiapoptotic factors (Rehman et al. 2004). Study I confirms that the stromal-
vascular fraction extracted from adipose tissue is heterogenic. The expression profile 
of hASC indicated the presence of cells with multilineage differentiation potential 
(CD90, CD105 and CD73) (Dominici et al. 2006) and pericytes (CD140b), and a 
lack of mature endothelial cells (CD31 and CD144), macrophages and monocytes 
(CD68 and CD14). There was a moderate expression of CD34, which has been 
shown to be expressed in endothelial progenitors (Yang et al. 2011). A hASC 
population of CD90+/CD34+ cells was shown to be capable of differentiating into 
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endothelial cells and form capillary-like structures (De Francesco et al. 2009). 
Interestingly, there was also a report suggesting adipose stromal cells may enhance 
endothelial differentiation of progenitor cells (Rubina et al. 2009). These further 
defend the use of hASC in in vitro formation of vasculature. As CD142 has been 
shown to negatively influence the adipogenesis potential of hASC (Schwalie et al. 
2018), this marker should be added to routine quality testing panels of hASC 
populations to be used for adipogenesis studies. The use of heterogeneous cell 
populations however, is one way to add complexity and in vivo-likeness to cultures 
and hence it might not be beneficial to sort unwanted cell types, but rather note the 
differences in different batches of cells. The heterogeneity of the hASC population 
adds multiple vascular stroma cell types including contractile cells and fibroblasts to 
the angiogenesis model (I), thus allowing the model to depict vascularization and its 
surroundings better than a homogenous stem cell population. 
6.3 Induction of angiogenesis 
To achieve relevant biological aspects and good experimental reproducibility, the 
composition of the cell culture medium is essential. The development of 
angiogenesis stimulation medium in study I was conducted by testing multiple 
stimulation media compositions of which the most optimal was chosen to be used 
in the angiogenesis model for the induction of vascular formation. The criteria for 
the most optimal medium were that it induced extensive reproducible vascular 
network formation and that the vascular structures showed in vivo vascular markers 
and morphology; an intact endothelial layer, lumen, basement membrane, 3D tubule 
structure, junctions and pericytes. Exclusion criterion for stimulation medium 
candidates was over induction of endothelial cells i.e. the formation of cell clumps, 
which contain an extremely dense vascular network. These cannot be analyzed 
reliably and hence the stimulation medium should not produce these cell aggregates.  
The development of new induction medium for angiogenesis showed that serum-
free media produced an extensive vascular network in the hASC and HUVEC co-
culture system (I). When creating a defined medium, the replacement of serum is the 
first step as serum contains unknown concentrations of unknown molecules, which 
bind different chemicals differently (Shen et al. 2013). For the testing of chemicals 
in vitro model media has to be defined to know all possible interactions between 
chemical and media components. Also, guidelines for good cell culture practice 
(GCCP) and the ECVAM Scientific Advisory Committee (ESAC) recommend the 
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use of serum-free media (Coecke et al. 2005, ESAC 2008). A serum-free medium 
database has also been set up to ease the transition away from the use of animal 
serum (Brunner et al. 2010). In the clinical application of cells, regulations have to 
be followed carefully and the use of a defined medium is especially important to 
avoid the risk of unknown components causing unknown reactions including 
infections and severe immune reactions in the recipient. Successful efforts have been 
made to develop serum-free media and freezing protocols to ensure the safety of 
cells used in cell therapies (Patrikoski et al. 2013, Heathman et al. 2015, 
Oikonomopoulos et al. 2015, Holm et al. 2010).  
In study I, serum was replaced with supplements found in blood in vivo including 
albumin and transferrin. All these are relevant supplements with specific purposes 
in human blood. Albumin has multiple physiological effects; it carries vitamins, fat 
(fatty acids, cholesterol), drugs and hormones, regulates colloid osmotic pressure, 
antioxidant properties, nitric oxide modulation and has buffer capabilities (Vincent 
2009, Vincent et al. 2014). Transferrin carries iron in the blood and delivers it to cells 
(Luck et al. 2012).  
In order to create an in vivo mimicking human in vitro model, the medium used in 
the model should be xeno-free. The medium developed in study I contains bovine 
serum albumin and heparin of bovine origin, but these can be replaced with human 
albumin or recombinant human protein. Only after these replacements could the 
produced vasculature be considered for clinical use in humans in for example 
implants. 
The components of the final defined serum-free angiogenesis induction were 
general angiogenic factors and vasculature related supplements VEGF, FGF-2, HY, 
HE and AA (I). VEGF and FGF are well known angiogenesis and vasculogenesis 
inducing growth factors and hence also targets of therapies aiming at influencing 
angiogenesis (Keifer et al. 2014, Goel et al. 2011, Li et al. 2014, Chae et al. 2017). 
Although hydrocortisone is not pro-angiogenic itself, it has a beneficial effect on 
angiogenesis (Goding 2009), but in excess can cause health effects like those seen in 
Cushing’s syndrome with impairment of microvascular reactivity (Prazny et al. 2008). 
HE has been shown to induce angiogenesis (Rema et al. 2012), likely due to its effect 
on VEGF165 (Ashikari-Hada et al. 2005). The importance of AA (vitamin C) on 
human health has been known for a long time (Hodges et al. 1971). AA is an essential 
nutrient for human endothelial cells as it is needed for their effective migration as 
well as for the synthesis of collagen type IV, an important component of basement 
membrane of blood vessels (Telang et al. 2007, Hodges et al. 1971). The angiogenesis 
process requires this deposition of mature type IV collagen in the basement 
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membrane. The correct folding of type IV collagen is dependent on the 
hydroxylation of proline by the iron-dependent enzyme prolyl hydroxylase, which 
requires AA to reduce iron to its ferrous state for reactivation of the enzyme (Myllyla 
et al. 1978). Hence AA is important for the formation of vascular structures. 
Along with the optimization of supplements, results showed that AA caused a 
dose dependent induction and inhibition of the vasculature (I). High concentrations 
of AA have been shown to inhibit angiogenesis (Mikirova et al. 2008). This inhibition 
of angiogenesis by AA has been shown to also inhibit tumor growth, with the use of 
high concentrations of AA proposed as a possible therapeutic strategy for treating 
cancer (Yeom et al. 2009). Due to the importance of AA on basement membrane 
formation, the depletion of AA has also been suggested as a cancer treatment 
strategy through angiogenesis (Telang et al. 2007). 
T3 was also a component of the novel serum-free medium developed in study I. 
It is a hormone produced by the thyroid gland, which stimulates the metabolic 
breakdown of glucose, fats, and proteins by inducing an increase in levels of various 
metabolic enzymes, including liver glucose 6-phosphatase, hexokinase, and 
mitochondrial enzymes for oxidative phosphorylation (Michienzi et al. 2007). T3 has 
been shown to be especially important in muscle cell differentiation (Muscat et al. 
1994) and protection against calcification of vascular smooth muscle cells (Chang et 
al. 2016). Based on these effects on muscle cells, T3 likely enables the presence of 
contractile cells around vascular structures. 
6.4 In vitro angiogenesis and tissue engineered vascular 
structures 
Due to the importance of vasculature, tissue engineered solutions have been created 
in vitro and in vivo for clinical needs and research purposes. As the current study is 
focused on in vitro angiogenesis research, in vitro angiogenesis models and vasculature 
are discussed further. 
The in vitro tissue engineered vessels, seen in Table 1, are usually cultured using 
macrovascular or microvascular endothelial cells isolated from human, murine, or 
bovine vessels. Endothelial cells can be grown alone on biomaterial or with another 
cell type (fibroblast, stromal cell) present, with or without biomaterial. In these 
studies we chose the macrovascular endothelial cell HUVEC as the endothelial cell 
type along with hASC to enable the presence of the relevant stroma cell population 
(I, III, IV). 
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Surprisingly many vascular constructs are still grown in the presence of serum 
from animal sources, although serum could be replaced as discussed above.  
Cryopreserved human microvascular structures, cell spheroids, and vascularized 
organ chips are 3D and more complex alternatives for vascular research. In recent 
years the development of tissue engineered vessels has shifted in developing these 
more complex vascular cultures utilizing 3D printing, lithographic microfabrication, 
microfluidistics and biomaterial scaffolds. 
The vasculature formed in study I had the morphology of in vivo vessels including 
an intact endothelial layer, basement membrane, 3D tubules with lumen, ECM 
proteins and surrounding pericytes. Endothelial shape changes and the resulting 
lumen formation is critical for the transformation of pre-vascular cords into a 
perfusable vascular system (Strilic et al. 2009). Lumen development is triggered by 
apical-basal polarity of endothelial cells in which CD144 plays a critical role in 
promoting the localization of polarity markers (Charpentier et al. 2014). Adipose 
stromal cells secrete factors that induce endothelial cell sprouting and lumen 
formation (Traktuev et al. 2008, Rubina et al. 2009). The presence of supporting 
stromal cells also enhances vascular basement membrane and lumen formation 
(Merfeld-Clauss et al. 2010, Newman et al. 2013, Stratman et al. 2009). Changes in 
ECM stroma and the interaction between stroma and vasculature are important in 
directing vessel growth (Hoying et al. 2014, Du et al. 2014). 
In study I, the vascular network was shown to be reproducible and extensive. The 
comparison of vascular structures induced by EGM-2 and ANG at an mRNA level 
showed some differences in the expression of angiogenic marker genes (I). These 
changes did not show a clear shift of angiogenesis towards early or late phases in 
either medium (I). However the expression of angpt-1, a marker for mature tubules, 
was significantly higher in ANG compared to EGM-2 medium indicating the 
maturity of vasculature formed in the ANG medium (I). Interestingly, the expression 
of IGF-1 was up-regulated in ANG (I). In vitro IGF-1 has been shown to stimulate 
the migration and tube-forming activity of endothelial cells (Shigematsu et al. 1999, 
Nakao-Hayashi et al. 1992). Leptin was also found to be up-regulated in ANG 
induced vasculature. Leptin signaling acts as a link between adipocytes and the 
vasculature (Sierra-Honigmann et al. 1998) and it increases the production of VEGF 
and enhances expression of MMP-2 and MMP-9 in HUVEC (Park et al. 2001). This 
enhancement was also seen in the results as an up-regulation of MMP-2 and MMP-
9 enzymes. 
The 3D vascular structures produced by the serum-free induction medium 
showed all relevant markers of angiogenesis and mature vasculature (I). This in vitro 
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angogenesis protocol has now been shown to also be a relevant test for screening 
chemical teratogenic effects (Toimela et al. 2017). As the vasculature network 
combines different organs of the body, it is of great interest in tissue engineering. 
Combining vasculature in different cell cultures in vitro has been shown to be 
beneficial in inducing the relevant in vivo morphology and functions not obtained 
without a vascular component (Vuorenpaa et al. 2014, Vuorenpaa et al. 2017).  
6.5 Induction of adipogenesis 
The induction of adipogenesis is most commonly induced by a chemical mixture of 
IBMX, synthetic glucocorticoid dexamethasone, insulin and glitazones (Kang et al. 
2009, Verseijden et al. 2009, Lequeux et al. 2009, Sarkanen et al. 2012b, Ghoniem et 
al. 2015, Foley et al. 2015, Rubin et al. 1978). The standard adipogenic cocktail has 
been criticized for only differentiating a small percentage of cells in culture. Other 
adipogenic factors, such as indomethacin and triiodothyronine, are also commonly 
used (Armani et al. 2010, Verseijden et al. 2009, Lequeux et al. 2009). To facilitate 
lipogenesis from glucose, biotin and pantothenate have also been utilized (Kang et 
al. 2009). Improved versions of induction medium have been developed for 
enhanced adipogenesis and one of these is adipogenic differentiation medium, which 
contained rosiglitazone (part of the TZD class), insulin, hydrocortisone, T3, IBMX 
and dexamethasone, but not contain indomethacin (Lequeux et al. 2009).  The 
adipogenesis/angiogenesis medium (ANG+T) developed in study II shares 
similarities with this optimized chemical medium as it contains insulin, 
hydrocortisone, T3 and 9.06 μM TZD troglitazone. Insulin mimics the role of IGFǦ
1 and activates MAPK (Qiu et al. 2001). IGF-1 mediates proliferation and 
differentiation of perivascular adipocytes (Liu et al. 2015).  
The majority of adipogenic protocols utilize fetal bovine serum (FBS) (Ruiz-
Ojeda et al. 2016) even though FBS is known to induce proliferation rather than 
aiding differentiation (Lee et al. 2012) and should be avoided for ethical reasons as 
well as for its unknown and highly variable mixture of components (Brunner et al. 
2010). However, new serum-free and human serum options have been developed, 
including the method developed in this study (II, IV, Volz et al. 2018b). We utilized 
human serum in ATE medium for the first three days of culture (II, IV). A 
completely serum-free medium containing DMEM/F12 supplemented with 
HEPES, NaHCO3, biotin, d-pantothenate, human transferrin, gentamicin, T3, 
insulin, hydrocortisone and IBMX or troglitazone for the initial 3 days has been 
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developed by others (Lee et al. 2014, Hauner et al. 2001). This completely serum-
free medium is similar to the one developed in study II but contains IBMX and 
hence will likely cause unwanted negative effects on HUVEC as discussed below.   
The criteria in study II for the most optimal adipogenesis medium was that it 
induced reproducible lipid accumulation and mature adipocyte gene expression while 
maintaining insulin sensitivity of adipocytes. The protocol that fulfilled these criteria 
i.e. induced insulin sensitive adipocyte differentiation included a culture of hASC 
cultured for 3 days in ATE medium (ATEm), followed by 6 days in serum-free 
adipogenesis/angiogenesis medium (ANG +T) containing 1,15 μM insulin and 9,06 
μM Troglitazone, a thiazolidinedione (TZD) compound, then the next 4 days in 
serum-free angiogenesis medium w/o insulin (ANG-I) (II). The ANG medium was 
first developed for inducing angiogenesis (I). This serum-free medium is now used 
for adipogenesis induction and adipocyte maturation together with ATE (II, IV). 
ATE contains growth factors, cytokines and chemokines obtained from mature 
adipose tissue, e.g., leptin, adiponectin, FGF-2, IL-6, IGF-1, VEGF (-A) and 
angiogenin, and has been shown to induce natural adipogenesis in vitro (Sarkanen et 
al. 2012b). ATE is produced from mature human adipose tissue and does not inhibit 
cell proliferation (Sarkanen et al. 2012b, Sarkanen et al. 2012c). FGF-2 found in 
ANG medium is also shown to support the proliferation of multipotent cells and 
maintaining their differentiation ability (Tsutsumi et al. 2001).  
The new adipogenesis protocol included incubation of cells with troglitazone and 
T3 (II, IV). TZDs are PPAR agonists, which stimulate adipogenesis and the 
redistribution of lipids from liver and muscle into adipose tissue (Greenberg et al. 
2006) and activate AMP-activated protein kinase (AMPK), resulting in enhanced 
glucose uptake into adipose tissues and muscle (Fryer et al. 2002). Previous in vitro 
studies suggest that a combination of T3 and TZD signaling enhances the adipogenic 
differentiation potential (Ortega et al. 2009, Gerhold et al. 2002). On its own, T3 has 
been shown to interact with the two primary thyroid receptor isoforms expressed in 
fat tissue: thyroid receptor a1 (TRa1) and its antagonist receptor a2 (TRa2). The 
binding of T3 to TRa1 induces adipogenesis while TRa2 negatively regulates the 
activity of T3 (Ortega et al. 2009). This mechanism and the synergistic effect with 
TZDs are likely the reason for the beneficial effect seen with T3 on adipogenesis. 
The glucocorticoid hydrocortisone used in ANG has been shown to increase the 
secretion of leptin by cultured rat adipose tissue (Mick et al. 2000). Glucocorticoid 
excesses in clinical cases has caused increased fat mass and obesity through the 
accumulation of white adipocytes (Hochberg et al. 2015, Barclay et al. 2015). Based 
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on these, hydrocortisone is also a relevant compound for adipogenesis and adipocyte 
maturation. 
6.6 In vitro adipocyte differentiation 
Many protocols for creating in vitro adipocytes have been developed over the years. 
A lot has been learnt about the mechanisms of adipogenesis from studies of 
adipogenic cell lines, such as mouse 3T3-L1 cells and mouse 3T3-F442A cells 
(Cristancho et al. 2011). However, these cell lines differ from primary cells in that 
the triglycerides are stored in many droplets instead of one, and in 3T3-L1 and 3T3-
F442A cells the expression of leptin is much lower than in primary adipocytes 
(Cristancho et al. 2011). Hence better cell sources and adipogenesis methods are 
needed, and have already been developed. New human cell-based methods offer 
biologically relevant and accurate tools to study human adipose tissue related 
diseases. 
The mouse 3T3-L1 cell line is the most commonly used cell type in in vitro adipose 
tissue studies (Ruiz-Ojeda et al. 2016), but the use of human mesenchymal cells is 
increasing. Among human mesenchymal cells, hASC are a feasible source for adipose 
tissue engineering as they possess high proliferative and differentiation capacities. 
Primary hASC were utilized in this thesis’ studies (I, II, III, IV) and many other 
studies developing in vitro adipogenesis models (Verseijden et al. 2009, Lequeux et al. 
2009, Sarkanen et al. 2012b, Ghoniem et al. 2015, Foley et al. 2015). hASC can be 
obtained from different fat depots, which enables the study of differences between 
depots (Armani et al. 2010, Walker et al. 2014). The source of adipose precursor cells 
has been shown to have an impact on their replication speed, need for confluency 
prior to differentiation and adipogenic differentiation ability; with faster replicating 
cells having a better adipogenesis potential (Tchkonia et al. 2005). However, due to 
the fact that hASC are primary cells, heterogeneity of hASC may be a problem as 
well as the cultures having a limited life span, which restrains the time window for 
experimental procedures (Scroyen et al. 2013). When developing in vitro tissues for 
mimicking human adipocytes however, human adipose tissue derived cells are as 
relevant a cell source as possible. 
The protocol developed in study II induced reproducible lipid accumulation and 
expression of mature adipocyte genes (adiponectin, Glut4, AP2 and PPARγ) while 
maintaining the insulin sensitivity of adipocytes. The protocol did not selectively 
induce either brown or white adipocyte phenotypes (II).  The cells showed no 
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regression of adipocyte morphology and remained viable and attached to substratum 
for at least 10 weeks without replenishment of adipogenic medium components (Fig. 
4). The developed protocol contained human serum for the first 3 days, which could 
be criticized. The fully serum-free adipogenic medium developed by others has been 
shown to produce a high percentage of differentiated adipocytes and are insulin 
responsive (Lee et al. 2012). However, serum-free differentiation protocols do not 
seem to produce mature adipocyte morphology i.e. nuclei pushed to the side of the 
cell by one large lipid store, even at a 35 day time point (Lee et al. 2014), unlike our 
protocol (Fig. 4). Also, serum contains components that promote cell adherence 
including fibronection and laminin, which can be beneficial at the beginning of the 
culture. 
Hormone responses are one major criteria for differentiated adipocytes depicting 
healthy adipose tissue. In adipose tissue, adipocytes respond to insulin by inhibiting 
lipolysis and increasing glucose uptake, which initiates signaling via effectors like 
phosphatidylinositol-3 kinase and AKT1/2 with central roles in adipogenesis 
(Rutkowski et al. 2015, Watson et al. 2007, Kim et al. 2004, Garofalo et al. 2003, 
Choi et al. 2010b). Adipocytes should also respond to beta-adrenergic agonists 
through activation of lipolysis. The adipocytes developed in study II responded to 
the beta-adrenergic agonist isoproterenol by increasing lipolysis, which was then 
inhibited by insulin (Fig. 3). Insulin was also shown to increase glucose uptake in the 
differentiated adipocytes (II). 
6.7 Tissue engineered in vitro vascularized adipose tissue 
As adipose tissue is a highly vascularized tissue (Hausman et al. 2004), the interaction 
between vasculature and adipocytes is an important feature to have in in vitro cultures. 
In study III, the vascularized adipose tissue model was developed utilizing bottom-
up methods by first optimizing the building blocks of the model: in vitro 
vascularization and the differentiation method of adipocytes and combining the 
optimal components to form the vascularized adipose model. Study III showed that 
a higher number of cells was beneficial when adipogenesis was induced first, 
followed by angiogenesis induction, as in protocol P1. More mature adipocytes were 
obtained with P1 by first inducing adipogenesis rather than angiogenesis, although 
the vascular structures were not quite as branched as in P6, in which angiogenesis 
was induced first (III). However, if angiogenesis was induced first, as in P6, there 
was no need for a high confluency of hASC and the vascular network was densely 
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branched, although mature adipocyte markers were not as strongly expressed as in 
P1 (III). Two different triggers have been identified for angiogenesis in in vivo adipose 
tissue expansion: 1) angiogenesis is a response to hypoxia, which is caused by the 
enlargement of adipocytes and/or proliferation of adipocytes; and 2) angiogenesis is 
the result of developmental and/or metabolic signals in adipose tissue (Corvera et 
al. 2014). In the first mechanism, blood vessels are developed after adipocytes are 
depicted in P1, and in the second the vessels are developed during the development 
of adipose tissue depicted in P6. Both protocols are scaffold-free and are simpler 
and demand shorter culture times than other existing vascularized adipose tissue 
models (Kang et al. 2009, Borges et al. 2007, Borges et al. 2003, Sorrell et al. 2011).  
The protocol where adipogenesis was induced first, P1 (III), was further 
optimized by combining with the modified protocol of insulin-sensitive adipocytes 
(IV). This vascularized adipose tissue contained vasculature that was well branched 
and adipocytes showed expression of adipocyte genes and secreted relevant proteins 
for adipose tissue (IV). Vascular structures had pericytes present around tubules and 
adherence junctions were found between endothelial cells (IV). Adipocytes remained 
insulin sensitive and responded faster to insulin than adipocytes cultured alone (IV). 
The counteractive effect of vasculature on obesity and insulin-resistance in adipose 
tissue has also been shown in mouse models by others (Robciuc et al. 2016, Rupnick 
et al. 2002). In a study where angiogenesis in adipose tissue was induced by 
transduction of VEGFB in adipose tissue, diet-induced obesity and related metabolic 
complications were prevented in obese insulin-resistant mice (Robciuc et al. 2016). 
Activated endothelial cells in angiogenic vessels produce various cytokines and 
growth factors that promote adipose tissue growth and expansion (Cao 2007). Due 
to cell-cell interactions and their impact on cell mechanisms, co-cultures are essential 
for better understanding of the connections between adipocytes and surrounding 
cells in both healthy and diseased situations.  
The achievement of mature vascular structures in the in vitro adipocyte culture in 
study III and IV is noteworthy. Commonly used adipogenic cocktail treatments 
containing insulin, IBMX, biotin, pantothenate, DEX and thiazolidinediones, have 
been proposed to have a negative effect on endothelial cells and delay the growth of 
HUVEC (Kang et al. 2009, Foley et al. 2015). As a natural adipogenesis inducer ATE 
was utilized in study III and IV for priming of the initial induction of adipogenesis, 
thus there was no need to use the chemical cocktail commonly utilized by many 
others. ATE enables the proliferation of endothelial cells and has the potential to 
induce angiogenesis (Sarkanen et al. 2012b), with its effect on endothelial cells in 
culture opposite to components in a chemical induction cocktail.  
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The role of ECM produced by hASC and formed vascular structures (I) in culture 
is one important part of the model as it offers attachment places and support for the 
differentiation of adipocytes (Sorrell et al. 2011). The angiogenesis model developed 
here was shown to produce ECM and Collagen IV containing basement membrane 
(I), which also contributes to the in vivo-likeness of the growth environment of 
adipocytes, as collagen IV among others is also produced by adipocytes in in vivo 
adipose tissue (Sorrell et al. 2011, Aratani et al. 1988). 
Only a few vascularized adipose tissue models have been developed for in vitro 
use (Table 2) but their execution varies compared to the quite homologous 
composition of different adipogenesis induction media. Additional components 
such as biomaterial scaffolds may interfere with the cell–cell interactions or cause 
unwanted and unknown interactions between biomaterials and the studied cells or 
chemicals (Norotte et al. 2009, Higgins et al. 2003, Williams 2008). While these in 
vitro models mimic vascularized adipose tissue, they are complex, require long culture 
times and are laborious to transfer into routine use. Depending on the application, 
culture times might vary significantly. Implantable tissues are cultured significantly 
longer than in vitro test systems. 
The newly developed vascularized adipose tissue model from Volz et al., utilizing 
microvascular endothelial cells and serum-free medium might also be relevant to in 
vitro chemical testing, although they did not show insulin responses or chemical 
exposures (Volz et al. 2018a). They have a relevant endothelial source, microvascular, 
and the culture does not contain FBS. The collagen I coating they use is likely 
necessary in the absence of serum in the plating phase of cells. The vascularization 
model of Volz et al. (Volz et al. 2018a) seems however to be modest compared to 
the vascularized adipose tissue model protocol developed in this study (IV), likely 
due to their usage of a chemical adipogenesis cocktail. In the protocol developed in 
study IV, total culture time on a 48 well plate was 14 days from which hASC were 
cultured and differentiated alone for 7 days compared, to the 14 days of adipogenic 
pre-differentiation on a 24 well plate by Volz et al. (Volz et al. 2018a). Smaller well 
size has economic advantages as less cells and reagents are needed, and in addition, 
enables more high-throughput work.  
6.8 Effect of chemicals on vasculature and adipose tissue  
Obesity and changes in adipose tissue function are associated with multiple diseases. 
The treatments of these diseases and other chemicals are known to effect adipose 
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tissue, and also its vasculature. In cancer treatments, inhibition of angiogenesis is 
used as a method to restrict the growth of tumors. Many drugs have been developed 
for cancer angiogenesis inhibition. Bevacizumab, a humanized monoclonal antibody 
against all isoforms of VEGF-A, is one of these drugs. It has been approved for 
treatment of colorectal, lung, glioblastoma and renal cell carcinoma (Hsu et al. 2009). 
Eye conditions including proliferative diabetic retinopathy, age-related macular 
degeneration and retinal vein occlusion can also be treated by inhibiting angiogenesis 
with anti-VEGF (van der Giet et al. 2015). Hemangiomas, psoriasis, rheumatoid 
arthritis, endometriosis, atherosclerosis can be treated with anti-angiogenic agents as 
well (Yoo et al. 2013). Stimulation of angiogenesis has been proposed as a treatment 
for conditions caused by a lack of sufficient vascularization. Induction of collateral 
vessel formation in ischemia e.g. myocardial ischemia benefits from angiogenesis 
induction (Markkanen et al. 2005). Wound care has also been shown to benefit from 
the induction of angiogenesis, especially in diseases that affect vasculature, such as 
diabetes. Topical use of VEGF has also shown significant healing in wounds in 
diabetic mice compared to controls (Galiano et al. 2004). Reconstructive surgery 
benefits from angiogenesis stimulation as well (Yoo et al. 2013). 
Environmental chemicals have been shown to influence angiogenesis (Toimela 
et al. 2017, Sarkanen et al. 2011). To date, it is not mandatory to test new chemicals 
for their angiogenic effects, however there might be substances in our environment 
that influence angiogenesis and health. Unexpected effects can also be caused by 
drug treatments. Ibuprofen and acetylic salicylic acid are pain killers that have been 
shown to cause teratogenicity. These and other teratogenic agents have been seen to 
inhibit angiogenesis in the angiogenesis model developed in study I, which indicates 
angiogenesis inhibition might be behind teratogenicity in many cases (Toimela et al. 
2017). The amount of drugs and chemicals with angiogenic effects proves the need 
for reliable in vitro models of angiogenesis like the one developed in study I. 
Although obesity is a condition targeted with drug treatments, many strategies 
primarily target organs other than adipose tissue. Some drug candidates influence the 
brain and suppress appetite, others influence the gut to limit free fatty acid formation 
and inhibit their adsorption (Pilch et al. 2006). Insulin sensitizers like rosiglitazone 
and pioglitazone are used to control insulin responsiveness in diabetes (Pilch et al. 
2006). These are PPARγ agonists and as they induce adipogenesis, weight gain has 
been linked to the treatment (Evans et al. 2004). Obesity and related comorbidities 
could be managed by influencing the vasculature in adipose tissue or adipocytes, as 
discussed above (Robciuc et al. 2016, Elias et al. 2012).  
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Adipose tissue is affected by environmental chemicals. New obesogens, 
chemicals increasing adipose tissue are continuously found. Many of these 
obesogens are also endocrine disruptors, which is not surprising as adipose tissue is 
an endocrine organ. From the chemicals used in original publication IV, mancozeb, 
butylparaben bisphenol a, bis-(2-ethylhexyl) phthalate and tributyltin chloride, are 
classified as endocrine disruptors by EU categorization (Groshart et al. 2000). 
Exposure to known chemicals were performed to confirm responses of the 
developed vascularized adipose tissue model were correct and suitable for testing 
chemical effects. The vascularized adipose tissue model developed in this study 
showed various responses to chemicals; changes in lipid accumulation, amount of 
vasculature, and in gene expression levels (IV). Lipid accumulation was not quite as 
visible as expected, although the gene expression results showed an increased 
expression of adipocyte markers when lipid accumulation increased, as was expected 
(IV). To further improve the protocol for vascularized adipose tissue, a longer 
exposure time (now 7 days) or adjustments to energy levels in the protocol could be 
considered.  
Both adipocytes and vascularized adipose tissue were exposed to three of the 
studied chemicals; rosiglitazone, prochloraz and chlorpyrifos, and the effects of 
these chemicals were also studied at a gene expression level (IV). Rosiglitazone is a 
TZD and insulin sensitizing antidiabetic drug. Prochloraz is a fungicide and 
chlorpyrifos a pesticide. The results of the vascularized adipose tissue showed good 
concordance with previous reports both with regards to the adipogenic and 
angiogeneic properties of these chemicals (IV).  
In study IV, the exposure of vascularized adipose tissue to rosiglitazone caused 
elevated gene expression of FABP4, leptin, adiponectin and Glut4. This is in good 
concordance with the findings of others on the effects of rosiglitazone on adipocytes 
(Taxvig et al. 2012). Although we did not see the increase in lipid accumulation (IV) 
seen by others (Taxvig et al. 2012), the gene expression changes indicate an increase 
in adipogenesis (IV). Angiogenesis in the developed model increased (IV), which is 
consistent with an increase in adipose tissue vascularization in the in vivo exposure of 
humans (Gealekman et al. 2012), although contradictory results have been obtained 
in vitro (Sheu et al. 2006). 
We found that prochloraz was an adipogenesis inhibitor with EC50 at a 164μM 
concentration and could be classified as an inhibitor of adipogenesis (IV). All other 
studied genes, except PPARα, were expressed at a lower level than unexposed 
cultures (IV). Prochloraz has been shown to decrease adiponectin and leptin, and a 
decrease in lipid accumulation of 3T3 cells already at 50μM (Taxvig et al. 2012). We 
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did not see prochloraz impacting angiogenesis (IV), which is in concordance with 
the results of others (Kleinstreuer et al. 2011). Exposure to 50μM prochloraz 
increased expression of PPARα in vascularized adipose tissue compared to 
adipocytes alone (IV). In 3T3-L1 cells the 50μM concentration of prochloraz had no 
effect on PPARα or PPARγ (Taxvig et al. 2012). The increased levels of PPARα in 
vascularized adipose tissue in study IV is an intriguing finding. This could be caused 
by the interaction of adipocytes and vessels and their mural cells or the result of an 
effect of prochloraz on endothelial cells, but further mechanistic studies would be 
needed to confirm the mechanism(s). 
Chlorpyrifos caused an increase in viability/mitochondrial activity and seemed to 
inhibit lipid accumulation at lower concentrations and increase it at higher 
concentrations before inhibiting it again (IV). It has been reported that chlorpyrifos 
decreases lipid accumulation in 3T3 cells (Taxvig et al. 2012). Our results showed 
leptin significantly increased in expression in vascularized adipose tissue exposed 
with 10μM chlorpyrifos (IV) and the effect of this chemical at 10μM has been shown 
by others with increased secretion of the leptin protein (Taxvig et al. 2012). The 
angiogenic effect of chlorpyrifos was not seen in study IV nor in other reports (Jeon 
et al. 2016). 
In order to identify the effects of chemicals and drugs on humans, relevant 
screening models are needed for preclinical and safety testing. These models need to 
depict human metabolism and cell biology to show the effects of chemicals on 
humans. As discussed here, the angiogenesis model (I), insulin sensitive adipocyte 
protocol (II) and vascularized adipose tissue (IV) developed in these studies are 
relevant for studying human biology and the effects of drugs and chemicals. 
 
6.9 Future perspectives 
The models presented in the current study have multiple possible applications. As 
mentioned above, the developed serum-free medium (I) is suitable for culturing the 
vasculature and adipocytes (I, II, III, IV), and could be a valid option in multi-tissue 
cultures including multi-organ chips utilizing microfluidics. When multiple organs 
are cultured in the same system, connected by a blood mimicking medium suitable 
for multiple tissues, the in vitro system can get closer to really depicting in vivo biology. 
The vascularized adipose tissue model could be further optimized by lowering 
the troglitazone concentration and concentrations of VEGF and FGF-2 to better 
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allow the effect of chemicals influencing angiogenesis and adipogenesis to be seen 
(IV). Following the final adjustments, the vascularized adipose tissue model and 
adipocytes can be tested on a larger set of chemicals and their effects compared to 
those found in the literature. Following this, the models can be validated according 
to OECD guidelines (Environment Directorate 2005). In validation, the data results 
compared have to be considered carefully to ensure the reliability of the results given 
by the model. Human data from clinical trials is one relevant result with which the 
results given by a model should correlate, as they are obtained from humans. 
Validation ensures the utilization of these in vitro models in GLP facilities, which 
allows them to be used in chemical regulatory toxicity studies.  The developed 
angiogenesis model (I) has already been intra-laboratory validated (Toimela et al. 
2017) and has been offered to OECD as an in vitro test.  
In the future, the macrovascular cells, HUVEC, could be replaced with 
microvascular endothelial cells to further optimize the vascularized adipose tissue 
model. This would further increase the in vivo-likeness of this model. The 
angiogenesis model could also be modified to depict lymphangiogenesis by replacing 
HUVEC with lymphatic endothelial cells. This would broaden the variety of research 
fields for this model. 
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7 CONCLUSIONS 
The vascularized adipose tissue model created in this study is a promising tool for 
adipose tissue research and chemical testing. The components, vasculature and 
adipocytes, can easily be utilized by themselves or together, to study the effects each 
organ system has on the other.  
In the first study, the angiogenesis model developed earlier, based on a co-culture 
of hASC and HUVEC, was improved by developing a serum-free defined medium. 
In culture medium serum is a component with unknown composition and hence it 
causes unwanted and unknown effects on chemicals, including effects on the actual 
free concentration in the test and hence it reduces the reliability of test results. This 
developed serum-free medium produced an extensive vascular network with 
morphology resembling vessels in vivo including the intact endothelial layer, basement 
membrane, 3D tubules with lumen, extracellular matrix proteins and surrounding 
pericytes. Angiogenesis and vasculogenesis are extremely important developmental 
events. Hence, it is important that chemicals, especially drugs, are tested for their 
impact on these events and for that, reliable test platforms are needed.  
The second study focused on the development of an adipocyte differentiation 
protocol for differentiating hASC into adipocytes. The developed protocol produced 
in vivo-like insulin sensitive adipocytes. Insulin response is a critical feature in 
adipocytes. The lack of this response is present in diseases and hence there is interest 
in knowing more about it. In order to study the development of these diseases, 
models that accurately mimic human biology in healthy tissue are needed, as these 
can be used to induce a diseased state. The protocol for producing insulin sensitive 
adipocytes developed here, could also be applied to diseased adipocytes lacking a 
response. These could be used in the mechanistic studies of insulin response and its 
failures. 
The third study combining the vascular component and adipocytes together 
produced two protocols (P1 and P6) for creating a proof of concept model of 
vascularized adipose tissue. Both of these protocols produced vascularized adipose 
tissue models containing properly formed vasculature among lipid accumulating 
adipocytes. The culture conditions; culture time, timing of seeding of hASC and 
HUVEC, timing of differentiation media found best for producing mature adipocyte 
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(P1) were then utilized in the fourth study, which combined the adipocyte protocol 
developed in the second study with the in vitro vasculature developed in the first study 
to create the vascularized adipose tissue model. This vascularized adipose tissue 
model was shown to be insulin responsive. In addition, the vascularized adipose 
tissue model was shown to be relevant for testing chemicals due to the fact that the 
responses to known chemicals correlated to responses reported in the literature. The 
models and analysis methods depicted in this study are simple and robust enough to 
be used in high-throughput chemical studies.  
The models developed in this study will be validated according to OECD 
guidelines in a GLP laboratory. This way they can be utilized also for regulatory 
purposes. 
The complexity of adipose tissue makes the development of a truly in vivo-like 
adipose tissue a difficult task. With increasing understanding of adipose tissue 
biology and the adipogenesis process, the development of a relevant model is more 
and more feasible. More work is still to be done to compose an adipose tissue model 
that mimicks all phases of adipogenesis in an environment that fully depicts the in 
vivo environment of adipocytes. However, in vitro models carefully developed and 
thoroughly characterized, like the ones developed here, are already relevant in the 
development of effective therapies against obesity and metabolic disease, and for 
understanding the effects of different cellular components on adipose tissue and its 
functional failures. 
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Summary
The formation of blood vessels is a vital process in embryonic development and in normal physiology. Current vascular 
modelling is mainly based on animal biology leading to species-to-species variation when extrapolating the results 
to humans. Although there are a few human cell based vascular models available, these assays are insufﬁciently 
characterized in terms of culture conditions and developmental stage of vascular structures. Therefore, well characterized 
vascular models with human relevance are needed for basic research, embryotoxicity testing, development of therapeutic 
strategies and for tissue engineering.
We have previously shown that the in vitro vascular model based on co-culture of human adipose stromal cells (hASC) 
and human umbilical vein endothelial cells (HUVEC) is able to induce an extensive vascular-like network with high 
reproducibility. In this work we developed a deﬁned serum-free vascular stimulation medium (VSM) and performed 
further characterization in terms of cell identity, maturation and structure to obtain a thoroughly characterized in vitro 
vascular model to replace or reduce corresponding animal experiments.
The results showed that the novel vascular stimulation medium induced an intact and evenly distributed vascular-like 
network with morphology of mature vessels. Electron microscopic analysis assured the three-dimensional microstructure 
of the network containing lumen. Additionally, elevated expression levels of the main human angiogenesis-related genes 
were detected.
In conclusion, with the newly deﬁned medium the vascular model can be utilized as a characterized test system for 
chemical testing as well as in creating vascularized tissue models.
Keywords: serum-free media, angiogenesis, mesenchymal stromal cells, coculture techniques
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1  Introduction#
The formation of the blood vessel network is a vital process in 
growth and organ development (Carmeliet and Jain, 2011; Car-
meliet, 2005). In the embryo, endothelial precursor cells form 
new vessels that differentiate into a primitive vascular network 
(vasculogenesis) (Carmeliet and Jain, 2011). Subsequent ves-
sel sprouting (angiogenesis) creates a network of arteries and 
veins as well as capillaries that facilitate the exchange of gases 
and metabolites (Carmeliet and Jain, 2011; Adams and Alitalo, 
2007). To reach this level of complex organization, the imma-
ture vascular network must mature at the level of the vessel wall 
*Authors contributed equally to this work.
#Abbreviations 
AA, ascorbic acid; APC, allophycocyanin; BSA, bovine serum albumin; CD144, vascular endothelial cadherin; EGF, epidermal growth factor; EGM-2, endothelial 
cell growth medium-2; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; FGF-2, basic fibroblast growth factor; hASC, human adipose stromal cells; 
HE, heparin sodium salt; HS, human serum; HUVEC, human umbilical vein endothelial cells; HY, hydrocortisone (cortisol); IGF-I, insulin-like growth factor I; 
PBS, phosphate buffered saline; RT, room temperature; PDGFRћ, platelet derived growth factor beta; PE, phycoerythrin; PE-CY7, phycoerythrin-cyanine; SFM, 
basal serum-free medium; њSMA, alpha smooth muscle actin; TRITC, tetramethyl rhodamine isothiocyanate; VEGF, vascular endothelial growth factor; VSM, 
vascular stimulation medium; vWf, von Willebrand factor
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morphology and as a whole network. Morphological maturation 
involves recruitment of mural cells, deposition of extracellular 
matrix and organ-speciÀc specialization of cells, such as inter-
endothelial junctions and surface receptors. Maturation of the 
network involves branching and expanding the network to meet 
local, tissue-speciÀc demands (Jain, 2003).
Since the formation and maintenance of the vascular network 
is a complex process, problems related to its regulation are com-
mon (Ucuzian and Greisler, 2007). Inadequate vessel mainte-
nance or growth causes ischemia in myocardial infarction and 
neurodegenerative or obesity-associated disorders, whereas 
excessive vascular growth or abnormal remodeling promotes 
cancer, inÁammatory disorders and eye diseases (Potente et 
al., 2011). Moreover, genetic studies have shown that perturb-
ing embryonic vascular development can have adverse conse-
quences from benign vascular malformation to embryolethality 
and congenital defects (Knudsen and Kleinstreuer, 2011).
Angiogenesis models are important tools for studying the 
mechanisms of angiogenesis and the therapeutic strategies to 
modulate neovascularization (Ucuzian and Greisler, 2007). Due 
to an increasing amount of compounds affecting the vascular 
system, accurate vasculogenesis and angiogenesis models are 
needed for chemical safety testing and for drug development 
(Sarkanen et al., 2011; Bishop et al., 1999). Currently, preclini-
cal animal models are dominantly used for angiogenesis testing 
although they are not considered optimal in efÀcacy or relevance 
to humans. The most commonly used in vivo angiogenesis as-
says include the chick chorioallantoic membrane (CAM) assay, 
Matrigel plug assay, zebraÀsh embryo system, corneal micropo-
cket assay, rat/mouse hind limb ischemia model and rat aortic ring 
assay (Norrby, 2006; Auerbach et al., 2003). Despite the advan-
tage of providing more information on complex cellular interac-
tions compared to in vitro models, animal models are burdened 
by several disadvantages, such as variability, animal-speciÀcity 
and ethical concerns (Norrby, 2006). Human cell based models 
have the potential to be valuable tools in predicting effects in 
man. However, the human relevance of these in vitro models 
needs to be conÀrmed in terms of cell identity, physiological ar-
chitecture and functionality (Bale et al., 2014; Hartung, 2011). 
In addition, the developmental stage of the model system and a 
deÀned medium composition are critical, especially when toxi-
cological applications are considered. Serum-free medium with 
xeno-free and deÀned supplements is considered essential for in 
vitro models to decrease the variation between experiments due 
to unknown components in the medium, and further, unknown 
binding properties of these components (Shen et al., 2013; Brun-
ner et al., 2010; van der Valk et al., 2010). Currently, culture 
media are still commonly supplemented with serum, although 
it has a highly uncharacterized composition, including various 
cytokines and growth factors, as well as a lot-to-lot variability 
(Lindroos et al., 2011; Brunner et al., 2010). 
We and others have shown that adipose stromal cells and um-
bilical vein endothelial cells are capable of self-assembling into a 
dense, three-dimensional vascular-like network (Sarkanen et al., 
2012; Merfeld-Clauss et al., 2010; Verseijden et al., 2010). While 
adipose stromal cells secrete factors that induce endothelial cell 
(EC) sprouting and lumen formation (Rubina et al., 2009; Trak-
tuev et al., 2008; Rehman et al., 2004; Kilroy et al., 2007; Bishop 
et al., 1999), the supporting stromal cells also enhance vascular 
basement membrane and lumen formation (Merfeld-Clauss et 
al., 2010; Newman et al., 2013; Stratman et al., 2009). 
The aim of this study was to develop a deÀned medium and 
further characterize the in vitro vascular model developed by us, 
which is composed of human adipose stromal cells (hASC) and 
human umbilical vein endothelial cells (HUVEC) (Sarkanen et 
al., 2012). Our results showed that the new vascular stimula-
tion media (VSM) developed in this study produces an exten-
sive vascular-like network with mature properties and provides 
a valid alternative to commercial EGM-2 medium when com-
paring vascular-like network formation capacity. This vascular 
model has the potential to be used in the safety and efÀcacy 
assessment of angiogenic compounds. In addition, the vascular-
like network combined with target cells, such as cardiomyocytes 
(Vuorenpää et al., 2014), can be used as a tissue engineering 
platform to create vascularized tissue models. 
2  Materials and methods
This study conforms to the principles outlined in the Declaration 
of Helsinki. The human adipose tissue samples were obtained 
from surgical operations and human umbilical cords were re-
ceived from caesarean sections with individual written informed 
consent at Tampere University Hospital, Tampere, Finland. The 
use of hASC and HUVEC were approved by the Ethics Com-
mittee of the Pirkanmaa Hospital District, Tampere, Finland 
with permit numbers R03058 and R08028, respectively. 
Isolation and culture of human adipose stromal cells
hASC were isolated from human adipose tissue by using a me-
chanical and enzymatic procedure described previously (Sar-
kanen et al., 2012). BrieÁy, human adipose tissue specimens 
were mechanically cut into small pieces and enzymatically di-
gested with 0.15% collagenase I (Invitrogen, Paisley, Scotland, 
UK) in Dulbecco’s ModiÀed Eagle’s Medium Nutrient Mixture 
F-12 (DMEM/F12, Gibco, Invitrogen, Carlsbad, CA, USA). 
hASC were cultured in DMEM/F12 supplemented with 10% 
human serum (HS, Lonza Group Ltd, Basel, Switzerland) and 
1% L-Glutamine (Gibco). The cells were tested for mycoplasma 
contamination (MycoAlert® Mycoplasma Detection Kit, Lonza 
Group Ltd) before experimental use. 
Isolation and culture of human umbilical vein endothelial cells
HUVEC were isolated from human umbilical cord veins using 
0.05% collagenase I as described previously (Sarkanen et al., 
2011). The cells were cultured in EGM™-2 Endothelial Cell 
Growth Medium-2 (EGM-2, Lonza Group Ltd). Before use the 
cells were tested for mycoplasma contamination (MycoAlert® 
Mycoplasma Detection Kit, Lonza).
Establishment of the co-culture forming the vascular-like 
network
Co-culture of hASC and HUVEC was established as described 
previously (Sarkanen et al., 2012). BrieÁy, hASC were seeded in 
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EGM-2 (Lonza) at 20,000 cells/cm2. After 1-3 h HUVEC were 
seeded on top of hASC at 4,000 cells/cm2. The hASC were used 
at passage 2 and HUVEC at passage 4 in the co-culture (passage 
number increased at seeding). The day after plating, the stimula-
tion media were applied to the co-culture (see Tab. 1): 1) EGM-2 
containing epidermal growth factor, vascular endothelial growth 
factor A (VEGF), Àbroblast growth factor 2 (FGF-2), insulin-
like growth factor I (IGF-I), ascorbic acid (AA), heparin, hydro-
cortisone (HY), antibiotic mix: 30 g/ml gentamicin and 15 ng/
ml amphotericin and 2% fetal bovine serum (FBS); 2) EGM-2/
HS, where 2% FBS was replaced with 2% HS; 3) serum free ba-
sal medium (SFM); 4) Vascular stimulation medium (VSM). 
In this Àrst media comparison study, the AA, HY and heparin 
in VSM were taken from the EGM-2 kit and used according 
to the manufacturer’s protocol (concentrations of these are not 
publicly available). After that, concentrations of AA, heparin 
sodium salt from bovine intestinal mucosa (HE) and HY pur-
chased from Sigma were optimized for VSM. In the concentra-
tion optimization study the tested concentrations of AA were 0, 
50, 100, 200, 500, 1000 and 2000 g/ml; of HY 0, 20, 200, 1000, 
and 2000 ng/ml and of HE 0, 50, 500, 10,000 and 50,000 ng/ml. 
The concentrations of 10 ng/ml VEGF and 1 ng/ml FGF-2, used 
for VSM, had been optimized in our previous study (Sarkanen 
et al., 2012). The co-cultures were grown for 6 days prior to 
immunocytochemistry or quantitative real-time PCR (qPCR) 
processing. Stimulation medium was changed once during the 
6 day culture. 
Quantitative real-time PCR 
Genes activated in co-culture of hASC and HUVEC in EGM-
2 medium versus co-culture in VSM were analyzed by qPCR. 
Total RNA was extracted at day 6 using the RNAeasy minikit 
(Qiagen) following the manufacturer’s protocol. A step to elimi-
nate genomic DNA contamination was included in the isolation 
and performed with RNase-free DNase set (Qiagen). Reverse 
transcription of total RNA to cDNA was performed using RT2 
First Strand Kit (Qiagen) following the manufacturer’s instruc-
tions. 
Human Angiogenesis RT2 ProÀler™ PCR Array (Qiagen, Va-
lencia, California, USA) was used to proÀle the expression of 
84 key angiogenesis-related genes (the comprehensive list of 
genes included in the array can be found in http://www.sabio-
sciences.com). The array was performed according to the man-
ufacturer’s protocol using BioRad CFX96 Real Time System 
(BioRad Laboratories, USA). The array contained Àve house-
keeping genes and controls, including genomic DNA control, 
Reverse Transcription Control and Positive PCR controls. The 
co-culture of hASC and HUVEC grown in EGM-2 medium was 
used as a control. Three independent experiments with the array 
were performed using the same cells. 
Immunocytochemistry
To analyze the vascular-like network formation and different 
cell types present in hASC and HUVEC co-culture, immunocy-
tochemical staining was performed. In primary antibody stain-
ing, endothelial cell speciÀc antibody for rabbit anti-human von 
Willebrand factor IgG (anti-VWF, 1:100, F3520, Sigma) with 
common pericytic marker Ơ-human smooth muscle actin (mon-
oclonal anti-SMA clone 1A4, 1:200, M0851, DAKO), vascular 
smooth muscle cell marker smooth muscle myosin heavy chain 
(anti-SMMHC, clone hSM-V, 1:800, M7786, Sigma), contrac-
tile smooth muscle cell marker calponin (anti-calponin, clone 
hCP, 1:800, C2687, Sigma), pericytic and smooth muscle cell 
progenitor marker platelet derived growth factor receptor-ơ 
(anti-PDGFRơ, clone PDGFR-B2, 1:800, P7679, Sigma), vas-
cular endothelial cadherin (CD144,Clone 55-7H1, 1:50, 555661, 
BD Pharmingen), monoclonal occludin (clone 1G7, 1:300, 
WH0004950M1, Sigma) or basement membrane marker colla-
gen IV (anti-COLIV, clone COL-94, 1:500, C1926, Sigma), all 
anti-human and all produced in mouse, except vWf, were used. 
Co-culture was Àxed with 70% ethanol at day 6. After Àxa-
tion, the cells were permeabilized with 0.5% Triton-X100 (MP 
Biochemicals, Ohio, USA) and non-speciÀc binding sites were 
blocked with 10% bovine serum albumin (BSA, Roche Diagnos-
tics Corporation, Indianapolis, USA). Primary antibody in 1% 
BSA was applied to the cells. Secondary antibodies used were 
polyclonal goat anti-rabbit IgG tetramethylrhodamine (TRITC, 
1:50, T6778 Sigma), anti-rabbit IgG A568 (1: 400, A11011, In-
vitrogen) and anti-mouse IgG Áuorescein isothiocyanate (FITC, 
1:100, F4143, Sigma). After immunocytochemical staining the 
Tab. 1: Stimulation media tested in vascular model
Acronym Basal medium Serum Growth factors Supplementation
EGM-2 EBM-2 2% FBS VEGF, FGF-2, IGF-I,  hydrocortisone, ascorbic acid, heparin,  
   epidermal growth factor GA-1000
EGM-2/HS EBM-2 2% HS VEGF, FGF-2, IGF-I, hydrocortisone, ascorbic acid, heparin,  
   epidermal growth factor GA-1000
basal SFM DMEM/F12 –   ITS, BSA, NaP, L-glutamine, T3,
VSM DMEM/F12 – VEGF, FGF-2 ITS, BSA, NaP, L-glutamine, T3,  
    hydrocortisone, ascorbic acid,  
    heparin sodium salt
0.1% ITS (insulin-transferrin-sodium selenite media supplement), 1.28 mM L-glutamine, 1% BSA (bovine serum albumin),  
2.8 mM NaP (sodium pyruvate), 100 IU/ml P/0.1 mg/ml S, 0.1 nM T3 (3,3’,5-triiodo-L-thyronine sodium salt), HS (human serum),  
FBS (fetal bovine serum), VEGF (vascular endothelial growth factor A), FGF-2 (Àbroblast growth factor 2), IGF-I (insulin-like growth  
factor I), GA-1000 (30 g/ml gentamicin and 15 ng/ml amphotericin), VSM (vascular stimulation medium), SFM (serum free medium)
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vascular-like network was analyzed and photographed with 
Nikon Eclipse TS100 inverted Áuorescence microscope (Nikon, 
Tokyo, Japan) and Nikon digital sight DS-U2 camera (Nikon). 
Images were further processed with NIS Elements (Nikon, To-
kyo, Japan) and Adobe Photoshop CS3-software (Adobe Sys-
tems Incorporated, San Jose, CA, United States). 
Flow cytometric surface marker expression analysis of  
HUVEC and hASC
hASC were cultured in hASC medium (passage 1) for 6-7 days 
and HUVEC were cultured in EGM-2 medium (passage 3) for 
3 days prior to surface marker expression analysis using a BD 
FACSCanto II Áow cytometer (BD Biosciences, Erembodegem, 
Belgium). For the Áow cytometry analysis cells were divided 
into 5 ml polystyrene round bottom FACS tubes (BD, New Jer-
sey, USA) at 250,000 cells per tube. The cells were washed once 
with warm staining buffer (1% BSA in PBS) and centrifuged 
at 131 x g for 5 min, after which they were stained either for 
surface markers or for intracellular markers. 
Fixation and permeabilization were only performed for stain-
ing of intracellular markers. The Àxation was conducted by 
incubating the samples for 30 min in 2% paraformaldehyde 
in PBS at room temperature (RT). The cells were then centri-
fuged at 500 x g for 5 min. Permeabilization of the cells was 
performed by 10 min incubation in 0.1% Triton-X100 in PBS at 
RT after which the cells were centrifuged at 500 x g for 5 min 
and washed once or twice with staining buffer before addition 
of antibodies. 
The labelled mouse anti-human antibodies used were intra-
cellular vWf-A2-allophycocyanin IgG2b (APC, #IC27641A) 
and eNOS- phycoerythrin IgG1 (PE, #560103), and surface 
markers CD144-FITC IgG1 (#560411), CD73-Phycoerythrin-
Cyanine IgG1 (PE-CY7, #561258), CD309-PE IgG1 (#560872), 
CD68-FITC IgG2b (#562117), NG2-PE IgG1 (#FAB2585P), 
CD90-FITC IgG1 (#561969), CD105-V450 IgG1 (#561447), 
CD34-APC IgG1 (#561209), CD140b-PE IgG2a (#558821), 
CD31-V450 IgG1 (#561653), CD45-PE IgG1 (#560975), 
CD14-FITC IgG1 (#561712). Isotype controls mouse IgG2b-
APC (#IC0041A), Mouse IgG1-PE-CY7 (#557872), mouse 
IgG1-PE (#559320), mouse IgG1-FITC (#555748), mouse 
IgG2b-FITC (#556655), mouse IgG1-V450-(#642268), mouse 
IgG1-APC (#550854), mouse IgG2a-PE (#551438). All anti-
bodies and their corresponding isotype controls used in the Áow 
cytometry analysis were purchased from BD except NG2, vWf 
and IgG2b-APC, which were purchased from R&D Systems. 
Labelled antibodies were added into cell suspension in cold 
staining buffer and incubated on ice for 30 min in the dark. After 
incubation the cells were washed once with staining buffer and 
twice with PBS. Surface marker stained cells were centrifuged 
at 200 x g for 5 min and intracellular marker stained cells were 
centrifuged for 5 min at 500 x g. 
Flow cytometry analysis was performed with cells suspended 
in ice cold PBS and 5,000 events were analyzed per sample. 
Compensation was done with compensation particles, i.e., BD™ 
CompBeads (BD) according to the manufacturer’s instructions. 
The results were analyzed with BD FACSDiva™ Software 
(BD). The positive expression was obtained by gating 98% of 
the events isotype control results and then inverting the gate to 
obtain a percentage of positively stained cells in the samples. 
The results were calculated as percentages with SD.
Electron microscopy
hASC and HUVEC co-culture was performed in 24-well UpCell 
plates (ThermoFisher) for transmission electron microscopy 
(TEM) and on glass cover slips coated with 0.1% gelatin for 
scanning electron microscopy (SEM). Co-culture was main-
tained for 6 days and washed twice with PBS prior to Àxation. 
SEM specimens were Àxed in 2% glutaraldehyde in 0.1 M 
phosphate buffer after which the SEM samples were dehydrat-
ed in alcohol and dried in Baltec critical point dryer (Baltec, 
CPD030, Balzers, Liechtenstein). A layer of platinum was sput-
tered onto the specimens with a sputter coater (Agar ScientiÀc, 
Stansted, England). Specimens were examined in a Zeiss Ultra 
Plus scanning electron microscope, (Carl Zeiss MT – Nanotech-
nology System Division, Carl Zeiss NTS GmbH, Oberkochen, 
Germany) using 5 kV as an accelerating voltage.
TEM specimens were detached from the temperature sensi-
tive 24-well UpCell plate and transferred to Àxative with 1% 
glutaraldehyde, 4% formaldehyde mixture in 0.1 M phosphate 
buffer for 10 min. The cell sheet was immersed in 2% agarose in 
distilled water and postÀxed in 1% osmiumtetroxide, dehydrat-
ed in acetone and embedded in Epon LX 112 (Ladd Research 
Industries, Vermont, USA). Thin sections were cut with Leica 
Ultracut UCT ultramicrotome, stained in uranyl acetate and lead 
citrate and examined in a Philips CM100 transmission electron 
microscope. Images were captured by a Morada CCD camera 
(Olympus Soft Imaging Solutions GMBH, Munster Germany).
Quantitative analysis of vascular-like network formation
Vascular-like networks, i.e., vWf-positive tubule structures 
formed in different stimulation media, were imaged using Cell-
IQ (Chipman tech., Tampere, Finland) with 10x objective and 
5x5 grid. The quantitation of the area of the vascular-like net-
work was performed using ImageJ software (National institutes 
of health, NIH, Maryland, USA) for the image analysis. Im-
ages were Àrst converted to 8-bit gray scale, then background 
was subtracted and Ànally the binary threshold function was 
adjusted to obtain the best contrast of the vascular-like network 
against the background. With these settings, the total area of 
vascular-like network was calculated as the total number of pix-
els in images with set threshold.
Statistical analysis
Statistical analyses were performed and graphs processed with 
GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, 
USA). The results concerning vascular-like network forma-
tion were subjected to one-way ANOVA followed by Dunnett’s 
post-test when applicable. The results were reported as total 
area ± SD and differences were considered signiÀcant when 
p < 0.05*, p < 0.01** and p < 0.001***. 
PCR results were analyzed with the PCR Array Data Analy-
sis Web Portal (http://www.SABiosciences.com/pcrarraydataa-
nalysis.php). The following formula was used to calculate the 
relative amount of the transcripts of the co-culture of hASC and 
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CD144 and CD31 and macrophage/monocyte markers CD68 
and CD14 were very low (< 1.4%). 
HUVEC were shown to express endothelial marker CD31 
and a specialized vascular endothelial marker CD144 at a high 
level (> 70%). Angiogenic endothelial marker CD105 and cell 
surface enzyme CD73 were found in the HUVEC population 
(57-68%). Markers for macrophages/monocytes (CD68) and 
mural cells (NG2) were low ( 2%). 
3.2  VSM induced optimal vascular-like  
network formation
Of the different stimulation media (Tab. 1), VSM induced an 
optimal vascular-like network formation (Fig. 1). The imaging 
analysis showed morphological differences in the vascular-like 
network in VSM compared to EGM-2 medium. VSM produced 
a uniformly distributed vascular-like network with connected 
branches and fewer cell aggregates. Low serum (2%) and se-
HUVEC in the VSM compared to transcripts of the co-culture 
in EGM-2 medium: ƋƋCT = ƋCT (VSM) ï ƋCT (EGM-2). A 
two-fold change compared to housekeeping gene GAPDH was 
considered signiÀcant. 
3  Results
3.1  Phenotypic characterization 
Phenotypic characterization of the cells used in the vascular 
model was performed by analyzing the surface and intracellular 
markers of hASC and HUVEC separately (Tab. 2). The mesen-
chymal stem cell markers CD73, CD90 and CD105 were highly 
expressed (> 64%) in hASC. Also, pericyte marker PDGFR-ơ 
(CD140b) was strongly expressed (> 52%) in the hASC popu-
lation. Hematopoietic marker CD34 was moderately expressed 
(< 40%), whereas the expression levels of endothelial markers 
Tab. 2: Phenotypic characterization of human adipose stromal cells (hASC p1) and human umbilical vein  
endothelial cells (HUVEC p3)  
The expression of surface and intracellular markers was analysed by Áow cytometry (5000 events per sample).  
Results are shown as percentage of positive cells.
Cells Protein Antigen Positive cells % SD n
hASC vWf von Willebrand factor 7.5 4.3 11
 CD144 vascular endothelial cadherin 1.4 2.9 9
 eNOS endothelial nitric oxide synthase 0.7 1.1 8
 CD140b PDGF Receptor b 52.8 16.0 6
 CD45 leukocyte common antigen 16.4 14.9 6
 CD14 expressed on monocytes/macrophages 0.7 0.8 7
 CD68 expressed on macrophages and monocytes 1.1 1.4 8
 CD309 VEGF receptor 2 1.2 3.5 6
 CD31 platelet endothelial cell adhesion molecule 0.9 3.1 6
 NG2 chondroitin proteoglycan 31.8 29.1 8
 CD90 Thy-1 82.9 15.5 10
 CD105 endoglin 64.1 27.1 7
 CD73 ecto-5'-nucleotidase 88.8 6.7 12
 CD34 sialomucin-like adhesion molecule 40.9 34.3 10
HUVEC vWf von Willebrand Factor 45.6 13.2 13
 CD144 vascular endothelial cadherin 70.6 14.7 17
 CD309 VEGF receptor2 31.4 17.0 10
 CD73 ecto-5'-nucleotidase 68.7 17.1 14
 CD68 expressed on macrophages and monocytes 1.9 10.1 11
 eNOS endothelial nitric oxide synthase 48.4 18.4 13
 CD105 endoglin 57.4 26.6 9
 CD34 sialomucin-like adhesion molecule 43.1 18.6 9
 CD31 platelet endothelial cell adhesion molecule 81.3 13.7 8
 CD140b PDGF Receptor b 7.2 8.7 8
 NG2 chondroitin proteoglycan 2.0 1.1 7
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HUVEC in EGM-2 medium (control) and in VSM. Moderate 
differences in the expression of angiogenesis-related genes were 
detected between EGM-2 and VSM. In VSM, nine genes were 
up-regulated (Angpt1, F3, FIGF, IGF-I, LEP, MDK, MMP2, 
MMP9, PGF) and nine (CCL11, CXCL9, FN1, IL6, IL8, SER-
PINE1, TGFB2, THBS2, TIMP1) were down-regulated in com-
parison to EGM-2 medium. Fold changes and statistical sig-
niÀcances of the up- and down-regulated angiogenesis-related 
genes are shown in Table 3. 
3.4  Maturation stage, extracellular matrix 
production and 3D properties of the vascular-like 
network formed in VSM
Immunocytochemical staining of the vascular-like network 
formed in VSM showed the presence of platelet derived growth 
factor receptor-ơ (PDGFRơ) positive cells (Fig. 3D). Also, 
smooth muscle actin (SMA), smooth muscle myosin heavy 
chain (SMMHC) and contractile smooth muscle calponin posi-
tive cells surrounded the tubule structures (Fig. 3A-C). CD144 
and occludin positive staining indicated the presence of adher-
ence junctions between endothelial cells (Fig. 3E-F).
rum-free medium enabled stable cell attachment and induced a 
dense, connected vascular-like network with intact tubule walls. 
Human serum was found to induce a denser and more connected 
vascular-like network than FBS (Fig. 1).
In the supplement optimization several different concentra-
tions of ascorbic acid, heparin sodium salt and hydrocortisone 
were tested and compared to vascular-like network formed 
in EGM-2 medium. An optimal vascular-like network for-
mation was obtained with the AA concentration 100 g/ml 
(Fig. 2A), HE concentration 0-500 ng/ml (Fig. 2B) and HY 
concentration 0.2 g/ml (Fig. 2C). The results showed that a 
vascular-like network was formed in the absence of HE sup-
plement with minor morphological differences. However, low 
concentrations of HE (50-500 ng/ml) increased the total area 
of the vascular-like network signiÀcantly compared to EGM-
2 medium (Fig. 2B). 
3.3  Expression of angiogenesis-related genes  
in VSM compared to EMG-2
Expression of 84 angiogenesis-related genes was analyzed 
from a vascular-like network formed in co-culture of hASC and 
Fig. 1: Morphology of vascular-like network in 
different stimulation media with different serum 
concentrations 
Vascular-like networks were stained against Col IV (FITC, 
green) and vWf (TRITC, red). Co-localization is shown in 
the merged image. Vascular-like network formed in (A) 
commercial EGM-2 medium with 2% FBS, (B) serum-free 
VSM, (C) EGM-2 with 2% HS and (D) basal SFM. Scale 
bars 100 m in each Àgure. Col IV= collagen type IV, 
VWF= von Willebrand factor, VSM= vascular stimulation 
medium, FBS= fetal bovine serum, HS= human serum, 
SFM=basal serum free medium.
Fig. 2: Vascular-like network formation (area in pixels) in different 
concentrations of (A) ascorbic acid, (B) heparin sodium salt and  
(C) hydrocortisone in VSM
Vascular-like network formed in VSM supplemented with different 
concentrations of ascorbic acid, heparin sodium salt or hydrocortisone were 
compared to EGM-2 medium and differences presented as follows:  
p < 0.05*, p < 0.01** and p < 0.001***. An optimal vascular-like network 
formation was obtained with 100 g/ml ascorbic acid and 0.2 g/ml 
hydrocortisone. Heparin sodium salt could be used in concentrations 
0-500ng/ml. Results are depicted as total area with standard deviations,  
n = 5 in each supplement and concentration. 
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The phenotypic analysis of the building blocks of the vascular 
model, i.e., the hASC and HUVEC, was performed using Áow 
cytometry. HUVEC showed a strong expression of CD105 (en-
doglin), suggesting an active rather than quiescent state of the 
cells (Bernabeu et al., 2009). Interestingly, a recent study report-
ed a minor role of endoglin in vasculogenesis whereas VEGF-
induced angiogenesis was severely impaired in an endoglin de-
Àcient mouse embryonic stem cell model (Liu et al., 2014). The 
high expression of CD144 and CD31 supports the active status 
of HUVEC in the formation of intercellular junctions. The level 
of CD73, a 5'-ectonucleotidase that normally suppresses pro-
inÁammatory responses in human endothelial cells (Grunewald 
and Ridley, 2010) was high in our HUVEC analysis. Pericyte 
markers NG2 and CD140b (PDGFRơ) were low, indicating the 
absence of mural cells in the HUVEC population. 
This study conÀrms the earlier results shown by us (Sarkanen 
et al., 2012) and others (Lindroos et al., 2010; Traktuev et al., 
2008) that the stromal-vascular fraction extracted from adipose 
tissue is heterogenic. hASC expressed mesenchymal stem cell 
markers CD90, CD105 and CD73 at high levels, showing the 
Electron microscopic analysis conÀrmed the microstructure 
of the tubules formed in VSM. Tubules were shown to have 
a lumen, basement membrane and junctions (Fig. 4A-C). The 
three dimensional structure of the vascular-like network and 
shape of the tubules can be seen in the close-up image Figure 
4D.
4  Discussion
Present chemical safety testing and non-clinical drug develop-
ment rely mainly on animal biology although relevant safety 
testing data should be of human origin. Further, in vitro test 
systems should be thoroughly characterized in their human rel-
evance and functionality. In this study, we developed a novel 
vascular stimulation medium (VSM) and further characterized 
the in vitro human vascular model developed by us (Sarkanen et 
al., 2012). This deÀned in vitro vascular model has the potential 
to be used for safety assessment of compounds and for tissue 
engineering applications.
Tab. 3: Fold changes and statistical signiÀcance of expression of angiogenesis-related genes in vascular-like network formed 
in VSM compared to EGM-2 medium
Genes Target Fold change 2^(- ууCT) Statistical signiÀcance
Up-regulated genes    
ANGPT1 angiopoietin 1 2.964 *
F3 coagulation factor III 3.255 *
FIGF vascular endothelial growth factor D 3.043 ns
IGF-I insulin-like growth factor I 16.555 ns
LEP leptin 2.932 ns
MDK neurite growth-promoting factor 2 2.06 ns
MMP2 matrix metallopeptidase 2 2.011 *
MMP9 matrix metallopeptidase 9 3.919 *
PGF placental growth factor 2.319 *
ANGPT2 angiopoietin 2 1.769 **
Down-regulated genes   
CCL11 chemokine ligand 11 2.613 ns
CXCL9 chemokine ligand 9 2.197 ns
FN1 Àbronectin 1 2.295 *
IL6 interleukin 6 2.331 ns
IL8 interleukin 8 2.546 ns
SERPINE1 serpin peptidase inhibitor 3.465 **
TGFB2 transforming growth factor beta 2 2.080 ns
THBS2 thrombospondin 2 2.085 **
TIMP1 TIMP metallopeptidase inhibitor 1 5.01 **
VEFG-A vascular endothelial growth factor A 1.804 ns
TGFћ1 transforming growth factor beta 1 1.807 *
FGF-2 Àbroblast growth factor 2 1.917 ns
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there is a moderate expression of CD34; these are markers for 
mesenchymal stem cells and endothelial progenitors. A hASC 
population of CD90+/CD34+ cells was shown to be capable 
of differentiating into endothelial cells and form capillary-like 
structures (De Francesco et al., 2009). 
The expression of mature endothelial cell markers CD31 and 
CD144 in the hASC population was very low. Interestingly, 
there is a report suggesting that adipose stromal cells may en-
hance endothelial differentiation of progenitor cells (Rubina et 
al., 2009). However, another essential marker for endothelial 
progenitor cells, CD309 (VEGFR2) (Yoder, 2012), showed very 
low expression in the six hASC lines that were analyzed in this 
study. Therefore, the presence of an endothelial progenitor cell 
population in the stromal-vascular fraction needs to be studied 
further. 
Serum-free VSM was shown to produce a reproducible, ex-
tensive mature vascular-like network and provide a suitable al-
ternative to the commercial EGM-2 medium (previously used 
in the model, containing 2% FBS). Serum had a strong corre-
lation with vascular-like network formation. At higher serum 
(10%) concentrations the network was shorter with broken tu-
bule walls, and random detachment of the cell layer occurred 
(data not shown). In low- or serum free (0-2%) environment, 
presence of a cell population with multilineage differentiation 
potential. Pericyte markers CD140b (PDGFRơ) and NG2 were 
expressed at high to moderate level, supporting the Ànding that 
pericytes from the hASC population are lining the vascular-like 
network in our model. 
We also analyzed whether the population of endothelial pro-
genitor cells capable of vasculogenesis could be found in hASC 
as suggested by some earlier reports (Sarkanen et al., 2012; 
Miranville et al., 2004; Heydarkhan-Hagvall et al., 2008). The 
results showed that, in addition to the high expression of CD90, 
Fig. 3: Vascular-like network formed in serum-free VSM 
shows vascular maturation markers at day 6
њ-vWf-staining is shown in red in all Àgures. (A) Calponin-,  
(B) SMA- and (C) SMM-positive cells surrounding the vascular-like 
network. (D) њ-PDGFRћ stained pericytes are located along  
the tubules. (E) CD144- and (F) occludin-positive junctions can be 
found in the tubule structures. Scale bar 100 ѥm in each image. 
VSM= vascular stimulation medium, vWf = von Willebrand factor, 
SMA = smooth muscle actin, SMM = smooth muscle myosin  
heavy chain, PDGFRћ = platelet derived growth factor receptor ћ, 
CD144 = vascular endothelial cadherin.
Fig. 4: Transmission (A, B, C) and scanning (D) 
electron microscopy images of the vascular-like 
network cultured in VSM
(A) Mature tubule with lumen = L and extracellular matrix 
= ECM. The lumen is Àlled with debris from the apoptotic 
cells. Scale bar 2 m. (B) Close-up image with basement 
membrane = BM, adherence junction = AJ and lumen of 
the vascular-like tubules. Scale bar 2 m. (C) Tubule in 
earlier stage of vascular development showing endothelial 
cell with large nucleus (white arrow), lumen, adherence 
junctions and ECM. Scale bar 2 m. D) Scanning electron 
microscopy image shows the 3D structure and the tubule 
shape of the vascular-like network. Scale bar 2 m.  
VSM = vascular stimulation medium. 
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cular-like network. However, it produced cell aggregates at 
high concentrations whereas a lack of hydrocortisone induced 
a sparse vascular-like network. Our results suggest that hydro-
cortisone acts as a mitogen in the vascular model. Other sup-
plements of the VSM included ITS (insulin, transferrin, selenic 
acid medium supplement), BSA, sodium pyruvate, L-glutamine 
and T3 (3,3',5-triiodo-L-thyronine). The concentrations of these 
supplements were reported earlier by us (Vuorenpää et al., 2014) 
and were used in this study with minor modiÀcations. 
Lumen formation is critical for the transformation of cords in-
to a perfusable vascular system (Charpentier and Conlon, 2014). 
Electron microscopic analysis assured the formation of 3D vas-
cular microstructure including lumen in the novel VSM. Tubules 
at different stages of lumen development were detected, indicat-
ing the ongoing process of network formation at day 6. The ini-
tiation of lumen development is triggered by apical-basal polar-
ity of the endothelial cells in which CD144 plays a critical role 
in promoting the localization of polarity markers (Charpentier 
and Conlon, 2014). The electron microscopic analysis as well as 
immunocytochemistry results of this study showed that hASC 
and HUVEC co-culture actively produces extracellular matrix 
(ECM) components, including Àbrillins, thus creating natural 
3D scaffold around them. The reciprocal interaction between 
ECM stroma and vascular network is important in directing ves-
sel growth (Hoying et al., 2014; Du et al., 2014). The hASC and 
HUVEC co-culture gives mechanical support for other target 
cells, e.g., cardiomyocytes, and, additionally, the microenviron-
ment formed by the co-culture enhances target cell viability as 
reported previously (Vuorenpää et al., 2014). This 3D vascular 
model provides a more in vivo-like test system without an artiÀ-
cial scaffold that may interfere with the cell-cell interactions or 
affect the toxicological applications of the model.
In the genotypic analysis 84 human angiogenesis-related 
genes were studied. Nine genes were down-regulated and nine 
genes up-regulated in VSM compared to EGM-2 medium. The 
expression of angiopoietin 1, a marker for mature tubules, was 
signiÀcantly higher in VSM compared to EGM-2 medium, 
whereas angiopoietin 2, a marker for the early stage, i.e., sprout-
ing angiogenesis, was slightly upregulated in VSM. VEGF-A and 
FGF-2, indicators of early stage angiogenesis, were moderately 
yet not signiÀcantly down-regulated in VSM compared to EGM-
2. Since both media included VEGF and FGF-2, the expression 
of these growth factors was apparently unnecessary for the 
cells. On the contrary, placental growth factor (PGF) showed 
modest up-regulation in VSM. PGF and its receptor VEGFR-1 
are minimally expressed in adult quiescent vasculature, but are 
markedly up-regulated during pathological conditions (Carme-
liet et al., 2001). TGFơ1, a marker for tubule maturation, was 
slightly down-regulated in VSM. Vessel maturation relies partly 
on TGF-ơ signaling and TGF-ơ stimulates mural cell prolif-
eration and migration and production of ECM (Potente et al., 
2011). The gene expression analysis conÀrms the Ànding that 
VSM enhances the maturation of the vascular-like network.  
Interestingly, the expression of insulin like growth factor 
(IGF-I) showed the highest up-regulation in VSM. IGF-I treat-
ment in myocardial infarction has been shown to increase cir-
culating angiogenic growth factors, thus providing protection 
network formation increased, tubules were highly branched and 
tubule walls remained intact. In serum-free conditions we de-
tected thinner and more branched tubules as also reported by 
Yang and Xiong (Yang and Xiong, 2012). Serum-free medium 
is ideal for use in drug development, since serum is a complex 
mixture of components with unknown composition and protein 
binding afÀnities (Shen et al., 2013). Furthermore, a tissue con-
struct aimed for clinical therapy should be cultured in human 
serum or, preferably, in a serum-free environment to avoid the 
risk of infection and severe immune reactions in the recipient 
(Patrikoski et al., 2013; Lindroos et al., 2011, 2010; Holm et 
al., 2010). 
Fetal bovine serum (FBS), although being the most widely 
used growth supplement, holds ambiguous, unknown effects for 
cell culture and also raises ethical concerns due to the number 
of bovine fetuses needed for serum production (Gottipamula 
et al., 2013; Brunner et al., 2010). In this study, microscopical 
analysis showed that HS was more inductive for vascular-like 
network formation than FBS. Replacement of FBS with HS has 
been reported to support equal or higher proliferation rates and 
differentiation capacity of adipose stromal cells (Lindroos et al., 
2011; Brunner et al., 2010). Furthermore, human mesenchymal 
stem cells have been shown to maintain their immunophenotype 
and multilineage potential in serum-free medium (Patrikoski et 
al., 2013; Mark et al., 2013).
In this study we developed a deÀned vascular stimulation 
medium since commercial media producing companies do not 
necessarily publish the speciÀc composition of their media. 
This might complicate the use of commercial media in toxico-
logical studies as medium components may interact with test 
compounds. In addition to commonly used VEGF and FGF-2 
deÀned by us earlier (Sarkanen et al., 2011), we found that the 
network formation can be further improved by addition of AA, 
HE and HY. Ascorbic acid (vitamin C) is an essential nutrient for 
human endothelial cells necessary for their effective migration 
and for the synthesis of collagen type IV, an important compo-
nent of basement membrane (Telang et al., 2007). In this study, 
the formation of basement membrane around the tubules was 
impaired in the absence of AA (data not shown). However, AA 
inhibited angiogenesis at high concentrations (1000-2000 g/
ml) as reported previously (Mikirova et al., 2008). Therefore, 
AA is essential for collagen IV formation in basement mem-
brane at low concentrations.
Although HE is needed for the attachment of some growth fac-
tors to their cell surface receptors (Ashikari-Hada et al., 2005) 
and was found to be beneÀcial for the network formation, it did 
not induce a signiÀcant advantage to the morphology or branch-
ing of the tubules. Since HE is an animal derived substance it 
should rather be avoided where clinical applications are con-
cerned. The lack of need for added HE can be explained by the 
secretion of perlecan by HUVEC (Murikipudi et al., 2013; Sch-
lessinger et al., 2000). Our results correlate with earlier studies 
(Khorana et al., 2003; Jung et al., 2001) showing that HE inhib-
its vascular-like network formation at high concentrations.
Hydrocortisone, although not pro-angiogenic itself, has a 
beneÀcial effect on angiogenesis (Goding, 2009). In this study, 
hydrocortisone increased the number of branches in the vas-
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Gottipamula, S., Muttigi, M. S., Kolkundkar, U. and Seetharam, 
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Grunewald, J. K. and Ridley, A. J. (2010). CD73 represses pro-
inÁammatory responses in human endothelial cells. J InÁamm 
against myocardial ischemia in rats (Mathews et al., 2011). In 
vitro IGF-I stimulates migration and tube-forming activity of 
endothelial cells (Shigematsu et al., 1999; Nakao-Hayashi et 
al., 1992). Also leptin, a hormone secreted by adipocytes, was 
found to be up-regulated. Leptin signaling acts as a link between 
adipocytes and the vasculature (Sierra-Honigmann et al., 1998). 
It also increases the production of VEGF and enhances the ex-
pression of MMP-2 and MMP-9 (matrix metallopeptidases) in 
HUVEC (Park et al., 2001). This was seen as an up-regulation 
of MMP-2 and MMP-9 enzymes that are involved in degrada-
tion of the ECM at the early stages of angiogenesis (Kasper et 
al., 2007; Cornelius et al., 1998). 
In vivo studies in mice have revealed that the adult quiescent 
vasculature becomes less dependent on VEGF for its mainte-
nance (Gerber et al., 1999). However, during pathological con-
ditions – such as ischemia, inÁammation or malignancy – an-
giogenic endothelial cells are stimulated by increased VEGF 
levels (Carmeliet et al., 2001). The VEGF signaling pathways 
have been conclusively identiÀed as central for the processes of 
vasculogenesis, angiogenesis and lymphangiogenesis. VEGF-
D induces sprouting lymphangiogenesis when overexpressed 
in transgenic mice and also in various tumor models (Lohela 
et al., 2009). The up-regulation of vascular endothelial growth 
factor D (FIGF) as a marker for lymphangiogenesis suggests 
the versatile modiÀcations of our vascular model. In future ap-
plications, it may be possible to replace HUVEC with lymphatic 
endothelial cells to form a lymphangiogenesis model.
5  Conclusion
The vascular model characterized in this study forms a vascular-
like network with mature properties. The developed novel medi-
um provides a valid alternative to commercial EGM-2 medium 
and beneÀts the use of the model in toxicological studies as well 
as in efÀcacy studies in drug development. This characterized 
vascular model is currently under intra-laboratory validation 
that is performed according to OECD guidance document No. 
34 (OECD, 2005) to verify the reliability and human relevance 
of the test system with known reference chemicals. The vali-
dated vascular model will be used in toxicity testing and can be 
combined with other target cell types from different tissues to 
create complex, vascularized tissue models. 
References
Auerbach, R., Lewis, R., Shinners, B. et al. (2003). Angiogen-
esis assays: a critical overview. Clin Chem 49, 32-40. http://
dx.doi.org/10.1373/49.1.32
Adams, R. H. and Alitalo, K. (2007). Molecular regulation of 
angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 
8, 464-478. http://dx.doi.org/10.1038/nrm2183
Ashikari-Hada, S., Habuchi, H., Kariya, Y. and Kimata, K. 
(2005). Heparin regulates vascular endothelial growth fac-
tor165-dependent mitogenic activity, tube formation, and 
its receptor phosphorylation of human endothelial cells. J 
HUTTALA ET AL.
ALTEX 32(2), 2015 135
Mark, P., Kleinsorge, M., Gaebel, R. et al. (2013). Human mese-
chymal stem cells display reduced expression of CD105 after 
culture in serum-free medium. Stem Cells Int 2013, 698076. 
http://dx.doi.org/10.1155/2013/698076
Mathews, L., Nagaraja, H. and Chakravarthi, S. (2011). Insulin-
like growth factor-1 (IGF-1) reduces ischemic changes and 
increases circulating angiogenic factors in experimentally – 
induced myocardial infarction in rats. Vasc Cell 3, 13. http://
dx.doi.org/10.1186/2045-824X-3-13
Merfeld-Clauss, S., Gollahalli, N., March, K. L. and Traktuev, 
D. O. (2010). Adipose tissue progenitor cells directly interact 
with endothelial cells to induce vascular network formation. 
Tissue Eng Part A 16, 2953-2966. http://dx.doi.org/10.1089/
ten.TEA.2009.0635
Mikirova, N. A., Ichim, T. E. and Riordan, N. H. (2008). Anti-
angiogenic effect of high doses of ascorbic acid. J Transl Med 
6, 50. http://dx.doi.org/10.1186/1479-5876-6-50
Miranville, A., Heeschen, C., Sengenès, C. et al. (2004). Im-
provement of postnatal neovascularization by human adipose 
tissue-derived stem cells. Circulation 110, 349-355. http://
dx.doi.org/10.1161/01.CIR.0000135466.16823.D0
Murikipudi, S., Methe, H. and Edelman, E. R. (2013). The effect 
of substrate modulus on the growth and function of matrix-
embedded endothelial cells. Biomaterials 34, 677-684. http://
dx.doi.org/10.1016/j.biomaterials.2012.09.079
Nakao-Hayashi, J., Ito, H., Kanayasu, T. et al. (1992). Stimu-
latory effects of insulin and insulin-like growth factor I on 
migration and tube formation by vascular endothelial cells. 
Atherosclerosis 92, 141-149. http://dx.doi.org/10.1016/0021-
9150(92)90273-J
Newman, A. C., Chou, W., Welch-Reardon, K. M. et al. (2013). 
Analysis of stromal cell secretomes reveals a critical role for 
stromal cell-derived hepatocyte growth factor and Àbronectin 
in angiogenesis. Arterioscler Thromb Vasc Biol 33, 513-522. 
http://dx.doi.org/10.1161/ATVBAHA.112.300782
Norrby, K. (2006). In vivo models of angiogenesis. J Cell Mol 
Med 10, 588-612. http://dx.doi.org/10.1111/j.1582-4934.2006.
tb00423.x
OECD (2005). Guidance document No. 34 on the validation and 
international acceptance of new or updated test methods for 
hazard assessment. http://www.oecd.org/ofÀcialdocuments/
publicdisplaydocumentpdf/?doclanguage=en&cote=env/jm/
mono%282005%2914
Park, H. Y., Kwon, H. M., Lim, H. J. et al. (2001). Potential 
role of leptin in angiogenesis: Leptin induces endothelial cell 
proliferation and expression of matrix metalloproteinases in 
vivo and in vitro. Exp Mol Med. 33, 95-102. http://dx.doi.
org/10.1038/emm.2001.17
Patrikoski, M., Juntunen, M., Boucher, S. et al. (2013). De-
velopment of fully deÀned xeno-free culture system for the 
preparation and propagation of cell therapy-compliant human 
adipose stem cells. Stem Cell Res Ther 4, 27. http://dx.doi.
org/10.1186/scrt175
Potente, M., Gerhardt, H. and Carmeliet, P. (2011). Basic and 
therapeutic aspects of angiogenesis. Cell 146, 873-887. http://
dx.doi.org/10.1016/j.cell.2011.08.039
7, 10. http://dx.doi.org/10.1186/1476-9255-7-10
Hartung, T. (2011). From alternative methods to a new toxi-
cology. Eur J Pharm Biopharm 77, 338-349. http://dx.doi.
org/10.1016/j.ejpb.2010.12.027
Heydarkhan-Hagvall, S., Schenke-Layland, K., Yang, J. Q. et al. 
(2008). Human adipose stem cells: A potential cell source for 
cardiovascular tissue engineering. Cells Tissues Organs 187, 
263-274. http://dx.doi.org/10.1159/000113407
Holm, F., Ström, S., Inzunza, J. et al. (2010). An effective se-
rum- and xeno-free chemically deÀned freezing procedure for 
human embryonic and induced pluripotent stem cells. Hum 
Reprod 25, 1271-1279. http://dx.doi.org/10.1093/humrep/
deq040
Hoying, J. B., Utzinger, U. and Weiss, J. A. (2014). Formation 
of microvascular networks: Role of stromal interactions di-
recting angiogenic growth. Microcirculation 21, 278-289. 
http://dx.doi.org/10.1111/micc.12115
Jain, R. K. (2003). Molecular regulation of vessel maturation. 
Nat Med 9, 685-693. http://dx.doi.org/10.1038/nm0603-685
Jung, S. P., Siegrist, B., Wade, M. R. et al. (2001). Inhibition of hu-
man angiogenesis with heparin and hydrocortisone. Angiogen-
esis 4, 175-186. http://dx.doi.org/10.1023/A:1014089706107
Kasper, G., Dankert, N., Tuischer, J. et al. (2007). Mesenchy-
mal stem cells regulate angiogenesis according to their me-
chanical environment. Stem Cells 25, 903-910. http://dx.doi.
org/10.1634/stemcells.2006-0432
Khorana, A. A., Sahni, A., Altland, O. D. and Francis, C. W. 
(2003). Heparin inhibition of endothelial cell proliferation 
and organization is dependent on molecular weight. Arte-
rioschler Thromb Vasc Biol 23, 2110-2115. http://dx.doi.
org/10.1161/01.ATV.0000090671.56682.D7
Kilroy, G. E., Foster, S. J., Wu, X. et al. (2007). Cytokine pro-
Àle of human adipose-derived stem cells: Expression of ang-
iogenic, hematopoietic, and pro-inÁammatory factors. J Cell 
Physiol 212, 702-709. http://dx.doi.org/10.1002/jcp.21068
Knudsen, T. B. and Kleinstreuer, N. C. (2011). Disruption of 
embryonic vascular development in predictive toxicology. 
Birth Defects Res C Embryo Today 93, 312-323. http://dx.doi.
org/10.1002/bdrc.20223
Lindroos, B., Aho, K. L., Kuokkanen, H. et al. (2010). Dif-
ferential gene expression in adipose stem cells cultured in 
allogeneic human serum versus fetal bovine serum. Tissue 
Eng Part A 16, 2281-2294. http://dx.doi.org/10.1089/ten.
TEA.2009.0621
Lindroos, B., Suuronen, R. and Miettinen, S. (2011). The po-
tential of adipose stem cells in regenerative medicine. Stem 
Cell Rev 7, 269-291. http://dx.doi.org/10.1007/s12015-010-
9193-7
Liu, Z., Lebrin, F., Maring, J. A. et al. (2014). Endoglin is dis-
pensable for vasculogenesis, but required for vascular en-
dothelial growth factor-induced angiogenesis. PLoS One 9, 
e86273. http://dx.doi.org/10.1371/journal.pone.0086273
Lohela, M., Bry, M., Tammela, T. and Alitalo, K. (2009). VEGFs 
and receptors involved in angiogenesis versus lymphang-
iogenesis. Curr Opin Cell Biol 21, 154-165. http://dx.doi.
org/10.1016/j.ceb.2008.12.012
HUTTALA ET AL.
ALTEX 32(2), 2015136
placing fetal bovine serum in mammalian in vitro methods. 
Toxicol In Vitro 24, 1053-1063. http://dx.doi.org/10.1016/j.
tiv.2010.03.016
Verseijden, F., Posthumus-van Sluijs, S. J., Pavljasevic, P. et al. 
(2010). Adult human bone marrow- and adipose tissue-de-
rived stromal cells support the formation of prevascular-like 
structures from endothelial cells in vitro. Tissue Eng Part A 
16, 101-114. http://dx.doi.org/10.1089/ten.TEA.2009.0106
Vuorenpää, H., Ikonen, L., Kujala, K. et al. (2014). Novel in 
vitro cardiovascular constructs composed of vascular-like 
networks and cardiomyocytes. In Vitro Cell Dev Biol Anim 
50, 275-286. http://dx.doi.org/10.1007/s11626-013-9703-4
Yang, Z. and Xiong, H.-R. (2012). Culture conditions and 
types of growth media for mammalian cells. In L. Cec-
cherini-Nelli and B. Matteoli (ed.), Biomedical Tissue Cul-
ture (3-18). InTech. ISBN 978-953-51-0788-0. http://dx.doi.
org/10.5772/3071
Yoder, M. C. (2012). Human endothelial progenitor cells. 
Cold Spring Harb Perspect Med 2, a006692. http://dx.doi.
org/10.1101/cshperspect.a006692
Conﬂict of interest statement
None of the authors have any conÁicts of interest. 
Acknowledgements
We thank the treating staff in Tampere University Hospital as 
well as the donors for collaboration concerning the donations of 
umbilical cords and adipose tissue samples. We thank Dr Raija 
Sormunen at University of Oulu for EM imaging and assist-
ance in result interpretation. We thank Dr Katriina Aalto-Setälä 
and Liisa Ikonen in BioMediTech for their collaboration in the 
project. In FICAM we want to thank Ms Paula Helpiölä, Ms 
Mirja Hyppönen, Ms Hilkka Mäkinen and Ms Sari Leinonen for 
technical assistance.
Funding for the project was provided by Pirkanmaa Centers 
for Economic Development, Transport and the Environment, 
City of Tampere, Finnish Funding Agency for Technology and 
Innovation, Ministry of Education and Culture, Ministry of Ag-
riculture and Forestry, Pirkanmaa Cultural Foundation, The Di-
abetes Research Foundation and FinPharma Doctoral Program. 
Correspondence to 
Hanna Vuorenpää, MSc 
FICAM, Finnish Centre for Alternative Methods,  
School of Medicine
FI-33014 University of Tampere
Finland 
Phone: +35 8401904105
Fax: +35 8335516170 
e-mail: hanna.vuorenpaa@uta.À 
Rehman, J., Traktuev, D., Li, J. et al. (2004). Secretion of 
angiogenic and antiapoptotic factors by human adipose 
stromal cells. Circulation 109, 1292-1298. http://dx.doi.
org/10.1161/01.CIR.0000121425.42966.F1
Rubina, K., Kalinina, N., EÀmenko, A. et al. (2009). Adipose 
stromal cells stimulate angiogenesis via promoting progenitor 
cell differentiation, secretion of angiogenic factors, and en-
hancing vessel maturation. Tissue Eng Part A 15, 2039-2050. 
http://dx.doi.org/10.1089/ten.tea.2008.0359
Sarkanen, J. R., Mannerström, M., Vuorenpää, H. et al. (2011). 
Intra-laboratory pre validation of a human cell based in 
vitro angiogenesis assay for testing angiogenesis modula-
tors. Front Pharmacol 1, 147. http://dx.doi.org/10.3389/
fphar.2010.00147
Sarkanen, J. R., Vuorenpää, H., Huttala, O. et al. (2012). Adi-
pose stromal cell tubule network model provides a versatile 
tool for vascular research and tissue engineering. Cells Tissues 
Organs 196, 385-397. http://dx.doi.org/10.1159/000336679
Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A. et al. (2000). 
Crystal structure of a ternary FGF-FGFR-heparin complex 
reveals a dual role for heparin in FGFR binding and dimeriza-
tion. Mol Cell 6, 743-750. http://dx.doi.org/10.1016/S1097-
2765(00)00073-3
Shen, Q., Wang, L., Zhou, H. et al. (2013). Stereoselective bind-
ing of chiral drugs to plasma proteins. Acta Pharmacol Sin 
34, 998-1006. http://dx.doi.org/10.1038/aps.2013.78
Shigematsu, S., Yamauchi, K., Nakajima, K. et al. (1999). IGF-
1 regulates migration and angiogenesis of human endothelial 
cells. Endocr J 46, Suppl S, 59-62. http://dx.doi.org/10.1507/
endocrj.46.Suppl_S59
Sierra-Honigmann, M. R., Nath, A. K., Murakami, C. et al. 
(1998). Biological action of leptin as an angiogenic fac-
tor. Science 281, 1683-1686. http://dx.doi.org/10.1126/sci-
ence.281.5383.1683
Stratman, A. N., Malotte, K. M. and Mahan, R. D. (2009). Peri-
cyte recruitment during vasculogenic tube assembly stimulates 
endothelial basement membrane matrix formation. Blood 114, 
5091-5101. http://dx.doi.org/10.1182/blood-2009-05-222364
Telang, S., Klem, A. L., Eaton, J. W. and Chesney, J. (2007). 
Depletion of ascorbic acid restricts angiogenesis and retards 
tumor growth in a mouse model. Neoplasia 9, 47-56. http://
dx.doi.org/10.1593/neo.06664
Traktuev, D. O., Merfeld-Clauss, S., Li, J. et al. (2008). A popu-
lation of multipotent CD34-positive adipose stromal cells 
share pericyte and mesenchymal surface markers, reside in a 
periendothelial location, and stabilize endothelial networks. 
Circ Res 102, 77-85. http://dx.doi.org/10.1161/CIRCRESA-
HA.107.159475
Ucuzian, A. A. and Greisler, H. P. (2007). In vitro models 
of angiogenesis. World J Surg 31, 654-663. http://dx.doi.
org/10.1007/s00268-006-0763-4
van der Valk, J., Brunner, D., De Smet, K. et al. (2010). Op-
timization of chemically deÀned cell culture media – re-
PUBLICATION 
II 
Differentiation of human adipose stromal cells in vitro into insulin-sensitive adipocytes 
Huttala O, Mysore R, Sarkanen JR, Heinonen T, Olkkonen VM, Ylikomi T 
Cell and Tissue Research 2016;366(1):63-74 
https://doi.org/10.1007/s00441-016-2409-7 
Post print version of the publication printed with the permission of the copyright holders. 
 
  
  
 
 
 
 
1 
 
 
Differentiation of human adipose stromal cells in culture into insulin 
sensitive adipocytes  
Huttala O1, Mysore R2, Sarkanen JR3,4, Heinonen T1, Olkkonen VM2,5, Ylikomi T3,4 
1 FICAM, University of Tampere, Finland 
2 Minerva Foundation Institute for Medical Research, Helsinki, Finland 
3 Cell Biology, University of Tampere, Finland 
4 Science Centre, Pirkanmaa Hospital District, Finland 
5 Department of Anatomy, Faculty of Medicine, University of Helsinki, Finland 
Corresponding author: Outi Huttala, outi.huttala@uta.fi, Medisiinarinkatu 3, 33520 Tampere, Finland. 
Phone: +358503186357 fax:+35833641482 
Abstract: Adipose tissue related diseases such as obesity and type 2 diabetes are worldwide 
epidemics. In order to develop in vitro adipose tissue cultures which mimic more faithfully the 
physiology in vivo, new well characterized and publicly accepted differentiation methods of human 
adipose stem cells are needed. The aims of this study were (i) to improve the existing natural adipose 
tissue extract (ATE)-based induction method and (ii) to study the effects of differentiation method on 
insulin responsiveness of the resulting adipocytes. Different induction media were applied on human 
adipose stromal cell (hASC) monocultures to study the differentiation capacity of the induction media 
and the functionality of the differentiated adipocytes. Cells were differentiated for 14 days to assess 
triglyceride accumulation per cell and adipocyte-specific gene expression (PPARȖ, adiponectin, AP2, 
leptin, Glut4, Prdm16, CIDEA, PGC1-Į, RIP140, UCP and ADCY5). Insulin response was studied by 
measuring glucose uptake and inhibition of lipolysis after incubation with 100 or 500 nM insulin. The 
selected differentiation method included 3-day induction with adipose tissue extract, 6 days in serum-
free medium supplemented with 1.15 M insulin and 9.06 M Troglitazone, followed by 4 days in a 
defined serum- and insulin-free stimulation medium. This protocol induced prominent general 
adipocyte gene expression, including markers for both brown and white adipocytes, and triglyceride 
accumulation. Moreover, the cells were sensitive to insulin as observed from increased glucose uptake 
and inhibition of lipolysis. This differentiation protocol developed provides a promising approach for 
induction of hASC adipogenesis to obtain functional and mature human adipocytes.  
Key words: Adipocyte, adipogenesis, in vitro differentiation, maturity, adipose stromal cells 
INTRODUCTION 
The prevalence of adipose tissue related diseases, such as obesity and type 2 diabetes, have reached 
worldwide epidemic proportions. In addition to type 2 diabetes, obesity and overweight are associated 
with an increased incidence of other comorbidities including several cancer types, sleep apnea, 
asthma, degenerative joint disease, hypertension, renal failure, stroke, and cardiovascular disease 
(Switzer et al. 2013, van Baak 2013). As the prevalence of obesity has increased, also the need to 
study adipose tissue and find treatments to related diseases has raised. The growing interest creates 
the need to develop better methods to study the process of adipogenesis and adipose tissue function. 
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Adipose tissue is not only a depot for energy storage, but a dynamic endocrine organ secreting 
bioactive factors that control systemic insulin sensitivity, energy metabolism, immune responses and 
cardiovascular homeostasis (Gu and Xu 2013, Choi et al. 2010a). Adipose tissue can expand via 
adipocyte hypertrophy, where existing cells grow in size, or by hyperplasia, increase in adipocyte 
number, which requires progenitor cells to differentiate into adipocytes (Spalding et al., 2008). New 
adipocytes develop through adipogenesis, which is typically described as a two-phase process that 
includes commitment and terminal differentiation (Cristancho and Lazar 2011, Rosen and 
MacDougald 2006). In the determination phase, stem cells transform into committed preadipocytes 
(Rosen and MacDougald 2006). Commitment is followed by a growth arrest after which an 
appropriate mixture of adipogenic and mitogenic signals are needed for terminal differentiation 
(Gregoire 2001). In terminal differentiation, preadipocytes transform into insulin-sensitive, lipid 
synthesizing and transporting mature adipocytes that secrete adipocyte-specific secretory products 
(Rosen and MacDougald 2006, Gregoire et al. 1998). Differentiation into mature adipocyte phenotype 
is typically characterized by chronological changes in the expression of the early, intermediate and 
late mRNA/protein markers (Gregoire et al. 1998).  
Insulin is an important regulator of adipocyte metabolism. It promotes the synthesis and storage of 
triglycerides and inhibits their catabolism (Rutkowski et al. 2015). In the high fed state, insulin binds 
to its receptor on adipocytes and causes the translocation of glucose transporter 4 (Glut4) from the 
cytosol to the cell surface, thus allowing effective glucose influx into the adipocytes (Rutkowski et 
al. 2015, Watson and Pessin 2007). The influx of glucose is not merely necessary for ATP production, 
as glucose is also needed for effective adipocyte lipid packaging (Bederman et al. 2009, Guan et al. 
2002). Insulin also inhibits lipolysis by activating phosphodiesterase 3B, which inactivates the 
function of cAMP (Choi et al. 2010b). Thus, the downstream activation of protein kinase A (PKA), 
adipose triglyceride lipase (ATGL) and hormone sensitive lipase (HSL) is inhibited (Choi et al. 
2010b).  
The complex pathways of lipid metabolism are highly species specific (Bergen and Mersmann 2005). 
Thus, new human cell based methods offer biologically relevant tools to study human adipose tissue-
related diseases. Currently available cell models include preadipocyte cell lines that are already 
committed to the adipocyte lineage and multipotent stem cells that are able to commit to different 
lineages, including adipocyte, muscle and bone (Armani et al. 2010). Multipotent stem cells used in 
adipogenesis assays include embryonic stem cells and adipose stromal cells (ASC) obtained from 
adipose tissue (Armani et al. 2010). ASC can be obtained from various species (including humans) 
and from different fat depots, which enables the study of differences between species and depots 
(Gregoire et al. 1998, Armani et al. 2010). ASC have been proved as a feasible source for adipose 
tissue engineering as they possess high proliferative and differentiation capacity (Girandon et al. 
2011).  However, due to the fact that ASC are primary cells, the heterogeneity of ASC may be a 
problem as well as cultures having a limited life span, which restrains their time window for 
experimental procedures (Gregoire et al. 1998, Scroyen et al. 2013). 
In order to achieve maximal adipogenic differentiation in vitro, cell culture models treated with 
adipogenic cocktails, typically including supraphysiological concentrations of insulin, 
dexamethasone (DEX) and isobuthylmethylxanthine (IBMX) have been developed (Gregoire 2001, 
Armani et al. 2010, Ntambi and Young-Cheul 2000). Other adipogenic factors, such as indomethacin, 
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glucocorticoids, troglitazone and triiodothyronine, are also commonly used (Armani et al. 2010). 
Improved versions of induction medium have been developed for enhanced adipogenesis. Among 
those, Lequeux et al. (Lequeux et al. 2009) composed an improved adipogenic differentiation medium 
in which they replaced indomethacin by adding rosiglitazone, hydrocortisone and triiodothyronine to 
the basic adipogenic ingredients isobutyl-methylxanthine and dexamethasone. Also new ways of 
adipogenesis induction have been studied. We have previously developed a novel cell-free 
angiogenesis- and adipogenesis-inducing agent, adipose tissue extract (ATE), from mature human 
adipose tissue. ATE contains a wide number of promoters of e.g.  adipogenesis and it has shown to 
induce dose-dependent adipogenesis and angiogenesis in vitro (Sarkanen et al. 2012a). ATE is 
produced from mature human adipose tissue without affecting cell viability, the final mixture 
containing a majority of growth factors, cytokines and chemokines present in mature adipose tissue 
(Sarkanen et al. 2012a). The advantage of ATE is that it can be used to induce natural adipogenesis 
in vitro and the majority of adipose stromal cells are committed towards adipocytes (Sarkanen  et al. 
2012a). However, due to the content of ATE, as seen in its dual role as adipogenesis and angiogenesis 
inducing agent, the differentiation may not be driven into fully differentiated adipocytes.  
 
The aim of the present study was to find the most effective adipocyte in vitro differentiation protocol 
mimicking natural adipogenesis. The adipogenic effect of ATE was further studied and improved, 
and the additional components and combinations needed for optimal adipocyte differentiation and 
maturation were investigated. To assess the functionality of the differentiated adipocytes, their insulin 
responsiveness was monitored.  
 
MATERIALS AND METHODS 
This study conforms to the principles outlined in the Declaration of Helsinki. The human adipose 
tissue samples were obtained from waste material of surgical operations and human umbilical cords 
were received from caesarean sections with informed consents at Tampere University Hospital, 
Tampere, Finland. The use of human adipose stromal cells (hASC) was approved by the Ethics 
Committee of the Pirkanmaa Hospital District, Tampere, Finland with permit number of 
R03058,respectively. 
Isolation and culture of human adipose stromal cells 
Adipose stromal cells (hASC) were isolated from human adipose tissue by using mechanical and 
enzymatic procedure as described previously (Sarkanen et al. 2012b). Briefly, human adipose tissue 
specimens were mechanically cut into small pieces and enzymatically digested with 0.15 % 
collagenase I (Invitrogen, Paisley, Scotland, UK) in Dulbecco’s Modified Eagle’s Medium Nutrient 
Mixture F-12 (DMEM/F12, Gibco/ Invitrogen, Carlsbad, CA). The cells were tested for mycoplasma 
contamination (MycoAlert® Mycoplasma Detection Kit, Lonza Group Ltd, Basel, Switzerland) 
following the isolation and characterized for markers CD73, CD90 and CD105 (BD) with flow 
cytometer FACSCAnto II (BD) according to Huttala et al. 2015, before experimental use. 
Adipose tissue extract 
Adipose tissue extract (ATE) was produced as described previously (Sarkanen et al. 2012a) with 
slight modification to the ratio of medium to fat. Briefly, the human adipose tissue sample was 
manually cut into small pieces. The sample was then incubated in DMEM/F12 in ratio of 2:3 i.e. 2 
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parts manually dissected fat and 3 parts DMEM/F12, for 24 hours at 37 °C in 5 % CO2 humified 
atmosphere. This was then centrifuged at 200 x g for 3 min and liquid was filtered through 0.2m 
filter. To determine the protein content of the extract Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Waltham, MA) was used according to manufacturer’s instructions using BSA as a 
standard. Results were measured after 30 min incubation at 37 °C at 562 nm with Varioskan™ Flash 
Multimode Reader (Thermo Scientific). ATE was stored at -20 °C until used. Patches were not 
pooled. 
Cell culture set up for differentiation protocols  
To initiate adipogenic differentiation, hASCs were plated at passage 2 at a density of 20,000 cells/cm2 
in hASC medium (Table 1). The next day, different differentiation media (Table 1) were applied on 
hASCs according to scheme seen in Table 2. Troglitazone (Trogl, Sigma-Aldrich, St. Louis, MO) 
was used at concentration of 4 g/ml (9.06M). Combination of hASC medium and serum-free 
medium was used as the negative and ATE as positive control for adipocyte differentiation (Table 2). 
The culture time for all the treatments was 14 days.  
Triglyceride accumulation  
The triglyceride accumulation was determined as a relative amount of triglycerides per cell. This was 
done by first determining the relative cell number by using Cell Proliferation Reagent WST-1 (Roche 
Life Science, Indianapolis, IN) according to the manufacturer’s instructions. Briefly, 50 l /48-well 
plate well of WST-1 reagent was added in the culture medium on day 14. After 1.5h incubation at 37 
°C 5 % CO2 the absorbances were measured at 450 nm with Varioskan™ Flash Multimode Reader 
(Thermo Scientific). Accumulation of triglycerides was analyzed from the same wells from which 
the WST-1 analysis was done by using AdipoRed Assay reagent (Lonza, Basel, Switzerland) 
according to manufacturer’s instructions. Briefly, at the end point of cultivations, the culture was 
washed with DPBS, Then AdipoRed reagent diluted with PBS was added on the plate and after 10 
min incubation at room temperature, absorbances were measured with Varioskan™ Flash Multimode 
Reader (Thermo Scientific) with excitation at 485 nm and emission at 572 nm. 
Morphological analysis 
For the microscopic inspections, cultures were washed with DPBS and fixed using cold 70 % EtOH, 
left in DPBS and stored at +4 °C until imaging. Microscopic imaging was done with Nikon Eclipse 
Ti-S inverted fluorescence microscope (Nikon, Tokyo, Japan) and Nikon digital sight DS-U2 –
camera (Nikon) and automated imaging with Cell-IQ (Chipman Tech., Tampere, Finland) with 10x 
objective and 5x5 grid. Confocal imaging was done with LSM710 and with Zeiss Axio Observer Z1 
inverted microscope (Carl Zeiss, Oberkochen, Germany). Images were further processed with NIS 
Elements (Nikon, Tokyo, Japan), ZEN 2012 software (Carl Zeiss) and Adobe Photoshop CS3-
software (Adobe Systems Incorporated, San Jose, CA).  
RNA isolation and gene expression analysis  
At day 14 the cell cultures where washed with PBS and total RNA isolated with PureLink® RNA 
Mini kit (Ambion/Life Technologies). Five-six wells/treatment where combined to form each total 
RNA sample. Samples were obtained from three independent cell culture experiments. Reverse 
transcription was carried out by using the VILO® kit (Invitrogen, Carlsbad, CA). Messenger RNAs 
were quantified by quantitative reverse transcriptase PCR (qPCR) with the gene-specific primer pairs 
for PPARȖ, adiponectin, AP2, leptin and Glut, by using 36B4 (acidic ribosomal phosphoprotein) and 
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SDHA (succinate dehydrogenase complex, subunit A) as housekeeping references (primer sequences 
s. Electronic Supplementary Material, Table S1). Relative gene expression results were calculated by 
normalizing the Ct values with the geometric mean of the two housekeeping genes.  
For the analysis of brown and white adipocyte-typical mRNAs primer pairs for Prdm16, CIDEA, 
PGC1-Į, UCP, RIP140, leptin and adenylate cyclase (ADCY5) were used (s. Electronic 
Supplementary Material, Table S1). These were analyzed from two independent cell culture 
experiments; two cDNA syntheses and qPCR analyses (each in triplicate wells) were carried out from 
each (n=4). Relative gene expression levels were calculated by normalizing the Ct values with the 
geometric mean of the two housekeeping genes. 
Assays for insulin responsiveness 
Glucose uptake test 
At day 14, DMEM/F12 (Gibco) was changed on the cells and incubated for 2 h at 37 °C 5 % CO2. 
Cells were then exposed to 100 nM or 500 nM insulin and incubated at 37 °C 5 % CO2 for 30 min 
and [3H]-2-deoxy-D-glucose (0.2 Ci/well, Perkin Elmer, Waltham, MA) was added for another 
20 min. The cells were washed twice with ice cold PBS and then lysed in 0.1 % sodium dodecyl 
sulfate (SDS). The radioactivity of the samples was measured by liquid scintillation counter 
Wallac1410 (Perkin Elmer) using OptiPhase HiSafe 2 oscillation liquid (Perkin Elmer). Total protein 
content of the samples was analyzed with Pierce™ BCA Protein Assay Kit (Thermo Scientific) as 
described above, and total protein content was used to normalize the results. 
Inhibition of lipolysis 
At day 14 the medium was removed, cells were washed with PBS (Gibco/Life Technologies) and 
DMEM/F12 (Gibco/Life Technologies) was added on the cells. After two hours, 2 M Isoproterenol 
was added and incubated for 1.5 hours after which 100 nM or 500 nM insulin (Sigma-Aldrich) was 
added. After 15 min, 30 min or 45 min incubation medium was collected and the amount of glycerol 
released was assessed with EnzyChrom Adipolysis Assay Kit (BioAssay Systems, Hayward, CA) 
according to manufacturer’s instructions. The fluorescence was measured with Varioskan™ Flash 
Multimode Reader (Thermo Scientific) at Iex 530 nm and Iem 585 nm. Following the collection of the 
medium, cells were lysed with 0.1 % sodium dodecyl sulfate (SDS) and protein content was measured 
with BCA kit as described above. Protein content was used to normalize the results. 
Statistical analysis 
Statistical analyses were performed and graphs processed with GraphPadPrism 5.0 (GraphPad 
Software, Inc., San Diego, CA). The results concerning triglyceride accumulation were subjected to 
One-way ANOVA followed by Dunnett’s post-test. The results concerning gene analysis, glucose 
uptake and lipolysis were subjected to two-way anova followed by Tukey post test. The results were 
reported as mean ± SD and differences were considered significant when p<0.05*, p<0.01**, 
p<0.001*** or p<0.0001****.  
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RESULTS 
Effects of the differentiation protocols on triglyceride accumulation 
Eleven different differentiation protocols (Table 2) for hASC were tested to find the most effective 
differentiation protocol for mature in vivo like adipocytes. The first phenotypic criterion assessed was 
triglyceride accumulation, as determined by AdipoRed staining at day 14. When comparing the 
accumulation of triglycerides per relative cell number, the cells grown by protocols 2, 6, 7 and 11 
differed significantly from the undifferentiated cells (Table 2 and Fig. 1). Morphological examination 
of cultures stained with AdipoRed revealed that the pattern of lipid accumulation was 
morphologically most different between protocol 2 (ATE induction) and protocol 7 (3-day induction 
with ATE, 6 days in serum-free medium supplemented with 1.15 M insulin and 9.06 M 
Troglitazone, followed by 4 days in a defined serum- and insulin-free stimulation medium) (Fig. 1). 
ATE induced triglyceride accumulation with many small cytoplasmic lipid droplets in nearly all of 
the cells in the culture, but the amount of the accumulated lipid per cell was modest compared to 
protocol 7 cells. Protocol 7 induced accumulation of lipid in fewer cells than plain ATE induction but 
the size of the lipid storage in individual cell was greater. The outcome of protocol 6 resembled 
protocol 7, while that of protocol 11 resembled protocol 2 (Fig. 1). 
Effect of differentiation protocols on gene expression 
The expression of adipocyte marker mRNAs PPARȖ, adiponectin, leptin, AP2 and Glut4 were studied 
in the differentiated cells at day 14. Adipose stromal cells differentiated with protocols 3, 6, 7, 10 and 
11 showed the most elevated expression of the gene markers (s. Electronic Supplementary Material, 
Fig. S1). Based on the results of the triglyceride accumulation, three of the new protocols, protocols 
6, 7 and 11, were chosen to a closer inspection at gene expression level (Fig. 2). Protocol 7 yielded 
consistently the highest and most even expression of PPARȖ, Glut4, AP2 and adiponectin. Expression 
of leptin mRNA in all cell specimens, except for those from protocol 11, remained low. Protocols 2 
and 6 did not yield significant upregulation of the studied genes compared to undifferentiated control.  
To investigate whether the tested adipocyte differentiation protocols selectively induce a brown or a 
white adipocyte-like phenotype, we performed qPCR analysis of mRNAs typical of brown 
adipocytes, PRDM16, CIDEA, UCP1, and PGC1Į; and white adipocytes, ADCY5, RIP140, and leptin 
with protocols 2, 6, 7 and 11 with undifferentiated cells (protocol 1) as control (Fig. 3). The protocols 
2, 6 and 7 resulted in elevated expression of the brown adipocyte markers PRDM16, CIDEA, and 
UCP1, while PGC1Į expression was induced only under conditions 6 and 7. Of the white adipocyte 
markers, ADCY5 was induced under conditions 6 and 7, while RIP140 was only marginally affected. 
Of note, leptin was induced most prominently by protocol 11, but not by protocol 7.  
Insulin responsiveness of the adipocytes  
Glucose uptake 
Glucose uptake by undifferentiated control cells and the most promising differentiation method, 
protocol 7 adipocytes was studied by employing [3H]deoxyglucose (Fig.4). The cells were treated for 
30 min with 100 or 500 nM insulin prior to the uptake assays. The differentiated cells showed a 
significant insulin-induced enhancement of glucose uptake at 100 nM concentration of insulin, when 
compared to the undifferentiated control.  
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Lipolysis 
The ability of insulin to inhibit lipolysis in undifferentiated control cells and protocol 7 adipocytes 
was monitored by measuring glycerol released in the growth medium after exposure of the cells to 0, 
100 or 500 nM insulin at time points of 15, 30 and 45 min (Fig. 4) at day 14. In the control cells, 
treatment with 500nM insulin enhanced, rather than inhibited, the release of glycerol, whereas a 
marked (50-80%) inhibition of lipolysis was evident in protocol 7 differentiated cells upon treatment 
with 500 nM insulin, at all the studied time points.  
DISCUSSION 
Differentiation of pre-adipocytes into adipocytes is defined by the acquisition of a lipid-filled 
morphology and appropriate hormone responsiveness, signaling pathways and metabolism 
(Novakofski 2004).  In the last phase of adipocyte differentiation, preadipocytes transform into 
insulin-sensitive, lipid synthesizing and transporting mature adipocytes that secrete adipocyte-
specific secretory products (Stephens 2012, Rosen and MacDougald 2006, Gregoire 2001, Gregoire 
et al. 1998). In order to develop a new, native-like human adipocyte in vitro model, eleven different 
in vitro differentiation protocols were studied using human adipose stromal cells (hASC) (Table 1 
and Table 2). The outcome was analyzed by using triglyceride accumulation, morphology of lipid 
deposits, and adipocyte gene expression as criteria. Of the tested differentiation strategies, the most 
promising (‘protocol 7’) was chosen for further studies of insulin responsiveness. This protocol 
consisted of culture of the hASC (i) for three days in adipose tissue extract (ATE) medium, (ii) for 
six days in serum-free medium with 1,15 M insulin and 9,06 M Troglitazone, a thiazolidinedione 
(TZD) compound, and (iii) for 4 days in serum-free medium in the absence of insulin. The expression 
of adipocyte marker genes (adiponectin, Glut4, AP2 and PPARȖ) was significantly higher in the 
selected differentiation protocol 7 than in the other protocols tested. Moreover, the resulting 
adipocytes were responsive to insulin as judged from glucose uptake and inhibition of lipolysis at 
insulin concentrations of 100 or 500 nM, respectively.  According to the criteria set for the 
differentiated adipocytes, protocol 7 produced mature native-like adipocytes.  
In complicated 3D cell cultures, the major challenge is to create a culture environment that allows the 
growth and differentiation of multiple cell types. We have previously developed angiogenesis 
stimulation medium for creating mature vascular structures from adipose stromal cells and endothelial 
cells in vitro (Huttala et al. 2015). This stimulation medium (SM), consisting of 5.5 M 
hydrocortisone, 0.1 nM 3,3’,5-Triiodo-L-thyronine sodium salt (T3), 1.15 M insulin, 1 % bovine 
serum albumin (BSA), 10 ng/ml vascular endothelial growth factor (VEGF) and 1 ng/ml fibroblast 
growth factor (FGF-2) as active components, was further used in the current study for adipogenesis 
induction and adipocyte maturation together with the adipose tissue extract (ATE) (Sarkanen et al. 
2012a). ATE is a cell-free angiogenesis- and adipogenesis-inducing agent from human adipose tissue. 
ATE contains a majority of growth factors, cytokines and chemokines present in mature adipose 
tissue, e.g. leptin, adiponectin, FGF-2, IL-6, IGF-1, VEGF (-A), and angiogenin, among others, and 
has potential to induce natural adipogenesis in vitro (Sarkanen  et al. 2012a). ATE has been shown to 
induce a homogenous adipogenic differentiation of hASC and to induce triglyceride accumulation 
comparable to treatment with commonly used adipogenic cocktail, with dexamethasone (DEX), 
insulin, indomethacin and isobutylmethylxanthine (IBMX) (Sarkanen et al. 2012a, Verseijden et al. 
2009; Ghoniem et al. 2015, Foley et al. 2015, Lequeux et al. 2009, Rubin et al. 1978). ATE was 
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shown to be essential component for triggering adipogenesis, as any of the tested media did not induce 
adipogenesis on their own (data not shown). ATE seemed to cause cell commitment towards 
adipocytes, but also cell proliferation. Therefore, constant addition of ATE was not beneficial for 
adipogenesis. The explanation for this may come from the multiple cytokines in ATE contributing to 
the adipose stromal cell commitment (Sarkanen et al. 2012a). Due to the multiple factors in the plain 
ATE induction adipogenesis may not be the dominant event in cell culture, which was also seen in 
the current study as relatively small lipid droplet size and fairly low level of adipocyte marker gene 
expression. The balance of contradictory signals experienced by preadipocytes in vivo influence 
whether cells undergo adipogenesis (MacDougald and Mandrup 2002). It is known that e.g. 
macrophage-derived proinflammatory factors impair adipogenesis (MacDougald and Mandrup 2002, 
Lacasa et al. 2007).  
Due to the improper maturation of adipocytes in plain ATE induction, this natural adipogenesis 
induction was modified and improved by adding 9.06 M troglitazone in serum-free stimulation 
medium and depleting both insulin and troglitazone from culture for the last days of the culture period. 
Although the SM is serum-free, it contains albumin which acts in vivo as a carrier of fatty acids that 
is needed for their internalization into cells (Walker et al. 2014). This novel treatment, protocol 7, a 
combination of ATE and other adipogenesis stimulators, resulted in smaller percentage of cells 
accumulating triglyceride droplets than plain ATE induction, but the lipid accumulation per cell was 
greater, the differentiated cells resembled fully differentiated native adipocytes in morphology. 
Another tested protocol 11 (incubation for the entire 14 days in ATE + serum-free SM) also resulted 
in prominent triglyceride accumulation; however, gene expression analysis demonstrated under these 
conditions only induction of leptin and PPARȖ, while the markers of more mature adipocytes, 
adiponectin and AP2, were not induced. Of note, protocol 11 produced the most homogenious lipid 
accumulation among cells and could thus represent a useful model for the study of the early stages of 
adipogenesis.  
The new differentiation method ‘protocol 7’ included incubation of the cells with TZD compound 
Troglitazone and T3. TZDs are PPAR agonists, which stimulate adipogenesis and the redistribution 
of lipids from liver and muscle into adipose tissue (Greenberg and Obin 2006). Moreover, they 
activate AMPK, a central sensor for nutrient status, resulting in enhanced glucose uptake into adipose 
tissues and muscle (Fryer et al. 2002). TZDs have also been shown to decrease 11ȕHSD-1 and 
increase adiponectin (Greenberg 2003). Work on preadipocytes among human adipose derived stem 
cells or ones developed in vitro from other cell lineages suggests that integration of T3 and TZD 
signaling enhances the adipogenic differentiation potential (Ortega et al. 2009, Gerhold et al. 2002). 
T3, on its behalf, interacts with the two primary thyroid receptor isoforms, thyroid receptor a1 (TRa1) 
and its antagonist receptor a2 (TRa2) expressed in fat tissue. The binding of T3 to TRa1 induces 
adipogenesis while TRa2 negatively regulates the activity of T3 (Ortega et al. 2009). These 
observations provide plausible explanations for the observed beneficial effects of the Troglitazone 
and T3-containing media on the adipogenic differentiation in the new differentiation protocol.  
The glucocorticoid hydrocortisone used in the SM has been shown to increase the secretion of leptin 
by cultured rat adipose tissue (Mick et al. 2000) and the synthetic glucocorticoid DEX is commonly 
used to induce adipogenesis as it increases the expression of c/EBP and PPARȖ (Wu et al. 1996). 
Clinical cases of glucocorticoid excess are characterized by increased fat mass and obesity through 
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the accumulation of white adipocytes (Hochberg et al. 2015, Barclay et al. 2015). Hydrocortisone has 
also been shown to increase the secretion of leptin by cultured rat adipose tissue (Mick et al. 2000), 
however, this was not seen in our study. Previously Lequeux et al. (Lequeux et al. 2009) also 
composed an improved adipogenic differentiation medium which was further studied by Ghoniem et 
al (Ghoniem et al. 2015). Lequeux et al. replaced indomethacin with 1M rosiglitazone (another 
TZD), 10nM hydrocortisone and 2 nM triiodothyronine (T3) and added the basic adipogenic 
ingredients 0.15 UI/ml insulin, IBMX and DEX. Our serum-free SM, which contains 5.5M 
hydrocortisone, 0.1nM T3 and 9.06 M TZD Troglitazone, is by parts similar to their differentiation 
medium. Although our concentrations are higher, we have no serum, IBMX and DEX, which could 
explain the need for higher concentrations of the active components we used. 
Angiogenic factors are known promote also adipose tissue growth and expansion (Cao 2014). 
Angiogenic factors FGF2 (Xiao et al. 2010, Marra et al. 2008, Tabata et al. 2000) and VEGF 
(Girandon et al. 2011), among others, have been used when creating new adipocytes (Lowe et al. 
2011). In addition, obesity is associated with elevated circulating levels of VEGF, particularly in the 
context of visceral adipose tissue expansion (Miyazawa-Hoshimoto et al. 2003, Fain et al. 2004). 
These findings prompted the use of VEGF and FGF2 in our SM medium. As ATE also contains 
several angiogenic inducers including VEGF and FGF-2 (Sarkanen et al. 2012a), it further enables 
the adipogenesis but could also be the reason for the lack of maturation in protocol 11 as large quantity 
of angiogenic factors may drive the differentiation towards angiogenesis hence preventing 
adipogenesis.  
A number of well-studied genes are characteristically expressed during adipocyte differentiation or 
in mature adipocytes. Peroxisome proliferator-activated receptor Ȗ (PPARȖ) induces adipocyte 
differentiation by regulating several genes critical for adipogenesis, lipid uptake and lipid metabolism 
(Schoonjans et al. 1996, Rosen et al. 1999) and is regarded as a mid-differentiation marker (Flynn 
and Woodhouse 2008). Its induction was detected in most of the differentiation protocols tested in 
the present study, and thus proved that all the protocols were directing the cells towards adipogenesis. 
Expression of the glucose transporter Glut4 has been shown to rise in the terminal stage of 
differentiation (Gregoire et al. 1998). Glut4 is activated and built into the plasma membrane upon 
insulin stimulation (Berenguer et al. 2010), and effect is enhanced by TDZ rosiglitazone (Martinez et 
al. 2010). In the present study, a strong induction of Glut4 was observed only in protocol 7, suggesting 
that this protocol produces a somewhat more mature adipocyte phenotype than the related protocol 6 
which lacks Troglitazone. The adipocyte hormone leptin is mainly produced and secreted by mature 
adipocytes (Gregoire 2001). Its main function is the regulation of the body energy balance (Coelho 
et al. 2013, Kershaw and Flier 2004, Gregoire 2001). Among the present adipogenesis schemes, leptin 
was prominently induced only in protocol 11 and mildly in protocol 2. One reason for low leptin 
expression could be a low energy supply in the serum-free medium at day 14. Both protocol 2 and 11 
contain human serum in addition to the ATE. They may thus support the cellular energy status better 
than the other tested conditions, potentially resulting in an induction of leptin.   
Adipocyte lipid binding protein 2 (AP2, also known as FABP4) on its behalf, is a cytoplasmic fatty 
acid chaperone expressed in adipocytes (Yang and Smith 2007) and considered to be a critical link 
between lipid metabolism, hormone action and cellular functions in adipocytes (Maeda et al. 2001). 
It triggers ubiquitination and subsequent proteosomal degradation of PPARȖ in the terminal stage of 
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adipocyte differentiation (Yang and Smith 2007, Rodriguez et al. 2007, van Beek et al. 2007, Gregoire 
et al. 1998). AP2 was found to be elevated in the hASC based obesogen screening model (Foley et 
al. 2015), as well as in our new differentiation method, protocol 7. Another adipocyte marker 
representing terminal differentiation is adiponectin (Flynn and Woodhouse 2008). It is a hormone 
that decreases free fatty acids (FFA) in serum, glucose and triacylglycerol concentrations (Fruebis et 
al. 2001) and is secreted exclusively by adipose tissue (Kershaw and Flier 2004). Adiponectin 
regulates the energy balance of the body via activation of AMP-activated protein kinase (AMPK) in 
the hypothalamus (Coelho et al. 2013). Strong induction of both AP2 and adiponectin upon the 
present protocol 7 suggests that this differentiation protocol produced relatively mature, terminally 
differentiated adipocytes.  
To investigate whether the adipocyte differentiation protocols 2, 6, 7 and 11 selectively induce a 
brown or a white adipocyte-like phenotype, we carried out qPCR analyses of mRNAs predominantly 
expressed in either one of these adipocyte types. As mRNAs abundant in brown adipocytes we  
employed PRDM16, CIDEA, UCP1, and PGC1Į (Shinoda et al. 2015; Seale et al. 2007), and in white 
adipocytes ADCY5, RIP140, and leptin (Knigge et al. 2015; Sawada et al. 2010; Maffei et al. 1995; 
Zhang et al. 1994). The previously published ATE treatment (Sarkanen et al. 2012a) and conditions 
6 and 7 resulted in elevated expression of the brown adipocyte markers PRDM16, CIDEA, and UCP1, 
while PGC1Į expression was induced only under conditions 6 and 7. The induction of brown 
adipocyte-typical messages was most prominent with protocol 6. Of the white adipocyte-typical 
messages, ADCY5 was induced under conditions 6 and 7, while RIP140 was only marginally affected. 
To conclude, none of the protocols tested selectively induces either the brown or the white adipocyte 
phenotype, but overall induction of adipocytic genes is observed. 
The role of insulin in adipocyte differentiation is evident as the regulation of adipose tissue 
metabolism is one of the central physiologic functions of insulin (Cohen 2006). Insulin stimulates the 
uptake of amino acids and glucose into adipocytes and initiates signaling via effectors like 
phosphatidylinositol-3 kinase and AKT1/2 with central roles in adipogenesis (Kim and Chen 2004, 
Garofalo et al. 2003) and represses lipolysis in adipocytes (Watson and Pessin 2007, Choi et al. 
2010b). It promotes the synthesis and storage of triglycerides and inhibits their catabolism 
(Rutkowski et al. 2015). When developing cell models for the mechanisms underlying adipose insulin 
sensitivity/resistance in metabolic disease, it would be essential to generate adipocyte cultures in 
which the insulin responsiveness characteristics of the donor tissue are preserved. Since adipocytes 
generally lose a lot of their insulin responsiveness in culture (Gerrits et al. 1993), this requirement 
forms a major challenge. In the present study we showed that ‘protocol 7’ adipocytes do respond to 
insulin in terms of two central parameters: glucose uptake (100 nM insulin) and inhibition of lipolysis 
(500 nM insulin), further supporting the view that this optimized protocol yields insulin-responsive 
adipocytes with patterns of lipid accumulation and gene expression resembling those of native human 
adipocytes. The lack of accelerated glucose uptake with 500 nM insulin (Fig. 4B) is most likely due 
to a negative feedback response to excessive insulin hyperstimulation (Ma et al. 2013). Further 
optimization of the differentiation protocol is therefore necessary. Moreover, the insulin 
responsiveness of adipocyte cultures could be increased by selecting well responsive hASC through 
a more profound characterization.   
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CONCLUSION 
In this study, a novel adipocyte differentiation protocol mimicking natural adipogenesis was 
developed. The new protocol employed natural inducer of adipogenesis, adipose tissue extract, our 
previously developed serum-free angiogenesis stimulation medium and the thiazolidinedione 
Troglitazone. The results showed that the new protocol produces adipocytes which accumulate 
triglycerides, express general adipocyte marker mRNAs and respond to insulin as judged by glucose 
uptake and inhibition of lipolysis. Our qPCR analyses suggested that the protocol does not selectively 
induce either the brown or the white adipocyte phenotype.  The cells showed no regression of 
adipocyte morphology and remained viable and attached to substratum for at least 10 weeks when 
the differentiation medium was removed. 
A functional model for human adipogenesis is a desirable tool that would enormously benefit adipose 
tissue and obesity research. This can be achieved by use of well characterized cells of human origin 
and a differentiation protocol that produces mature and functional in vivo-like adipocytes. The new 
differentiation protocol developed in this study and the adipocyte model generated with it from hASC 
represent a crucial step towards this goal. By developing it further it will be possible to create 
accurate, reliable and efficient test systems for the research of obesity and metabolic disease. 
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Figures 
 
Fig. 1 Cellular lipid accumulation in the differentiation protocols tested. a) Bar graph shows mean r 
SD for triglyceride accumulation in eleven different differentiation schemes. Protocol 2 (ATE 
induction), protocols 6, 7 and 11 showed a statistically significant difference when compared to the 
negative control (=undifferentiated cells) in one-way anova with Dunnett test, n6; *p<0.05; 
***p<0.001; ****p<0.0001. In the confocal images b) the undifferentiated cells, c) adipocytes from 
ATE induction and d) protocol 7 adipocytes stained with AdipoRed and DAPI at day 14. Scale bar, 
100 m 
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Fig. 2 Expression of Leptin, PPARȖ, Glut4, AP2 and Adiponectin mRNAs in adipocytes of selected 
protocols: undifferentiated control, protocol 2 (ATE induction), protocols 6, 7 and 11. Expressions of 
PPARȖ, Glut4, AP2 and Adiponectin were significantly higher in protocol 7 adipocytes than in other 
adipocytes. Leptin was expressed at the highest level in protocol 11 adipocytes. The bars represent 
mean r SD. Statistics calculated with Two-way anova and Tukey test, n=5; *p<0.05;**p<0.01, 
***p<0.001; ****p<0.0001 
 
Fig. 3 Expression of brown (PRDM16, CIDEA, UCP1, PGC1D) or white (ADCY5, RIP140, and 
leptin) adipocyte-typical mRNAs in the adipocytes differentiated with protocols 2, 6, 7 and 11. The 
results are from two independent cell culture experiments, two cDNA syntheses and qPCR analyses 
(each in triplicate wells) carried out from each experiment (n=4). The bars represent mean r SD. 
Statistics calculated with Two-way anova and Tukey test *p<0.05;**p<0.01 
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Fig. 4 Responses to 100 or 500 nM insulin at day 14 in undifferentiated control and protocol 7 
adipocytes. a) Released glycerol per total protein after insulin exposure. The cells were incubated 
with or without insulin for 15, 30 or 45 min. Protocol 7 responded to insulin at all studied time points. 
b) Glucose uptake. Glucose uptake was significantly higher in 100 nM insulin treated protocol 7 
adipocytes than in the adipocytes without insulin treatment. The bars represent mean r SD. The 
results were analyzed by two-way anova with Tukey post test, n6; ***p<0.001, ****p<0.0001 
 
Fig. S1 Expression of adipocyte marker mRNAs in the differentiated adipocytes. Expression of 
adiponectin, Glut4, AP2, leptin and PPARȖ in adipocytes differentiated by 11 protocols in the study. 
The bars represent mean r SD (n3). Statistical significances are not shown in the figure.  
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Table 1 Media used in the differentiation protocols, their abbreviations and content 
 Medium Abbreviation Content Manufacturer 
1 hASC  
medium 
hASC  
medium 
DMEM/F12 
10 % Human serum (HS) 
2 mM L-glutamine (L-glut) 
Gibco 
PAA 
Gibco 
2 Serum-
free 
medium 
SFM DMEM/F12 
2,56 mM L-glut 
0,1 nM 3,3’,5-Triiodo-L-thyronine sodium salt (T3) 
ITSTM Premix: 
6,65 g/ml (1,15 M) insulin 
6,65 g/ml Transferrin 
6,65 ng/ml seleniuous acid 
1 % Bovine serum albumin (BSA) 
2.8 mM Sodium puryvate (NaP) 
Gibco 
Gibco 
Sigma 
BD 
 
 
 
PAA 
Gibco 
3 ATE  
medium 
ATEm 1800 g/ml Adipose tissue extract (ATE) 
DMEM/F12 
10 % HS 
2 mM L-glut 
100 IU/ml Penicillin/0.1 mg/ml streptomycin 
- 
Gibco 
PAA 
GIBCO 
GIBCO 
4 Stimulation 
medium 
SM Serum free medium (See medium 2 above) 
supplemented with 
200 g/ml AA 
0,5 g/ml Heparin (HE) 
5,5 M: 2 g/ml Hydrocortisone (HY) 
10 ng/ml Vascular endothelial growth factor 
(VEGF) 
1 ng/ml Fibroblast growth factor (FGF-ȕ) 
 
 
Sigma 
Sigma 
Sigma 
R&D systems 
 
R&DSystems 
5 Stimulation 
medium 
w/o insulin 
SM -ins Same as Stimulation medium except for ITS (BD) 
which has been replaced with: 
6,65 g/ml Transferrin 
6,65 ng/ml Seleniuous acid 
 
 
Sigma 
Sigma 
6 ATE+ASM A+A Stimulation medium 
ATE medium 
 
Table 2 Differentiation protocols; culture settings and medium changes 
Protocol Day0 Day1 Day 3-4 Day 6-7 Day 10 Day 14 
1 
(undifferentiated 
control) 
 
 
 
Cell 
seeding 
in hASC 
medium 
on 48 
well plate 
20 000 
cells/ cm2 
hASCm SFM SFM SFM  
 
 
 
 
 
 
End point 
analysis 
2 
(ATE induction) 
ATEm ATEm ATEm ATEm 
3 ATEm SM SM SM 
4 ATEm ATEm SM SM 
5 ATEm SM SM SM-ins 
6 ATEm SM -ins 
+9M Trogl 
SM -ins 
+9M Trogl 
SM -ins 
+9M Trogl 
7 ATEm SM 
+9M Trogl 
---- 
(no medium 
change) 
SM -ins 
8 ATEm ATE 
+9M Trogl 
SM SM -ins 
9 ATEm SM SM-ins SM -ins 
10 ATEm SM SM SM -ins 
11 A+A A+A A+A A+A 
20 
 
 
Table S1 Primer sequences used in the quantitative PCR 
Gene Primer sequence 
36B4 Forward- ATGCTCAACATCTCCCCCTTCTCC 
Reverse- GGGAAGGTGTAATCCGTCTCCACAG 
ADCY5 Forward- TCTCCTGCACCAACATCGTG 
Reverse- CATGGCAACATGACGGGGA 
Adiponectin Forward- GGCCGTGATGGCAGAGAT 
Reverse- CCTTCAGCCCGGGTACT 
AP2 Forward- GCTTTTGTAGGTACCTGGAAACTT 
Reverse- ACACTGATGATCATGTTAGGTTTGG 
CIDEA Forward- GATGCCCTCGTCATCGCTAC 
Reverse- GCGTGTTGTCTCCCAAGGTC 
Glut4 Forward- TGGGCGGCATGATTTCCTC 
Reverse- GCCAGGACATTGTTGACCAC 
Leptin Forward- GCCCTATCTTTTCTATGTCC 
Reverse- TCTGTGGAGTAGCCTGAAG 
PGC1-D Forward- GCTTTCTGGGTGGACTCAAGT 
Reverse- GAGGGCAATCCGTCTTCATCC 
PPARȖ Forward- GATCCAGTGGTTGCAGATTACAA 
Reverse- GAGGGAGTTGGAAGGCTCTTC 
Prdm16 
 
Forward- CGAGGCCCCTGTCTACATTC 
Reverse- GCTCCCATCCGAAGTCTGTC 
RIP140 Forward- GGATCAGGTACTGCCGTTGAC 
Reverse- CTGGACCATTACTTTGACAGGTG 
SDHA Forward- CATGCTGCCGTGTTCCGTGTGGG 
Reverse- GGACAGGGTGTGCTTCCTCCAGTGCTCC 
UCP1 Forward- CAATCACCGCTGTGGTAAAAAC 
Reverse- GTAGAGGCCGATCCTGAGAGA 
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Abstract: Many adipose tissue-related diseases, such as obesity and type 2 diabetes, are worldwide epidemics. For studying these
diseases, relevant human cell models are needed. In this study, we developed a vascularized adipose tissue model where human
adipose stromal cells and human umbilical cord vein endothelial cells were cocultured with natural adipogenic and defined
serum-free angiogenic media for 14 days. Several different protocols were compared to each other. The protocols varied in cell
numbers and plating sequences. Lipid accumulation was studied with AdipoRed reagent, relative cell number with WST-1
reagent, gene expression of glut4, leptin, aP2, adiponectin, PPARc and PPARc2 with RT-qPCR. Secretion of adiponectin, leptin
and aP2 was analysed with ELISA. The immunostained vascular network was imaged with Cell-IQ and area quantified using
ImageJ. In this study, both angiogenesis and adipogenesis were successfully induced. Protocols produced strong lipid accumula-
tion, good vascular network formation and induced adipocyte-specific protein secretion and expression of studied adipocyte
genes. Results showed that cell numbers and cell plating sequences are important factors when aiming at in vitro standardized
tissue model. Presence of mature vasculature appeared leads to faster the maturation of adipocytes judged by the lipid accumula-
tion and gene expression results. The developed vascularized adipose tissue model is simple to use, easily modifiable to suit vari-
ous applications and as such, a promising new tool for adipose tissue research when, for example, studying the effect of
different cell types on adipose tissue function or for mechanistic studies.
Interest in studying adipose tissue and its functions is growing
along with the growing prevalence of obesity and the many
adipose tissue-related diseases, such as type 2 diabetes melli-
tus, which is already a worldwide epidemics [1]. Many experi-
mental animal models have been developed to study diabetes
[2], but due to species-specific differences, the results from
the animal models, although they increase the understanding
of the mechanisms behind diseases and adverse effects, are
weakly transferable to human situations [2–4]. Also, due to
new regulations which promote and demand replacement of
animal experiments, more human biology mimicking in vitro
experiment models is needed. Examples of such as are Direc-
tive 2010/63/EU [5], the cosmetics regulations [6] and the EU
chemicals legislation REACH [7].
More than being the energy storage, adipose tissue is an active
endocrine organ, which is particular closely associated with vas-
cular system. Enlargement of the adipose tissue can be supported
by new blood vessel formation, neovascularization, or by dilating
and remodelling of the already existing capillaries [8]. Mouse
studies have shown that induction of vessel expansion in obese
mice counteracts obesity and related metabolic complications [9]
but also contrary results have been obtained as inhibition of ves-
sel formation by an anti-angiogenic drug decreased fat pad
weights of normal mice by 12–22% and decreased their body-
weights in a dose-dependent and reversible manner [10].
Two different angiogenesis triggers in in vivo adipose tis-
sue expansion have been proposed: (i) angiogenesis is a
response to hypoxia, which is caused by the enlargement
of adipocytes and/or proliferation of adipocytes; or (ii)
angiogenesis is a result of developmental and/or metabolic
signals in adipose tissue; that is, blood vessels develop in
parallel or before the adipose tissue expansion [11]. There
are several studies supporting the role of hypoxia [11–13].
However, in foetal development, angiogenesis/vasculogenesis
precedes adipogenesis and blood vessel extracellular matrix
(ECM) develops before adipose tissue ECM development
[14]. The reciprocal interaction between ECM stroma and
vascular network has also been shown to be important in
directing vessel growth [15–17].
Current human cell in vitro vascularized adipose tissue
models are based on (i) culturing human adipose stromal cells
(hASC) and human umbilical cord vein endothelial cells
(HUVEC) on a scaffold such as porous silk protein scaffold
[18] or (ii) culturing human pre-adipocytes with human
endothelial cells in a fibrin glue matrix on a chick chorioallan-
toic membrane [19,20] or (iii) by adding multiple different cell
types into the culture [21]. While these models are mimicking
vascularized adipose tissue, they are complex, require long
culture times and are laborious to be transferred into routine
use. In addition, the additional components such as biomaterial
scaffolds may interfere with the cell–cell interactions or cause
unwanted and unknown interactions between material and the
studied cells or chemicals [22–24].
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The aim of this study was to develop a robust human vas-
cularized adipose tissue model without artificial scaffold.
Such model could be utilized in basic adipose tissue
research, for drug discovery and safety studies, and it could
also be modified to disease model, which could be used in
the studies of disease pathogenesis, development of interven-
tion therapeutics and screening of personalized therapeutics.
In the model, we used hASC and HUVEC to form coculture
in which adipogenesis was induced by the novel natural adi-
pogenesis inducer adipose tissue-derived extract (ATE) [25]
and angiogenesis by our previously developed defined
serum-free angiogenesis medium [26]. The defined serum-
free angiogenesis medium produces mature vascular struc-
tures in vitro [26], and this medium together with ATE dif-
ferentiates hASC to insulin-sensitive adipocytes [27]. In this
work, we compared several protocols to find the most opti-
mal for formation of vascularized adipose tissue bearing in
mind the use of the model as a routine standard model. The
formed vascularized adipose tissue was characterized for
morphology, lipid accumulation, secretion of adiponectin,
leptin and adipocyte protein 2 (aP2, also known as fatty
acid-binding protein 4) and the mRNA expression of glut4,
leptin, aP2, adiponectin, PPARc and PPARc2. The findings
of this article present two protocols, which are easy-to-use,
adjustable for different applications and relevant for culturing
a vascularized adipose tissue cell model.
Materials and Methods
Development strategy. Six different protocols (table 1) were
compared to each other for their capability to create vascularized
adipose tissue. The studied protocols had following variables: cell
number, cell plating time-point (on day 1 or on two separated days,
i.e. on days 1 and 7) and the differentiation process (adipogenesis
induced prior to angiogenesis or vice versa). Adipogenesis was
induced with the ATE and angiogenesis with the defined serum-free
angiogenesis medium. Adipogenesis is induced with ATE medium and
angiogenesis with angiogenesis medium. Three types of controls were
used (table 1) negative control with no induction, vasculature control
in which only angiogenesis was induced and adipocyte control in
which only adipogenesis was induced.
Isolation and culture of human adipose stromal cells and umbilical
cord vein endothelial cells. The human adipose tissue samples and
umbilical cords were obtained from Tampere University Hospital,
Tampere, Finland, with individual written informed consent. The use
of ATE, hASC and HUVEC was approved by the Ethics Committee
of the Pirkanmaa Hospital District, Tampere, Finland, with permit
numbers R03058 and R08028, respectively.
Human adipose stromal cells were isolated using collagenase I (Gibco,
Carlsbad, CA, USA) as described previously [26,28]. HUVEC were iso-
lated by cannulating the umbilical cord vein and infusing the vein with
collagenase I (Gibco) and cultured in endothelial cell growth medium
(EGM-2; Lonza, Basel, Switzerland) as described earlier [26,28]. Possible
mycoplasma contamination was tested with MycoAlert Detection Kit
(Lonza) from both cells before cryopreservation.
Human adipose stromal cells-HUVEC coculture plating and
differentiation protocols to form vascularized adipose tissue. In order
to find out the optimal plating time for hASC and HUVEC with
respect to the differentiation of the cells into adipocytes and blood
vessels, six different protocols were compared to each other (table 1).
On day 0, hASC (P1) were seeded in endothelial cell growth medium
(Lonza) at 20,000 cells/cm2 or 40,000 cm2 on 48-well NunclonTM D-
Surface (Sigma-Aldrich, Saint Louis, MO, USA) plates. In some
protocols, there was addition of hASC on day 7 (table 1) in 50 ll of
medium without changing the medium in the well. HUVEC (p3) were
seeded on top of hASC in 50 ll at 4000 cells/cm2 either on day 0 or
on day 7 depending on the plating strategy (table 1). Three different
hASC-HUVEC combinations were used, and all strategies were tested
with all of the hASC-HUVEC combinations.
Human adipose stromal cells-HUVEC cocultures were exposed to
adipogenic ATE medium [25] or angiogenesis medium [26] on day 1.
ATE was prepared as described earlier [27]. Composition of all media
used in the study is listed in table 2. Vasculature control was exposed
only to angiogenesis medium, adipocyte control only to ATE medium
and negative control (undifferentiated cells) to serum-free medium
(table 1). Differentiation media were changed on days 4, 8 and 11.
Analysis of the coculture. All analyses of the cultures were performed
on day 14.
Analysis of secreted proteins. Media samples were analysed for their
concentration of adiponectin, leptin and aP2 with Quantikine ELISA
(R&D Systems, Abingdon, UK), according to the manufacturer’s
instructions. Absorbance was measured at 450 and 540 nm.
Relative cell number. The relative cell number was defined using cell
proliferation reagent WST-1 (Roche Diagnostics, Basel, Switzerland)
according to the manufacturer’s instruction by incubating the reagent
for 1 hr and measured at 450 nm by multipoint measurement.
Lipid accumulation. The lipid accumulation was determined using
AdipoRed assay reagent (Lonza) according to the manufacturer’s
instructions from the same wells from which the WST-1 staining was
performed. The fluorescence was measured by multipoint
measurement with Varioskan Flash Multimode Reader (Thermo
Fischer Scientific, Waltham, MA, USA) with excitation at 485 nm
and emission at 572 nm.
Immunocytochemical stainings. To visualize and analyse the formed
vasculature, immunocytochemical stainings were performed. For this,
the same cell cultures, which were used for AdipoRed and WST-1
measurements, were stained.
Cells were fixed with 4% formaldehyde (Thermo Fisher Scientific)
at RT for 20 min. and treated with 0.5% Triton X-100 (MP Biochemi-
cals, Santa Ana, CA, USA) at RT for 15 min. and with 10% bovine
serum albumin (BSA; Roche Diagnostics) at RT for 30 min. Primary
antibodies, von Willebrand factor IgG (anti-vWf IgG produced in Rab-
bit, #F3520, Sigma-Aldrich; 1:100) and anti-collagen IV IgG (anti-
ColIV IgG produced in mouse, #C1926, Sigma-Aldrich, 1:500),
diluted in 1% BSA in DPBS with Ca and Mg (Lonza) were incubated
for 1 hr at RT or overnight at +4°C. Cells were then incubated for
40 min. at RT with secondary antibodies diluted in 1% BSA in DPBS,
FITC-labelled goat polyclonal antibody antimouse IgG (Sigma-
Aldrich, 1:100) and TRITC-labelled goat polyclonal antibody anti-rabbit
IgG (Sigma-Aldrich, 1:50).
Microscopic analyses. Vasculature and lipid accumulation were
imaged with Nikon Eclipse Ti-S inverted fluorescence microscope
(Nikon, Tokyo, Japan) and Nikon Digital Sight DS-U2 camera
(Nikon). Images were processed with NIS Elements (Nikon) and
Adobe Photoshop CS3 software (Adobe Systems Incorporated, San
Jose, CA, USA).
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Quantification of vasculature. To determine the area of vasculature,
immunostained cells were imaged with Cell-IQ (CM Technologies Oy,
Tampere, Finland) with 109 objective with grid of 5 9 5. Images were
stitched together with Cell-IQ Analyzer (CM Technologies Oy) and
further analysed with ImageJ software (The National Institutes of
Health, MD, USA). Images were converted to 8-bit grey scale, and the
background was subtracted. Then, binary threshold function was
adjusted to separate the tubules from background staining. The total
tubule area was calculated as the total number of pixels in images with
a set threshold. Results were plotted in GraphPad Prism (GraphPad
Software Inc, La Jolla, CA, USA). n was 12 for negative control,
adipocyte control, vasculature control and P1 and P5. For protocols 2
and 6, n was 5. Results are depicted as mean  standard deviations.
Gene expression. The cells were lysed with the lysis buffer from
PureLink RNA Mini Kit (Life Technologies, Carlsbad, CA, USA) so
that parallel sample cells from five to eight wells were lysed into
600 ll of the lysis buffer and combined as one sample. Isolation was
continued according to the instructions of the PureLink RNA Minikit
(Life Technologies). The 260/280 purity ratios were measured with
lPlate (Thermo Fischer) and Varioskan Flash Multimode Reader
(Thermo Fischer). Genomic DNA contaminations were eliminated
with PureLink DNase treatment (Life Technologies). The quality of
RNA samples was checked using QIAxcel RNA QC kit v2.0 (Qiagen,
Venlo, the Netherlands) and QIAxcel Advanced (Qiagen). cDNA was
synthesized with iScript cDNA synthesis kit (Bio-Rad, Hercules, CA,
USA) according to the protocol of the manufacture. cDNAs were then
preserved at 80°C until RT-qPCR.
qPCR to study mRNA expression of PPARc, PPARc2, Adiponectin,
Leptin, aP2 and Glut4 was performed with CFX96 Real-Time System
(Bio-Rad) and with iQTM SYBR Green Supermix (Bio-Rad). These
gene markers were chosen according to our previous study [27] and to
represent markers of different stages of adipocyte differentiation. The
specificity of the primer sequences was tested with NCBI/Primer-
BLAST. Primer concentration was 300 nM, and amount of template
was 30 ng. Thermal cycling conditions were as follows: 95°C 3 min.,
95°C 10 sec., 51–65°C (gradient) 15 sec., 72°C 30 sec., repeated 40
times. Melt curve analysis was performed at 55–95°C (0.5°C incre-
ment/10 sec.). Housekeeping genes and adipocyte marker genes used
in this study are listed in table 3. The quality of amplified DNA was
studied with gel electrophoresis using high sensitivity DNA analysis
kit (Agilent Technologies, Santa Clara, CA, USA) and Agilent 2100
Bioanalyzer (Agilent Technologies) according to the manufacturer’s
instructions.
Data handling and statistical analyses.
Quantification of lipid accumulation. To achieve a lipids/cell value,
normalized AdipoRed assay absorbance values were divided with
mean WST-1 assay absorbance values for the protocol in question.
Normalization and AdipoRed WST-1 ratio calculations were made
with Microsoft Excel 2013 (Microsoft Corporation, Redmond, WA,
USA). n was 12.
Quantification of secreted leptin, aP2 and adiponectin. From the
ELISA analysis, protein concentration results were obtained by
subtracting the 540 nm reading from the 450 nm absorbance values,
creating the standard curve and calculating the concentrations of the
studied proteins. These results were then divided by the relative cell
number, that is WST-1 results. In ELISA samples, adipocyte control
and P2 and P6 contain cytokine-rich ATE and hence the protein
concentrations are compared to each other. Similarly, negative control,
P1 and P5 were compared to each other. n was 3.
Table 1.
Plating and differentiation details of different protocols tested on hASC-HUVEC cocultures.
Protocol
name
hASC
plating day(s)
Number of
hASC/well
HUVEC
plating day
Number of
HUVEC/well Medium on days 1–7 Medium on days 8–14
P1 Day 0 22,000 cells Day 7 4400 cells ATE medium Angiogenesis medium
Day 7 22,000 cells
P2 Day 0 22,000 cells Day 0 4400 cells Angiogenesis medium ATE medium
Day 7 22,000 cells
P3 Day 0 44,000 cells Day 0 4400 cells ATE medium Angiogenesis medium
P4 Day 0 44,000 cells Day 0 4400 cells Angiogenesis medium ATE medium
P5 Day 0 22,000 cells Day 0 4400 cells ATE medium Angiogenesis medium
P6 Day 0 22,000 cells Day 0 4400 cells Angiogenesis medium ATE medium
Negative control Day 0 44,000 cells Day 0 4400 cells Serum-free Basic medium Serum-free Basic medium
Vasculature control Day 0 22,000 cells Day 0 4400 cells Angiogenesis medium Angiogenesis medium
Adipocyte control Day 0 22,000 cells – – ATE medium ATE medium
ATE, adipose tissue-derived extract; hASC, human adipose stromal cells; HUVEC, human umbilical cord vein endothelial cells.
Table 2.
Composition of differentiation media used in the study.
Medium Components Manufacturer
ATE medium DMEM/F-12 Gibco
1800 lg/ml ATE
10% Human serum PAA Laboratories
(Pasching, Austria)
2 mM L-Glutamine Gibco
50 units/ll Penicillin-50
lg/ll streptomycin
Gibco
Serum-free
Basic edium
DMEM/F-12 Gibco
1% BSA Biosera (Boussens,
France)
2.8 mM Sodium puryvate Gibco
2.56 mM L-Glutamine Gibco
ITS supplement: BD Biosciences (NJ,
USA)
6.65 lg/ml Insulin
6.65 lg/ml Transferrin
6.65 ng/ml Selenious
0.1 nM 3,3,5-Triiodo-L-
thyronine sodium salt
Sigma-Aldrich (MO,
USA)
Angiogenesis
medium
Serum-free medium
200 lg/ml Ascorbic acid Sigma-Aldrich
2 lg/ml Hydrocortisone: Sigma-Aldrich
1 ng/ml FGF-b R&D Systems
10 ng/ml VEGF R&D Systems
0.5 lg/ml Heparin Sigma-Aldrich
ATE, adipose tissue-derived extract; BSA, bovine serum albumin.
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RT-qPCR result quantification. qPCR data were analysed using
CFX96 Real-Time System software (Bio-Rad). The relative
quantification of mRNA expression data was calculated using DCt
method with Microsoft Excel 2013 (Microsoft Corporation, Redmond,
WA, USA) with the following equation:
For the expression analysis, adipocyte control was used as control.
Four biological replicates of each strategy were analysed (n = 4).
Statistics. All results were plotted, and statistical analyses were
performed with GraphPad Prism (GraphPad Software Inc.). Results are
depicted as mean  standard deviation. Results from lipid
accumulation, Cell-IQ image analysis and RT-qPCR were subjected to
one-way analysis of variance (ANOVA), followed by Tukey’s multiple
comparison test. Results for protein secretion were subjected to one-
way analysis of variance (ANOVA), followed by Sidak’s multiple
comparison test. Differences were considered significant when
*p < 0.05, **p < 0.01 and ***p < 0.001.
Results
Practical considerations.
Cell detachment occurred when high number of cells was pla-
ted at once on the same day, that is in protocols P3 and P4
(table 1). Due to this issue, those protocols were omitted from
further analyses even though both produced dense tubule net-
work and evenly distributed AdipoRed staining. All other pro-
tocols (P1, P2, P5 and P6) were analysed further. When the
same number of cells was plated on two separate days (P1
and P2), that is half on day 1 and other half on day 7, no
detachment was observed from the culture vessel during the
14-day culture. However, P2 and P6, in which angiogenesis
was induced prior to adipogenesis, were found to detach from
the culture vessel easier than P1 and P5 during handling the
cultures.
Lipid accumulation.
Cultures were stained with AdipoRed lipid dye on day 14.
The lipid accumulation was strong and evenly distributed
throughout the culture in all studied protocols (P1, P2, P5 and
P6), including the adipocyte control (fig. 1). Negative control
and vasculature control showed only slight staining with
AdipoRed (fig. 1).
Lipid accumulation was quantified by calculating the ratio
between the normalized AdipoRed values and WST-1 values
giving relative lipids/cell value (fig. 2). Adipocyte control
(p = 0.0021) and protocol P6 (p = 0.0008) accumulated sig-
nificantly more lipids than negative control. P5 accumulated
significantly less lipids than adipocyte control (p = 0.0253).
P6 accumulated significantly more lipids than P2 (p = 0.0455)
and P5 (p = 0.0091).
Formation of vasculature.
Vasculature was visualized with immunocytochemical stainings
and imaged, and the area covered by tubules was quantified.
Figure 1 presents the morphology of vasculature for protocols
P1, P2, P5 and P6. Branched vascular networks were obtained
in vasculature control as well as in all protocols but were not
observed in the negative control or in the adipocyte control. The
networks were more dense and more branched when they had
14 days to mature (in vasculature control, as well as in P2 and
P6) compared to those in P1 and P5, which had 7 days to differ-
entiate (table 1). The stainings showed intact outer basement
membrane (collagen IV) and inner endothelial layer (vWf) in all
of the samples (fig. 1). The width of the formed vascular struc-
tures in tubule control and in different strategies did not differ
markedly from each other as observed with microscope.
Table 3.
Studied genes and the primer sequences used.
Gene name Abbreviation Primer sequence (50–30) Function
Succinate dehydrogenase
complex, subunit A
SDHA F: CATGCTGCCGTGTTCCGTGTGGG Used as a housekeeping gene in this study
R: GGACAGGGTGTGCTTCCTCCAGTGCTCC
Acidic ribosomal
phosphoprotein P0
36B4 F: ATGCTCAACATCTCCCCCTTCTCC Used as a housekeeping gene in this study
R: GGGAAGGTGTAATCCGTCTCCACAG
Leptin – F: GCCCTATCTTTTCTATGTCC Adipose tissue secretory product [37]
R: TCTGTGGAGTAGCCTGAAG
Adiponectin – F: GGCCGTGATGGCAGAGAT Adipose tissue secretory product [37]
R: CCTTCAGCCCGGGTACT
Adipocyte protein 2
(fatty acid-binding protein 4)
AP2 F: GCTTTTGTAGGTACCTGGAAACTT Carrier protein for fatty acids [38]
R: ACACTGATGATCATGTTAGGTTTGG
Glucose transporter type 4 Glut4 F: TGGGCGGCATGATTTCCTC Insulin-responsive glucose transporter [47]
R: GCCAGGACATTGTTGACCAC
Peroxisome proliferator-
activated receptor c
PPARc F: GATCCAGTGGTTGCAGATTACAA Transcription factor in adipogenesis [48]
R: GAGGGAGTTGGAAGGCTCTTC
Peroxisome proliferator-
activated receptor c variant 2
PPARc2 F: CAGTGTGAATTACAGCAAACC Transcription factor in adipogenesis, adipocyte-
specific variant [49]R: ACAGTGTATCAGTGAAGGAAT
2ðCtðmean of housekeeping genes SDHAand 36B4; studied protocolÞ  CtðGene of interest; studied protocolÞÞ=
2ðCtðmean of housekeeping genesSDHA and 36B4; controlÞ  CtðGene of interest; controlÞÞ
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The area of the vascular networks was quantified from Cell-
IQ images with ImageJ (fig. 2). Out of the studied protocols
(P1, P2, P5 and P6; table 1), P1 was the only studied protocol
which produced significantly less tubules than vasculature
control (p = 0.0012). However, P1 also contained adequate
vascular network as shown in fig. 1, although not as extensive
as in other protocols.
Secretion of adipocyte-specific proteins.
ELISA was performed for the quantification of adipocyte-speci-
fic proteins in the samples collected from the culture media on
day 14 (fig. 3). Medium of adipocyte control, P2 and P6 con-
tained cytokine-rich ATE, and hence, these medium samples
were compared to each other. Samples from P1 and P5 did not
contain ATE, and they were compared to the negative control,
which contained the same basal medium as the protocols did.
Secretion of adiponectin was significantly increased in P6
compared to adipocyte control and P2 (p = 0.0062 and
p = 0.0011, respectively). Also aP2 secretion was significantly
increased in protocol P6 compared to adipocyte control and
P2 (p = 0.0024 and p = 0.0002, respectively). Significantly
more leptin was secreted in P1 (p = 0.0001) and P5
(p < 0.0001) than in the negative control. Leptin secretion
was also significantly higher in protocol P6 than in P2
(p = 0.0150).
The adipocyte-specific mRNA expression in the formed
adipose tissue.
Expression of marker genes PPARc, PPARc2, aP2, adiponec-
tin, leptin and Glut4 was investigated on day 14. PPARc,
PPARc2, leptin, aP2 and glut4 were shown to be expressed in
P1, P2, P5 and P6, and there was no significant difference in
the expression between the studied protocols and adipocyte
control (fig. 4). Adiponectin expression was significantly
higher in P1 adipocytes when compared to adipocyte control
(p = 0.0115) or P5 (p = 0.0357). The expression of PPARc
and PPARc2 showed a trend that when general PPARc was
expressed at high level, PPARc2 was expressed at low level
A B C
D E
G
F
Fig. 1. Morphology of the vascularized adipose tissue models on day 14. Lipids are seen in orange/red; tubules are stained with anti-vWF-TRITC
(red) and anti-ColIV-FITC (green). (A) Negative control. (B) Adipocyte control with strong AdipoRed staining. (C) Vasculature control with strong
tubule network. (D) P1 produced tubules but only few branches. AdipoRed staining showed strong lipid staining within the cells. (E) P2 produced
well-branched tubule network and evenly spread AdipoRed staining. (F) P5 produced dense tubule network, but it was less dense than with (G) the
protocol 6. Both P5 and P6 show good AdipoRed staining. Images are obtained with Nikon Eclipse Ti-S inverted fluorescence microscope and
with 109 objective, scale bar is 100 lm.
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and vice versa. The gene expression results (fig. 4) are given
as relative expression using adipocyte control as control.
Discussion
In this study, we developed a human relevant vascularized
adipose tissue model aiming at standardized artificial scaffold-
free test for routine use. The used human ATE induces adipo-
genesis in hASC culture [25], and the vascular network was
constructed as published earlier by Huttala et al. [26]. ATE
has been found to be a superior inducer of adipogenesis over
the commonly used chemical induction cocktail [25]. The vas-
cular network, induced by serum-free angiogenesis medium,
has also been characterized earlier and found to produce opti-
mal, in vivo like vascular structures [26]. Six different proto-
cols were studied and characterized in this study. They were
evaluated by their reproducibility and their ability to induce
adipocyte-specific marker expression in the cultures. Simulta-
neously, the effect of the vasculature on the adipogenesis was
assessed.
Adipogenesis and angiogenesis were both successfully
induced, although differences were seen between the protocols
in triglyceride accumulation and in density of vascular net-
works. The results showed that dense vasculature which
existed before start of adipogenesis induction helped the pre-
adipocytes mature faster. Different cell plating and differentia-
tion protocols had a notable effect on the resulting cell model
and its technical repeatability. The most optimal protocols
based on triglyceride accumulated, sufficient vascular network
formation and relevant adipocyte-specific genes and protein
expression for building the vascularized adipose tissue model
were P1 and P6 (table 1). These protocols are scaffold-free,
and they are simpler and demand shorter culture time than
other existing vascularized adipose tissue models [18–21].
Due to the simplicity of these two protocols, two cells and
two induction medias, they can also be easily modified to suit
the various applications, for example effect of third cell type
on adipose tissue metabolism.
Vasculature formation in different protocols.
Dense vascular networks were induced with all protocols, and
the vasculature has been shown to be mature in 7 days [26].
Apart from the angiogenesis induced with the stimulation
Fig. 2. Lipid accumulation and area of vasculature in the vascularized adipose tissue models on day 14. (A) Adipocyte control and all protocols
show lipid accumulation; P5 was the only one, which accumulated significantly less lipids than the adipocyte control. (B) All protocols produced
dense tubular network except P1, which formed significantly less tubules compared to the vasculature control, P2 and P6. The bars represent
mean  S.D. n was 12 except for P5 and P6 for which the n was 5 due to detachment. *p < 0.05, **p < 0.01 and ***p < 0.001.
Fig. 3. Protein secretion of adipocytes in the studied protocols. Adipocyte control and P2 and P6 contain cytokine-rich adipose tissue-derived
extract, and hence, their results were compared to each another whereas negative control, P1 and P5 were compared to each other. (A) Secretion of
adiponectin was significantly increased in P6 compared to adipocyte control and P2. (B) aP2 was secreted significantly more in P6 than in the adi-
pocyte control and P2. (C) Secretion of leptin was significantly higher in P1 and P5 than in the negative control, and also higher in P6 than P2.
The bars represent mean  S.D. For lipid accumulation, n was 15, and for ELISA, n was 3. *p < 0.05, **p < 0.01 and ***p < 0.001.
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medium, the adipogenesis inductor, ATE, has also been shown
to induce angiogenesis [25]. Thus, the ATE treatment allows
further maturation of blood vessels while inducing adipogene-
sis in the model. In other published vascularized adipose tissue
models, adipogenic cocktail treatments, for example insulin,
IBMX, biotin, pantothenate, DEX and thiazolidinediones, have
been proposed to have a negative effect on endothelial cells
and delay the growth of HUVEC [18,29].
In this study, the cocultures where angiogenesis structure
was induced first (P2 and P6) tended to detach easier than the
ones where adipogenesis was induced first (P1 and P5). This
problem could be addressed by coating the culture vessels.
However, the addition of external materials can cause
unwanted and unknown interactions between the studied cells
or chemicals assembly [23].
Effect of vasculature on adipocyte differentiation.
Based on the commonly used adipogenesis markers PPARc,
PPARc2, leptin, adiponectin, Glut4 and aP2 [27,30,31], adi-
pogenic differentiation of hASC occurred in all protocols. In
addition, the gene expression results suggested that vasculature
has a positive effect in adipocyte differentiation. There was a
clear trend of higher expression of all the studied gene mark-
ers in the vascularized adipose model compared to the adipo-
cyte control even though statistically significant difference was
found only in adiponectin expression in protocol P1. The role
of ECM produced by the hASC and the formed vascular struc-
tures in the culture is one important part of the model as it
offers attachment places and support for differentiation of adi-
pocytes [21]. The hASC and HUVEC vascular network has
already been shown to produce ECM and collagen IV
Fig. 4. The expression of adipose tissue specific gene markers in the studied protocols. (A) PPARc, (B) leptin, (C) adiponectin, (D) aP2, (E)
PPARc2, (F) Glut4. P1 showed significantly increased the expression of adiponectin compared to adipocyte control and P5. The bars represent
mean with S.D. n was 4, *p < 0.05.
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containing basement membrane [26], and its role in adipogen-
esis should be studied further.
PPARc expression is considered a general marker for ongo-
ing adipogenesis and thus should be found in the adipocyte
models [29,32]. PPARc2 is more adipocyte-specific isoform of
PPARc [33,34], and it is transcriptionally regulated by nutri-
tion [33,35]. PPARc2 has been found to be important for the
storage of lipids in adipocytes in adipose tissue instead of
other organs, and hence, its proper expression is highly impor-
tant in obesity [36]. Our results support this and the finding of
Robciuc et al. [9] because the adipocytes in P6, which had
extensive vasculature prior to adipogenesis induction, had
strong expression of PPARc2 (fig. 4), and also the size of the
lipid storage per cell was largest of the studied protocols
(fig. 2). This is an interesting finding and should be studied
further.
Leptin and adiponectin, the most abundant secretory prod-
ucts of adipose tissue [37], are typically investigated when
studying the secretory properties of the formed adipose tissue
[30]. In our models, the expression of leptin was elevated
implying that functional adipose tissue was formed. P1 adipo-
cytes, which showed strong lipid accumulation, were also
secreting leptin, indicating the saturated state of the
adipocytes.
aP2 (also known as fatty acid-binding protein 4) regulates
the lipid trafficking and response in cells [38]. Along with
aP2, the glucose transporter Glut4 has been connected to the
terminal stage of differentiation in 3T3-L1 cells [32]. As
angiogenesis medium includes insulin, which increases glu-
cose influx through Glut4 and represses lipolysis in adipocytes
[39,40], it is possible that the combination of ATE and angio-
genesis media treatments enhances adipose tissue maturation
more than just ATE treatment in adipocyte control. Activated
endothelial cells in angiogenic vessels are known to produce
various cytokines and growth factors that promote adipose tis-
sue growth and expansion [41].
According to our findings, 1 week of adipogenesis induc-
tion was enough to produce mature adipocytes if there was a
dense and mature blood vessel network present prior to induc-
tion of adipogenesis; that is, vasculature was enabling a faster
differentiation of adipocytes. This was seen from the gene
expression results, which did not differ significantly regardless
of whether the adipocytes had 2 weeks (P1 and P5) or 1 week
(P2 and P6) to mature in the culture. The positive effect of
vasculature on adipose tissue has also been shown in mouse
models by others [9,10], and hence, it should be studied fur-
ther to reveal the underlying mechanisms of the interaction of
vasculature and adipocytes. This model provides a useful tool
for studying these mechanisms and the role of vasculature on
the adipocyte differentiation.
Technical aspects in model development.
When developing a multicellular tissue model with relatively
thick structures, gaining adequate and reproducible cell adher-
ence might be difficult. This essential feature largely defines
the applicability and repeatability of the otherwise functional
model. According to our results, plating density had the stron-
gest impact on the adherence of the cell model.
Foetal calf serum is the standard component of the pre-
sent test models although it might have unpredicted effects
during the culture. In addition to the lot-to-lot variation,
proteins in foetal serum may bind studied compounds and
affect the results obtained [42]. Therefore, the ultimate goal
is to use serum-free medium whenever possible. In our
model, the defined serum-free medium is present for
7 days in the culture. This makes the model less vulnera-
ble to batch variation and other unknown protein interac-
tions.
Cells of human origin should be used when studying human
effects especially when metabolism of test substances might
play a role [43–45]. However, only a few human cell-based
adipose tissue models have been developed so far [46]. Pri-
mary human cells utilized in this model might contain lot-to-
lot variation and thus cause difficulties in standardization.
However, the variation can be minimized by preset quality
control procedures which includes verification of sufficient
expression of prominent markers for each cell type used, for
example CD73, CD90 and CD105 for hASC [26] and mor-
phological monitoring of the cells.
Conclusions
As obesity is a severe and growing global problem, there is
an urgent need for well-characterized, functional and relevant
human in vitro models, which could be used in safety testing
of chemicals, in drug development as well as in biomedical
research of healthy and disease modelling tissue. Also new
legislations, such as REACH, are increasing the demand of
in vitro models. This study provides new information on com-
bining two components, vasculature and adipocytes, in culture
and led to the development of novel in vitro model for adi-
pose tissue studies. Both angiogenesis and adipogenesis were
successfully induced in the coculture with the protocols used
in this study. Presence of mature vasculature showed to be
beneficial; it appears to lead to further maturation of pre-adi-
pocytes and adipocytes. The underlying mechanisms of this
interaction should be studied further as they might provide a
target for therapeutic strategies.
The next step is to show with a set of reference chemicals
the applicability of the model for chemical testing on adipoge-
nesis, but even now, the model is ready to be used for adipose
tissue research when, for example, studying the effect of dif-
ferent cell types on adipose tissue function or for mechanistic
studies.
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